Author Index

Abou-Mohamed G, Nagarajan R, Ibrahim TM, Caldwell RW. Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing, 39
Abou-Mohamed G, *see* Nagarajan, 31
Almgren O, *see* Darpö, 539
Ambrosio G, *see* Napoli, 417
Ambrosioni E, *see* Borghi, 519
Andriani A, *see* Ranieri, 119
Antman EM, Seeling MS, Fleischmann K, Lau J, Kuntz K, Berkey CS, McIntosh MW. Magnesium in acute myocardial infarction: scientific, statistical, and economic rationale for its use, 297
Apstein CS, *see* Bernstein, 167
Arcaro G, *see* Covi, 321
Arita M, *see* Tatsukawa, 667
Assogba U, *see* Lepage, 567
Aupetit J-F, *see* Timour, 447
Averbuch M, *see* Schwartz, 75
Ayaori M, *see* Yoshida, 67

Balkan B, *see* Scheurink, 263
Bång A, *see* Herlitz, 485
Bartels GL, *see* Remme, 137
Battler A, *see* Leor, 413
Baudin B, Bénéteau-Burnat B, Giboudeau J. Cytotoxicity of amiodarone in cultured human endothelial cells, 557
Beamish R, *see* Dhalla, 231
Beamish R, *see* McKnight, 239
Becker RC, *see* Foley, 403
Bedol B, *see* Ernsberger, 275
Bellandi F, Dabizzi RP, Cantini F, Di Natale M, Niccoli L. Intravenous propafenone: efficacy and safety in the conversion to sinus rhythm of recent onset atrial fibrillation; a single-blind placebo-controlled study, 153
Belz GG, *see* Breithaupt-Grögler, 49
Bénéteau-Burnat B, *see* Baudin, 557
Benigno M, *see* Ferrari, 425
Bergstrand R, *see* Darpö, 539
Berkenboom G, Brékine D, Unger P, Gulbis B, Fontaine J. Coronary vasomotor responses in cyclosporine-treated piglets, 17
Berkenboom G, Brékine D, Unger P, Richelle M, Carpentier Y, Fontaine J. Effect of dietary supplementation with fish oil on cyclosporine A-induced vascular toxicity, 379
Berkey CS, *see* Antman, 297
Bernocchi P, *see* Ferrari, 425
Bernstein EA, Eberli FR, Silverman AM, Horowitz GL, Apstein CS. Beneficial effects of felodipine on myocardial and coronary function during low-flow ischemia and reperfusion, 167
Bertel O, *see* Sütsch, 717
Berti S, Palmieri C, Ravani M, Bonini R, Iascone MR, Clercio A, Manfredi C, Iervasi G, Ferrazzi P, Biagini A. Acute enoximone effect on systemic and renal hemodynamics in patients with heart failure, 81
Beurrier D, *see* Brembilla-Perrot, 549
Biagini A, *see* Berti, 81
Binetti G, Senni M, Colombo F, Tasca G, Mamprin F, Caporale R, Ferrazzi P, Gamba A, Glauber M, Troise G, Fiocchi R. Medical treatment of end-stage heart failure, 617
Birkenhäger WH, *see* de Leeuw, 803
Bohmeke T, *see* Weber, 113
Bolner A, *see* Covi, 321
Bonfantino MV, *see* Ranieri, 119
Bonhomme Y, *see* Puchev, 331
Bonini R, *see* Berti, 81
Bonnefont-Rousselot D, *see* Lepage, 567
Borghi C, Ambrosioni E. Clinical aspects of ACE inhibition in patients with acute myocardial infarction, 519
Boucher F, *see* Pucheu, 331
Bourely B, *see* Lepage, 567
Bradamante S, *see* de Jong, 767
Bradstreet TE, *see* Byyny, 313
Bralet J, *see* Marie, 593
Breithaupt-Grögler K, Leschinger M, Belz GG, Butzer R, Erb K, deMay C, Sinn W. Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta, 49
Brékine D, *see* Berkenboom, 17, 379
Brembilla-Perrot B, Jackquemin L, Terrier de la Chaise A, Beurrier D. Programmed ventricular stimulation after myocardial infarction does not help reduce the risk of ventricular events, 549
Brilla C, *see* Rupp, 251
Bruckert E, *see* Lepage, 567
Bruner HR, *see* Katz, 189
Bühler FR, *see* Schmitt, 101
Bui-Xuan B, *see* Timour, 447
Butzer R, *see* Breithaupt-Grögler, 49
Byon YK, *see* Gasser, 185
Byyny RL, Merrill DD, Bradstreet TE, Sweet CS. An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension, 313

Caldwell RW, *see* Abou-Mohamed, 39
Caldwell RW, *see* Nagarajan, 31
Cantini F, *see* Bellandi, 153
Caporale R, *see* Binetti, 617
Carayon A, *see* Grenier, 561
Cargnoni A, *see* Ferrari, 425
Carpentier Y, *see* Berkenboom, 379
Carré F, *see* Swynghedauw, 677
Cavallo A, *see* Ranieri, 119
Ceconi C, *see* Ferrari, 425, 623, 639
Chevalier B, *see* Swynghedauw, 677
Chiariello M, *see* Napoli, 417
Cianflone D, *see* Maseri, 751
Clairambault J, *see* Swynghedauw, 677
Clercio A, *see* Berti, 81
Close P, *see* Wood, 309
Clozel J-P, *see* Schmitt, 101
Collins L, *see* Ernsberger, 275
Colombo F, *see* Binetti, 617
Comans P, *see* Khoury, 179
Confortini R, *see* Ferrari, 623
Cosselink ATM, *see* Crijns, 145
Covi G, Sheiban I, Gelmini G, Arcaro G, Tonni S, Bolner A, Piemonte G, Lechi A. Left ventricular diastolic function during adrenergic stress in essential hypertension: acute and chronic effects of ACE inhibition, 321
Crea F, *see* Maseri, 751
Crijns HJGM, Cosselink ATM, Lie KI. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study, 145
Curello S, *see* Ferrari, 623, 639

Dabizzi RP, *see* Bellandi, 153
Darpö B, Almgren O, Bergstrand R, Franzén S, Edvardsson N. Assessment of frequency dependency of the Class III effects of almokalant: a study using programmed stimulation and recording of monophasic action potentials and ventricular paced QT intervals, 539
De Cesaris R, *see* Ranieri, 119
Decrinis M, *see* Stark, 531
de Groote P, *see* Millaire, 11
de Jong JW, de Jong R, Marchesani A, Janssen M, Bradamante S. Controversies in preconditioning, 767
de Jong R, *see* de Jong, 767
de la Motte S, *see* Silke, 573
Delattre J, *see* Lepage, 567
de Leeuw PW, Birkenhäger WH. Effects of antihypertensive drugs on various aspects of renal function, 803
de Leiris J, *see* Pucheu, 331
de May C, *see* Breithaupt-Grögler, 49

De Zeeuw S, *see* Gho, 775
Dhalla K, Rupp H, Beamish R, Dhalla N. Mechanisms of alterations in cardiac muscle Ca^{2+}-transport due to excess catecholamines, 231
Dhalla K, *see* Hilderman, 247
Dhalla N, *see* Dhalla, 231
Dhalla N, *see* Hilderman, 247
Dhalla N, *see* McKnight, 239
Di Minno G, Mancini FP, Margaglione M. hemostatic variables and ischemic cardiovascular disease: Do we need a concerted effort for more profitable future clinical investigations? 743
Di Natale M, *see* Bellandi, 153
Dolan I, *see* Schwartz, 75
Dollery CM. Atlas of coronary balloon angioplasty, 91
Drake M, *see* Silke, 573
Ducloux G, *see* Millaire, 11

Eber B, *see* Gasser, 351
Eberli FR, *see* Bernstein, 167
Edvardsson N, *see* Darpö, 539
Erb K, *see* Breithaupt-Grögler, 49
Ernsberger P, Koletsky P, Collins L, Bedol B. Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent, 275
Eskildsen-Helmond YEG, *see* Gho, 775

Faucon G, *see* Timour, 447
Fei L, *see* Liu, 369
Ferrari F, *see* Ferrari, 623
Ferrari R, Cargnoni A, Bernocchi P, Gaia G, Benigno M, Pasini E, Pedersini P, Ceconi C. Effects of felodipine on the ischemic heart: insight into the mechanism of cytoprotection, 425
Ferrari R, Ceconi C, Curello S, Ferrari F, Confortini R, Pepi P, Visioli O. Activation of the neuroendocrine response in heart failure: adaptive or maladaptive process? 623
Ferrari R, Ceconi C, Curello S, Pepi P, Mazzoletti A, Visioli O. Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease, 639
Ferrario CM, Flack JM. Pathologic consequences of increased angiotensin II activity, 511
Ferrazzi P, *see* Berti, 81
Ferrazzi P, *see* Binetti, 617
Filitti V, *see* Ranieri, 119
Fiocchi R, *see* Binetti, 617
Flack JM, *see* Ferrario, 511
Fleckenstein A, *see* Gasser, 185
Fleckenstein-Grün G, *see* Gasser, 185
Fleischmann K, *see* Antman, 297
Flessa C, *see* Iliodromitis, 341
Foley JA, Becker RC. Calcium channel antagonists in the modern era of coronary thrombolysis: benefit or detriment? 403
Fontaine J, *see* Berkenboom, 17, 379
Förster W, Paratt JR. The case for lowdose aspirin for the prevention of myocardial infarction: but how low is low? 727
Franzén S, *see* Darpö, 539
Frey G, *see* Gasser, 185
Fruhwald F, *see* Gasser, 351
Fuchi T, *see* Nakamura, 475
Fujiki A, Tani M, Yoshida S, Inoue H. Electrophysiologic mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline, pilsicainide, disopyramide, procainamide) in induction of atrioventricular re-entrant tachycardia, 159
Fujita T, *see* Nakamura, 475
Furberg CD, Psaty BM. Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspective, 463

Gaia G, *see* Ferrari, 425
Gamba A, *see* Binetti, 617
Gasser R, Byon YK, Frey G, FleckensteinGrün G, Fleckenstein A. Prevention by diltiazem and verapamil of vitamin D_3-induced myocardial calcium overload in rat papillary muscle: assessment with PVC ETH-123 calcium-selective microelectrodes, 185
Gasser R, Fruhwald F, Schumacher M, Seinost G, Reisinger E, Eber B, Keplinger A, Horvath R, Sedaj B, Klein W, Pierer K. Reversal of *Borrelia burgdorferi* associated dilated cardiomyopathy by antibiotic treatment? 351
Gavish A, *see* Khoury, 179
Gelmini G, *see* Covi, 321
Genade S, *see* Moolman, 125
Gho BCG, Eskildsen-Helmond YEG, De Zeeuw S, Lamers JMJ, Verdouw PD. Does protein kinase C play a pivotal role in the mechanism of ischemic preconditioning? 775
Giboudeau J, *see* Baudin, 557
Gjesdal K, *see* Klemsdal, 5
Glauber M, *see* Binetti, 617
Godfraind T, Salomone S. Calcium antagonists and endothelial function: focus on nitric oxide and endothelin, 439
Golan Y, *see* Schwartz, 75
Grenier O, Pousset F, Isnard R, Kalotka H, Carayon A, Maistre G, Lechat P, Guerot C, Thomas D, Komajda M. Captopril does not modulate acutely plasma endothelin-1 concentration in human congestive heart failure, 561
Gros C, *see* Marie, 593
Grover S, *see* Perreault, 787
Grynberg A, Ziegler D, Rupp H. Sympathoadrenergic overactivity and lipid metabolism, 223
Guerot C, *see* Grenier, 561
Gulbis B, *see* Berkenboom, 17
Gupta VK. Does magnesium supplementation have any role in acute myocardial infarction? No, 303

Haass M, Kübler W. Nicotine and sympathetic neurotransmission, 657
Hachisuka M, *see* Nakamura, 475
Hamilton VH, *see* Perreault, 787
Hampton JR. Alternatives to mega trials in cardiovascular disease, 759
Hardouin S, *see* Swynghedauw, 677
Harrison FJ, *see* Silke, 573
Herity NA, *see* Silke, 573
Herlitz J, Bång A, Sjölin M, Karlson BW. Five-year mortality after acute myocardial infarction in relation to previous history, level of initial care, complications in hospital, and medication at discharge, 485
Heusch G, *see* Rose, 347
Heymes C, *see* Swynghedauw, 677
Hilderman T, Mcknight K, Dhalla K, Rupp H, Dhalla N. Effects of long-term dietary restriction on cardiovascular function and plasma catecholamines in the rat, 247
Hiroe M, *see* Sekiguchi, 495
Hittel N, *see* Rosenthal, 59
Hjalmarsson Å, *see* Wiklund, 361
Horowitz GL, *see* Bernstein, 167
Horvath R, *see* Gasser, 351
Hosoai H, *see* Yoshida, 67

Iaina A, *see* Schwartz, 75
Iascone MR, *see* Berti, 81
Iberg N, *see* Schmitt, 101
Ibrahim TM, *see* Abou-Mohamed, 39
Iervasi G, *see* Berti, 81
Iliodromitis EK, Papadopoulos C, Paraskevaidis IA, Kyriakides ZS, Flessa C, Kremastinos DTh. Protection from preconditioning can be reinstated at various reperfusion intervals, 341
Imamura H, *see* Kinoshita, 527
Inoue H, *see* Fujiki, 159
Inoue T, *see* Nakamura, 475
Ishikawa T, *see* Yoshida, 67
Isnard R, *see* Grenier, 561
Isobe M, *see* Kinoshita, 527
Isobe M, *see* Sekiguchi, 495

Jackquemin L, *see* Brembilla-Perrot, 549
Janssen M, *see* de Jong, 767
Jasmin G, Proschek L. Prevention by cromakalim of spontaneously occurring cardiac necroses in polymyopathic hamsters, 587
Jasson S, *see* Swynghedauw, 677
Jaudon M-C, *see* Lepage, 567

Kalotka H, *see* Grenier, 561
Karlson BW, *see* Herlitz, 485
Katz E, Nicod P, Bruner HR, Waeber B. Changes in treatment during and after hospitalization in patients taking drugs for cardiovascular diseases, 189
Kelly J, *see* Silke, 573
Keplinger A, *see* Gasser, 351
Keren A. Does magnesium supplementation have any role in acute myocardial infarction? Yes, 307
Keren A, *see* Khoury, 179
Khoury Z, Comans P, Keren A, Lerer T, Gavish A, Tzivoni D. Effects of transdermal nicotine patches on ambulatory ECG monitoring findings: a doubleblind study in healthy smokers, 179
Kinoshita M, *see* Liu, 23
Kinoshita M, *see* Nakamura, 475
Kinoshita O, Sekiguchi M, Isobe M, Takenaka H, Yazaki Y, Imamura H. Radiofrequency catheter ablation of supraventricular tachycardias in patients with hypertrophic cardiomyopathy, 527
Kiowski W, *see* Sütsch, 717
Kitada Y. Contrasting effects of betaxolol and propranolol on Ca^{2+}-activated contractions in skinned fibers from canine coronary arteries and ventricular muscles, 581
Klein W, *see* Gasser, 351
Klemsdal TO, Gjesdal K. Intermittent or continuous transdermal nitroglycerin: still an issue, or is the case closed? 5
Koletsky P, *see* Ernsberger, 275
Komajda M, *see* Grenier, 561
Kornowski R, *see* Schwartz, 75
Krauss XH, *see* Remme, 137
Kremastinos DTh, *see* Iliodromitis, 341
Krujissen HACM, *see* Remme, 137
Kübler W, *see* Haass, 657
Kuntz K, *see* Antman, 297
Kyriakides ZS, *see* Iliodromitis, 341

Lamers JMJ, *see* Gho, 775
Lamontanara G, *see* Ranieri, 119
Lau J, *see* Antman, 297
Lavoie F, *see* Perreault, 787
Lechat P, *see* Grenier, 561
Lechi A, *see* Covi, 321
Leenen FHH. 1,4-Dihydropyridines versus beta-blockers for hypertension: Are either safe for the heart? 397
Leor J, Battler A. Calcium channel blocker debate: true lies? 413
Lepage S, Bonnefont-Rousselot D, Bruckert E, Bourely B, Jaudon M-C, Delattre J, Assogba U. Antioxidant status of hypercholesterolemic patients treated with LDL apheresis, 567
Lepori M, *see* Scherrer, 215
Lerer T, *see* Khoury, 179
Leroy O, *see* Millaire, 11
Leschinger M, *see* Breithaupt-Grögler, 49
Levo Y, *see* Schwartz, 75
Li J, *see* liu, 369
Li K, Rouleau JL. altered responsiveness to endothelin-1 of myocardium from pacing-induced heart failure model in the dog, 107
Lichtlen PR. Controversies concerning calcium antagonists, 409
Lie KI, *see* Crijns, 145
Liu Q, Nakae I, Takahashi M, Takaoka A, Kinoshita M. Tilisolol hydrochloride dilates coronary arteries through an ATP-sensitive K^+-channel opening mechanism in dogs, 23
Liu P, Fei L, Wu W, Li J, Wang J, Zhang X. Effects of hypothyroidism on the vulnerability to ventricular fibrillation in dogs: a comparative study with amiodarone, 369
Lochner A, *see* Moolman, 125

McIntosh MW, *see* Antman, 297
McKnight K, Rupp H, Beamish R, Dhalla N. Modification of catecholamine-induced changes in heart function by food restriction in rats, 239
McKnight K, *see* Hilderman, 247
Maisch B, *see* Rupp, 251
Maistre G, *see* Grenier, 561
Malfroy B, *see* Pucheu, 331
Mamprin F, *see* Binetti, 617
Mancini FP, *see* Di Minno, 743
Mancini GBJ. Emerging concepts: angiotensin-converting enzyme inhibition in coronary artery disease, 609
Manfredi C, *see* Berti, 81
Mangin L, *see* Swynghedauw, 677
Mansier P, *see* Swynghedauw, 677
Marchesani A, *see* de Jong, 767
Margaglione M, *see* Di Minno, 743
Marie C, Mossiat C, Gros C, Monteil T, Bralet J. Effect of prolonged inhibition of neutral endopeptidase on cardiac hypertrophy in rats with myocardial infarction, 593
Marx D, *see* Stark, 531
Masieri A, Cianflone D, Pasceri V, Crea F. The risk and cost effective individual patient management: the challenge of a new generation of clinical trials, 751
Mazzoletti A, *see* Ferrari, 639
Medigue C, *see* Swynghedauw, 677
Merrill DD, *see* Byyny, 313
Messerli FH. Hypertension in postmenopausal women (book review), 387
Milani M, *see* Ranieri, 119
Millaire A, Leroy O, de Groote P, Santré C, Ducloux G. Usefulness of diltiazem in the acute management of supraventricular tachyarrhythmias in the elderly, 11
Moalic J-M, *see* Swynghedauw, 677
Monteil T, *see* Marie, 593
Moolman JA, Genade S, Tromp E, Lochner A. No evidence for mediation of ischemic preconditioning by alpha$_1$adrenergic signal transduction pathway or protein kinase C in the isolated rat heart, 125
Morigami N, *see* Nakamura, 475
Mossiat C, *see* Marie, 593
Myers T, *see* Nagarajan, 31

Nagarajan R, Abou-Mohamed G, Myers T, Caldwell RW. A novel catecholamine, arbutamine, for a pharmacological cardiac stress agent, 31
Nagarajan R, *see* Abou-Mohamed, 39
Nakae I, *see* Liu, 23
Nakamura H, *see* Yoshida, 67
Nakamura Y, Yamaoka O, Uchida K, Morigami N, Sugimoto Y, Fujita T, Inoue T, Fuchi T, Hachisuka M, Ueshima H, Shimakawa H, Kinoshita M, SHIga Pravastatin Study (SHIPS) Group. Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: results of SHIPS (SHIga Pravastatin Study), 475
Napoli C, Chiariello M, Palumbo G, Ambrosio G. Calcium-channel blockers inhibit human low density lipoprotein oxidation by oxygen radicals, 417
Niccoli L, *see* Bellandi, 153
Nicod P, *see* Katz, 189
Nishio E, *see* Yoshida, 67

Opie LH. Calcium channel antagonists should be among the first-line drugs in the management of cardiovascular disease, 455
Opie LH. Molecular cardiology for the cardiologist, 90
Opie LH. Seven books on heart rhythm, 89
Opie LH. The STONE Study (Shanghai Trial of Hypertension in the Elderly: a meeting report, 467
Opie LH. Two book reviews, 599
Owlya R, *see* Scherrer, 215

Palnieri C, *see* Berti, 81
Palumbo G, *see* Napoli, 417
Papadopoulos C, *see* Iliodromitis, 341
Paraskevaidis IA, *see* Iliodromitis, 341
Paratt JR, *see* Förster, 727
Pasceri V, *see* Maseri, 751
Pasini E, *see* Ferrari, 425
Pedersini P, *see* Ferrari, 425
Pepi P, *see* Ferrari, 623, 639
Perreault S, Hamilton VH, Lavoie F, Grover S. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia, 787
Piemonte G, *see* Covi, 321
Pierer K, *see* Gasser, 351

Pitt B. Effect of ACE inhibitors on endothelial dysfunction: unanswered questions and implications for further investigation and therapy, 469
Poppe H, *see* Stark, 531
Pousset F, *see* Grenier, 561
Proschek L, *see* Jasmin, 587
Psaty BM, *see* Furberg, 463
Pucheu S, Boucher F, Sulpice T, Tressalet N, Bonhomme Y, Malfroy B, de Leiris J. EUK-8, a synthetic catalytic scavenger of reactive oxygen species protects isolated iron-overloaded rat heart from functional and structural damage induced by ischemia/reperfusion, 331

Ranieri G, Filitti V, Andriani A, Bonfantino MV, Lamontanara G, Cavallo A, Milani M, De Cesaris R. Effects of isradipine sustained release on platelet function and fibrinolysis in essential hypertensives with or without other risk factors, 119
Ravani M, *see* Berti, 81
Reisinger E, *see* Gasser, 351
Remme WJ, van der Ent M, Bartels GL, van Schelven D, van Hoogenhuyze DCA, Krauss XH, Krujissen HACM, Storm CJ. Acute hemodynamic effects of preloaddependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure, 137
Richelle M, *see* Berkenboom, 379
Riegger GAJ. Role of the renin-angiotensin system as a risk factor for control of morbidity and mortality in coronary artery disease, 613
Rose J, Heusch G. Attenuation of regional myocardial stunning by felodipine, 347
Rosendorff C. Endothelin, vascular hypertrophy, and hypertension, 795
Rosenthal J, Hittel N, Stumpe KO. Pranidipine, a novel calcium antagonist, once daily, for the treatment of hypertension: a multicenter, doubleblind, placebo-controlled dose-finding study, 59
Rouleau JL, *see* Li, 107
Rouleau JL, *see* Vantrimpont, 711
Rupp H. Nutritional disorders: a target for sympathetic outflow regulating drugs--(1_1-agonists), 213
Rupp H, *see* Dhalla, 231
Rupp H, *see* Grynberg, 223
Rupp H, *see* Hilderman, 247
Rupp H, *see* McKnight, 239
Rupp H, Maisch B, Brilla C. Drug withdrawal and rebound hypertension: differential action of the central antihypertensive drugs moxonidine and clonidine, 251

Salomone S, *see* Godfraind, 439
Santré C, *see* Millaire, 11
Sasayama S. Inotropic agents in the treatment of heart failure: despair or hope? 703
Sayer JW, Timmis AD. Angiotensin-converting enzyme inhibitors and coronary artery disease, 631
Scherrer U, Owlya R, Lepori M. Body fat and sympathetic nerve activity, 215
Scheurink A, Balkan B, Strubbe J, van Dijk G, Steffens A. Overfeeding autonomic regulation and metabolic consequences, 263
Schmitt R, Clozel J-P, Iberg N, Bühler FR. Prevention of neointima formation by mibefradil after vascular injury in rats: comparison with ACE inhibition, 101
Schumacher M, *see* Gasser, 351
Schwartz D, Kornowski R, Schwartz IF, Dolan I, Weinreb B, Averbuch M, Golan Y, Levo Y, Iaina A. Prediction of renal impairment in elderly patients with congestive heart failure treated with captopril, 75
Schwartz IF, *see* Schwartz, 75
Schwartzl I, *see* Stark, 531
Sedaj B, *see* Gasser, 351
Seeling MS, *see* Antman, 297
Seinost G, *see* Gasser, 351
Sekiguchi M, Yazaki Y, Isobe M, Hiroe M. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations, 495
Sekiguchi M, *see* Kinoshita, 527
Senni M, *see* Binetti, 617
Sheiban I, *see* Covi, 321
SHIga Pravastatin Study (SHIPS) Group, *see* Nakamura, 475
Shige H, *see* Yoshida, 67
Shimakawa H, *see* Nakamura, 475
Silke B, de la Motte S, Spiers P, Herity NA, Drake M, Kelly J, Harrison FJ. Haemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters, 573
Silverman AM, *see* Bernstein, 167
Sinn W, *see* Breithaupt-Grögler, 49
Sjölin M, *see* Herlitz, 485
Spiers P, *see* Silke, 573
Stark G, *see* Stark, 531
Stark U, Stark G, Schwarzl I, Poppe H, Marx D, Decrinis M, Tritthart HA. Effects of AWD 23-111, a new antiarrhythmic substance, on cardiac conduction and refractoriness, 531
Steffens A, *see* Scheurink, 263
Storm CJ, *see* Remme, 137
Strubbe J, *see* Scheurink, 263
Stumpe KO, *see* Rosenthal, 59
Sugimoto Y, *see* Nakamura, 475
Sulpice T, *see* Pucheu, 331
Sung RJ, *see* Yu, 687
Sütsch G, Bertel O, Kiowski W. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans, 717
Suzukawa M, *see* Yoshida, 67
Swedberg K, *see* Wiklund, 361
Sweet CS, *see* Byyny, 313
Swynghedauw B, Jasson S, Chevalier B, Clairambault J, Hardouin S, Heymes C, Mangin L, Mansier P, Medigue C, Moalic J-M, Thibault N, Carré F. Heart rate and heart rate variability, a pharmacological target, 677

Takahashi M, *see* Liu, 23
Takaoka A, *see* Liu, 23
Takenaka H, *see* Kinoshita, 527
Tani M, *see* Fujiki, 159
Tasca G, *see* Binetti, 617
Tatsukawa Y, Arita M. Effects of KT-362, a sarcolemmal and intracellular calcium antagonist, on calcium transients of cultured neonatal rat ventricular cells: a comparison with gallopamil and ryanodine, 667
Taylor SH, *see* Weber, 113
Terrier de la Chaise A, *see* BrembillaPerrot, 549
Thadani U. Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure, 735
Thibault N, *see* Swynghedauw, 677
Thomas D, *see* Grenier, 561
Timmis AD, *see* Sayer, 631
Timour Q, Bui-Xuan B, Faucon G, Aupetit J-F. Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia, 447
Tonni S, *see* Covi, 321
Tressalet N, *see* Pucheu, 331
Tritthart HA, *see* Stark, 531
Troise G, *see* Binetti, 617
Tromp E, *see* Moolman, 125
Tzivoni D, *see* Khoury, 179

Uchida K, *see* Nakamura, 475
Ueshima H, *see* Nakamura, 475
Unger P, *see* Berkenboom, 17, 379

van der Does R, *see* Weber, 113
van der Ent M, *see* Remme, 137
van Dijk G, *see* Scheurink, 263
van Hoogenhuyze DCA, *see* Remme, 137
van Schelven D, *see* Remme, 137
Vantrimpont P, Rouleau JL. Medical treatment of heart failure: the Canadian Cardiovascular Society's Consensus Conference revisited, 711
van Zweiten P. Modulation of sympathetic outflow by centrally acting antihypertensive drugs, 283
van Zweiten PA. Current and newer approaches in the drug treatment of congestive heart failure, 693
Verdouw PD, *see* Gho, 775

Visioli O, *see* Ferrari, 623, 639

Waagstein F, *see* Wiklund, 361
Waeber B, *see* Katz, 189
Wang J, *see* Liu, 369
Weber K, Bohmeke T, van der Does R, Taylor SH. Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients, 113
Weinreb B, *see* Schwartz, 75
Wiklund I, Waagstein F, Swedberg K, Hjalmarsson Å. Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC Trial, 361
Wood JM, Close P. Renin inhibitors: cardiovascular drugs of the future? 309
Wu W, *see* Liu, 369

Yamaoka O, *see* Nakamura, 475
Yazaki Y, *see* Kinoshita, 527
Yazaki Y, *see* Sekiguchi, 495
Yellon DM. Cardiac SPECT imaging, 91
Yoshida H, Suzukawa M, Ishikawa T, Shige H, Nishio E, Hosoai H, Ayaori M, Nakamura H. Effects of beta-blockers on HMG CoA reductase and LDL receptor activity in cultured human skin fibroblasts, 67
Yoshida S, *see* Fujiki, 159
Yu JCL, Sung RJ. Clinical efficacy of propantheline bromide in neurocardiogenic syncope: pharmacodynamic implications, 687

Zhang X, *see* Liu, 369
Ziegler D, *see* Grynberg, 223

Subject Index

A23187, cyclosporine and coronary endothelial function, 17, 18, 20
A-81988, 514
Ablation
  fast pathway, 529
  slow pathway, 528, 529
Ablation techniques, catheter, to cure ventricular tachycardias, 164–165
Acebutolol
  after MI, 95% confidence intervals and point estimates for relative risk reduction, late-entry trials, 763
  APSI study of, 761
Acetylcholine, 264, 611, 632, 658, 691, 776
  C_x-induced vascular toxicity and fish oil, 380, 381, 382
  intracoronary administration to assess quinapril effect, 469, 470
Acetylcholine-induced contractions, cyclosporine and coronary endothelial function, 17–21
Acetylcholine-induced relaxations, 379, 381, 383
Acetylsalicylic acid, 528, 715
  risk indicators for death after AMI, 485, 486, 487, 489
Acidosis, 111, 297, 332, 662, 767, 769
Acrylamide gel electrophoresis, of low density lipoprotein, 418, 419, 421
Action potential plateau, 537
Action potentials, 587, 590, 658
  almokalant and, 544
  blockade of shortening, 776
  KT-362 and Ca^{2+} transients, 667–674
  spontaneous activity and, 678, 682
  vesnarinone and, 705
Acute Infarction Ramipril Efficacy (AIRE) study, 520, 521, 635, 642, 712, 754, 761
Acute myocardial infarction (AMI), 632
  ACE inhibitors and, 519–524, 639–642
  calcium antagonist use, 167, 409–411, 455–459, 464
  catecholamine release after, and arrhythmias, 244, 245
  magnesium supplementation role, 297–300, 303–304, 307
  risk indicators for death after, 485–489
Acyl coenzyme A cholesterol acryltransferase (ACAT), 68
Adalat CC, safety documentation for SR in hypertension, 464
Adams-Stokes syndrome, 502
Adenosine, 125, 611, 679, 776
  and catecholamines, 767–768
  and glycolysis, 769
  relationship with prostacyclin, 730
  triggering activation of protein kinase C, 767–768, 771
Adenosine A_1- antagonist, 771
Adenosine A-1 receptor, 125, 770, 775, 778
Adenosine deaminase, 41
Adenosine diphosphate (ADP), 704
  myocardial infarction for, 728, 732
Aenosine diphosphate-Adenosine triphosphate (ADP-ATP) carrier, 704
Adenosine nucleotide translocase, 768
Adenosine receptors, preconditioning, 345
Adenosine triphosphate (ATP), 728, 732, 769, 771
  amiodarone effect on, 376
  felodipine and cardiac protection, 425–427, 428, 430–435
  felodipine effect on content, 174, 175, 176
  levels and heart failure, 704
  mitochondrial Ca^{2+} overload, 234
ATPase
  involvement in preconditioning, 767, 768
  sarcolemmal Ca^{2+}-stimulated, 232
ATPase inhibitor (IF_1), 768
Adenylate cyclase, 703
  /cAMP pathway, 730
  endothelium-1 response in failing myocardium, 107
  isoform content, 678
Adenylcyclase, stimulation by isoprenaline, 624
Adenylyl cyclase, inhibition of, 513
Adibendan, 699
Adipocyte beta$_3$-adrenergic receptors, 36, 39, 42–46
Adipocytes
  hamster brown, arbutamine effect, 39, 43, 44, 45
  rat white, arbutamine effect, 39, 43, 44, 45
Adiposity, obesity and autonomic regulation, 263, 267–268, 269–270
Adrenal cortex, endothelial receptors in, 795
Adrenal glands, 298
  angiotensin receptors, 512
Adrenal medulla, nicotine and, 657, 658
Adrenergic neuromuscular terminals, 691
Adrenergic receptors, arbutamine activity, 39–46
Adrenergic stress, diastolic function and angiotensin II in hypertension, 321–328
Adrenergic tone, 691
Adrenergic transduction system, myocardial, 677, 679–680, 683
Adrenoceptor antagonists, calcium ion transport systems, and excess catecholamines, 231, 236, 237
Adrenoceptors, calcium ion transport systems, and excess catecholamines, 231, 236, 237
Adrenochrome, 235
Adverse effects, class I drugs on supraventricular tachycardia, 159–165
Affinity constants, of arbutamine and isoproterenol, 39
Afro-Americans, cardiac sarcoidosis incidence, 496
After contraction, 674
Afterdepolarization, 674, 705
Afterload, 635
Agarose gel electrophoresis, 418, 419, 420, 422
Age
  as factor in cardiac sarcoidosis, 496
  risk indicators for death after AMI, 485, 487, 488, 489
Aging, associated with heart response to adrenergic stimulation, 225
Agmatine, 287
Agonists
  nicotinergic, 658, 659
  parasympathetic, 679
  sensitivity, 658
AH 23848, 729
AH intervals, 528, 532, 533, 534
AIRE trial. *See* Acute Infarction Ramipril Efficiency study
Albumin, 570
Albuminal release, 799
Albumin excretion, urinary, 806–807
Alcohol, 745
Aldosterone, 7–8, 806
  ACE inhibitors in CAD patients, 641
  captopril and renal impairment, 78
  enoximone effect on renal and systemic hemodynamics, 83, 85–86
  in heart failure, 625, 626
  plasma levels of, 694, 698
  release of, 696, 697, 698
  secretion stimulated by sodium deprivation, 619
Aldosterone receptor antagonist, 694
Alinidine, 682
ALLHAT trial. *See* Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial
Almokalant, frequency-dependent effects of, 539–546
Alpha adrenergic alteration, 374, 376

Alpha-adrenergic blockers, 561, 804, 805
Alpha-adrenergic tone, beta-blockers and, 67
α-adrenoceptor mechanisms, 264, 266, 270
α-adrenoceptor-mediated increase, 657, 663
α-blockers, 804, 806
  renal hemodynamics and, 804
α-granules, 404
α-methyl-DOPA, 399, 713
  chemical stucture, 286
  safety during pregnancy, 286
  and sympathetic outflow, 283–288
α-methylnoradrenaline, 283, 284, 286, 287
α-myosin heavy-chain gene, 679
α-receptors, cardiac, 397, 400
α-tocopherol, 568
α_1-adrenergic agonists, 778, 795, 799
  in congestive heart failure, 111
  vascular hypertrophy in hypertension, 795
α_1-adrenergic receptors, 800
α_1-adrenergic signal transduction, 125–134
α_1-adrenoceptor agonists, 796
α_1-adrenoceptors, 695, 767, 768
  metoprolol vs. carvedilol in hypertensive patients, 113, 116
α_1-blockers, coronary artery disease and, 397, 399
α_1-receptors, 796
α_2-adrenergic receptors, 280
  and I_1-receptor agonists, 214
α_2-adrenoceptors, 251, 259, 260, 261, 659, 805
  centrally acting antihypertensives and sympathetic outflow, 283–288
  drug therapy and, 696, 697
  presynaptic inhibitory, 662
α_2 globulin, 632
α_2 receptor, mediated norepinephrine release
  dobutamine effect on, 37
  rebound hypertension and central acting drugs, 251–261
Alprenolol, after MI, 95% confidence intervals and point estimates for relative risk reduction, early-entry and late-entry trials, 762, 763
Alteplase (rtPA), 759, 760
Ambulatory treatment, cardiovascular disease treatment changes, 189–191
American College of Cardiology, 694
  American Heart Association Guidelines for the Evalaution and Management of Heart Failure, 712
  44th Annual Scientific Sessions, 712
  45th Annual Scientific Session of, 711, 713, 714
  meeting, March 1996, 705
American Heart Association in Anaheim, November, 1995, 409
Amiloride, 694
Amino-acid peptides, 795
Amino acids, 570, 658
  carboxyl-terminal, 795
Aminopeptidases, 512
Aminophylline, 770
Amiodarone, 550–555
  as CHF treatment, 561, 562
  cytotoxic concentrations, 559
  for dilated cardiomyopathy, 352
  for heart failure treatment, 711, 714, 715
  hypothyroidism and ventricular fibrillation, 369–376
  maintenance rates of sinus rhythm in studies, 149–150
  restoring sinus rhythm in atrial fibrillation patients, 156
Amino peptidases, 512
AMIS trial. *See* Aspirin Myocardial Infarction Study Research Group
Amlodipine, 397, 398, 399, 400, 410, 698, 712
  alone and with beta-blocker vs. diltiazem alone and with nitrate, 411
  alone or plus atenolol, 411
  classification and physiologic properties, 404
  for angina or arterial hypertension with systolic left ventricular dysfunction, 713
  for mild hypertension, 459
  heart failure study, 458
  in ALLHAT study, 411
  in PRAISE study, 411
  in PREVENT study, 411
  ischemic ventricular fibrillation and, 447–453
  safety documentation for SR in hypertension, 464
  vs. elgodipine, 578
Ampicillin, before tilisolol in canine coronary circulation study, 24
Amrinone, 620, 699, 704, 706
  effect on renal function or hemodynamics, 86
  vs. nanterinone, 142
Analog scales, 362
Analysis of variance (ANOVA), 568, 653, 669
Anchor proteins, 776
Anemias, clinical trials for treatment of, 752, 757
Anesthesiology, cardiac, drug therapy and, 699
Aneurysmectomy, 551
Angiitis, granulomatous, 501
Angina pectoris, 599
  ACE inhibitors effect, 640
  amlodipine treatment for, 713
  beta blocker effect on, 73
  calcium antagonists for treatment, 403, 455–459, 465, 466
  captopril effect, 471
  effort, 23
  effort, calcium antagonists for treatment, 455, 456, 458, 459
  effort, nitroglycerin effect in delay or prevention of, 599
  elgodipine hemodynamics during rest and exercise, 573, 574, 575, 578, 579
  felodipine treatment for, 713
  "hospitalized," 398
  hyperventilation-induced, 457
  major cause of, 23
  mega-trials, 759
  mild effort, 409
  mixed, 457
  nifedipine-induced, 398
  nitrates for heart failure, 712
  nocturnal attacks, 7, 8, 9
  partial drug therapy compliance and, 400
  pranidipine in hypertension, 59–66
  preinfarction, and preconditioning, 770
  rebound, 735
  recurrent, 550
  risk indicators for death after acute myocardial infarction, 485
  short-acting dihydropyridines and, 397, 398
  smoking effect on frequency of, 182, 183
  stable chronic, 398, 399
  stable, low-dose aspirin for prevention of myocardial infarction, 727, 728, 729, 731, 732
  stable, and nitrate tolerance and rebound, 735–741
  transdermal nitroglycerin therapy, 5–9
  transitory rest, 457
  true unstable, 457
  unstable, 398, 413–414, 457, 634–635, 643, 747, 751
  unstable, ACE inhibition and risk of, 610
  unstable, and aspirin therapy, 727, 728, 731, 732
  unstable, calcium antagonists and, 404
  unstable, diltiazem vs. nitroglycerin, 455, 456, 457
  unstable, enalapril and development of, 613
  unstable, hyperlipidemia and, 788
  unstable, mechanism responsible for, 739
  unstable, and nitrate tolerance and rebound, 735–741
  unstable, percentage reduction of risk, 756
  unstable, pravastatin study, 479
  variable threshold, 457
  vasoconstrictive, 456–457
  vasospastic, 410, 456–457
  vasospastic, smoking and, 663
Angina Prognosis Study in Stockholm (APSIS), 456, 458, 459, 461
Angioedema, 514, 515
Angiographic ejection fraction, 561

Angiographic ventriculography, *Borrelia burgdorferi* cardiomyopathy, 353
Angiography, 561, 633, 634
  CAD, 635
  to confirm dilated cardiomyopathy, 352
Angioneurotic edema, 310
Angioplasty. *See* Percutaneous transluminal coronary angioplasty
Angiotensin
  endothelin and vascular hypertrophy, 795–800
  -mediated efferent vasoconstriction, 805
  renal hemodynamics and, 804, 805
Angiotensin-converting enzyme (ACE), 511, 512, 514, 515
  activity, neutral endopeptidase prolonged inhibition effect, 594–596
  blockade of, 806
  serum determination and cardiac sarcoidosis, 497
  synthesis, induced in hypertension, 640
Angiotensin-converting enzyme gene, 613–615, 639
  D allele, 614, 632
Angiotensin-converting enzyme gene deletion polymorphism (ACE/ID), 614–615
  RAS as risk factor for myocardial infarction in coronary artery disease, 613–615
Angiotensin-converting enzyme genotype, 631, 633
Angiotensin-converting enzyme inhibitor (ACE-I), 21, 561, 563, 564
  and acute myocardial infarction, 519–524, 754
  antiatherogenic effect, 635, 641
  antiinflammatory effect, 633
  antiplatelet effect, 631, 635
  antiproliferative effects, 635
  aortic stiffness and, 50, 51, 56
  captopril and plasma endothelin-1 concentration modulation, 561–564
  captopril and renal impairment, 75, 78
  cardioprotective effect in coronary heart disease, 639–643
  cardioprotective effects, 609, 639–643
  cardiovascular disease treatment changes, 189–191
  CCB controversy and, 410
  cilazapril for antihypertensive therapy, 49–56
  and coronary artery disease, 397, 399, 609–611, 631–636
  delapril, 464
  diastolic function, adrenergic stress, and angiotensin II in hypertension, 321–328
  drug treatment of heart failure, 693, 694, 695, 696
  EDNO-mediated effects potentiated by, 383
  effect on endothelial dysfunction, 469–471
  effect on fibrinolysis and platelet functions, 122
  effect on neointima formation, 101–104
  effects after PTCA, 475, 477, 479
  enoximone effect on renal and systemic hemodynamics, 86
  as first-line treatment for CHF, 695, 697–698
  following myocardial infarction, 761
  for dilated cardiomyopathy, 352, 354, 358
  for end-stage heart failure, 617–620
  for heart failure, 624, 625–626
  for heart failure, recommended treatment by CCS, 712
  in non-insulin-dependent diabetics, 459
  long-term therapy, 514, 515
  losartan vs. enalapril safety and efficacy, 313–319
  mortality risk, 464, 466
  nanterinone hemodynamic effects in heart failure, 137–143
  non-sulfhydro-containing, 471
  PROFILE study outcomes, 713
  renal hemodynamics, 804, 805, 806, 807
  risk indicators for death after, 486, 487, 489
  sulfhydro-containing, 471
  to counteract nitrate tolerance mechanisms, 735, 738, 740, 741
  to reduce thrombotic coronary events, 405
  vasculoprotective effects, 609–610
  vs. calcium channel blockers, 414
  vs. renin inhibitors, 309–312
  with bosentan, 717, 721–722, 723
  with nitroglycerin patch therapy, 7
Angiotensin-converting enzyme I (ACE I), 696
Angiotensin I (AI), 309, 511, 512, 514–515, 563, 631, 632
  converted to angiotensin II, 471, 610
Angiotensin-(1–7)(A1–7)heptapeptide, 511, 512, 515
Angiotensin II (AII, AngII), 309, 311, 405, 561–564, 631–634, 778, 795–796
  and ACE inhibition, 610
  ACE levels regulated, 640, 641
  AMI and, 519, 522
  antagonism, 515
  bosentan effect, 719, 722–723
  captopril and renal impairment, 75, 77, 78
  concentration level in initial stages of heart failure, 625, 626
  and diastolic function, adrenergic stress in hypertension, 321–328
  endothelin release and, 795, 797–800
  formation affected by ACE inhibitors, 469–470, 471
  formation prevented by cilazapril, 104
  HRV and, 678
  hypertension and, 511–516
  inhibition of tissue production, 328
  mechanisms for influencing morbidity and mortality in coronary artery disease, 614
  neutral endopeptidase prolonged inhibition effect, 593, 596
  patient specific differences, 631
  plasma concentration, 563, 564
  receptor blockade, 515, 633
  renin-angiotensin system role as risk factor in coronary artery disease, 613–615
  stimulation of endothelin release, 445
  transient natriuresis and, 806
Angiotensin II antagonists, 514–515
  vs. renin inhibitors, 309, 310, 311
Angiotensin II-mediated coronary vasoconstriction, 635
Angiotensin II receptor antagonists, 697–698, 712
  losartan safety and efficacy, 313–319
  vs. renin inhibitors, 309–312
Angiotensin II receptors, 310, 311
  ACE inhibition effect on, 609, 610
  drug treatment of heart failure, 693–700
Angiotensin-(2–7), 512
Angiotensin II (AII)-receptor subtypes, 511–516, 697, 698
  type 1 (AT_1), 796, 798
  type 1a (AT_{1a}), 512
  type 1b (AT_{1b}), 512
  type 2 (AT_2), 511–516
Angiotensin II-specific receptor blockers, 515
  type 1 (AT_1), 512, 514
  type 2 (AT_2), angiotensin mechanisms in hypertension, 511–516
Angiotensin III, 512
Angiotensin-(3–7) pentapeptide, 512
Angiotensin IV, 512
  Angiotensin-(3–8), 512
Angiotensinogen, 309, 511, 512, 514, 632
Angiotensin peptides, 511, 512, 516
Angiotensin receptor antagonists, 806
Angiotensin-receptor blockers, hypertension and, 511–516
Angiotensin system, extrarenal, 513
2,5-anhydromannitol (2,5 AM), 265
Animal
  adrenergic activities of arbutamine, 39–46
  models for obesity, obesity and autonomic regulation, 263–271
Anipamil, 433
Anorexia nervosa, 244, 626
  long-term dietary restriction effects on heart function, 247
ANOVA test. *See* Analysis of variance
Anoxia, 660, 662

/reoxygenation on brain hippocampal slices, 338
Antagonist sensitivity, 658
Anterograde conduction, 529
Antiadrenergic drugs, 806
Antialdosterone drugs, with diuretics, 617, 618, 619, 620
Antiarrhythmia strategies, calcium antagonists and, 403
Antiarrhythmic drugs, 527, 536, 537, 688, 752, 762
adverse effects in induction of atrioventricular re-entrant tachycardia, 159–165
cardiovascular disease treatment changes, 189–191
Class I, 15, 536, 537, 549–552, 554, 555
Class 1a, 550
Class 1c, 537, 550
Class II, 549, 551
Class III, 369, 376, 531, 536–537, 549, 551, 554
Class III, frequency-dependent effects of almokalant, 539–546
for end-stage heart failure, 617, 621
for heart failure therapy, 711, 714
intravenous propafenone for recent onset atrial fibrillation, 153–156
KT-362, 667
programmed ventricular stimulation, 549–555
risk indicators for death after, 486, 487
with bosentan for chronic heart failure, 718
Antiarhythmic effect
of lower doses of aspirin, 730
type III, 714
Antiarrhythmic therapy, 677, 683
Antiarrhythmic therapy (book review), 89–90
Antibiotics
clinical trials determining risks involved, 752, 757
polymyxin B, 134
reversal of *Borrelia burgdorferi*, 351–358
Anticholinergic agents, 687, 688, 691, 692
side effects, 691
Anticoagulants, 747, 752
for end-stage heart failure, 617
for heart failure therapy, 711, 715
oral, cardiovascular disease treatment changes, 189–191
risk indicators for death after AMI, 485, 486, 487
Anticytokine, 707
Anti-ET (endothelin-1) antibody, 562
Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 399, 410, 411, 643
Antihypertensive drug therapy, 397, 399, 400, 511, 514, 515, 747, 795, 800
aortic stiffness and, 49–56
beta$_1$-selective blockers as, 67
drug classes, 805, 807
first-line approach, 400
long-term treatment, 410
partial compliance, 400
pranidipine in hypertension, 59–66
renal function and, 803–807
second line approach, 400
strategies, 405
third line approach, 400
Antiischemic activity, 697
Antiischemic drugs, long-term treatment, 410
Anti-murine TNF-α antibody, 706
Antimuscarinic effects, 691
Antinatriuresis, endothelin-1 induced, 720
Antiobesity effect, selective, 279, 280
Antioxidants
ACE inhibitor effect on defense mechanisms, 470
calcium channel blockers effects against free radical injury, 418, 422
and LDL apheresis, 567–571
Vitamin E protective effects, 234, 236, 237
Antiphospholipid antibodies, 746
Antiplatelet agents, 303, 475, 477, 479, 523, 743–747, 752
in meta-analyses, 760
low-dose aspirin for prevention of myocardial infarction, 727–733
Antiplatelet Trialists' Collaboration, 727, 731–732
Antiproliferative mechanisms, 514, 515
Anti-thrombotic effects, 706
Anti-tumor necrosis factor-α antibody, 627
Aorta
bovine, 559
endothelial cells, 798, 799
Aortic impedance, 599
Aortic stenosis, 679
Aortic stiffness, and antihypertensive therapy, 49–56
Apolipoprotein A-1 (Apo A-1), 730–731
Apolipoprotein B (Apo B), 569
/E receptor, 568
-containing antibodies, 569
Apolipoprotein B$_{100}$, evaluation on acrylamide gel electrophoresis, 417, 419, 421, 422
APSIS trial. *See* Angina Prognosis Study in Stockholm
Arachidonate, 380
Arachidonic acid, 223–227, 727
fatty acid profile altered, 232
sympathoadrenergic overactivity and lipid metabolism, 223
Arbutamine
adrenergic activities of, 39–46
chemical structure of, 32, 40
concentration-response curves, 42
interactions, 39
as pharmacological cardiac stress agent, 31–38
relative potency, with isoproterenol considered as unity, 45
Area under the curve (AUC), 563
L-arginine, 18, 19
Arginine vasopressin (AVP), 699, 795, 797
CHF and, 561
Arotinolol, vs. tilisolol in canine coronary circulation, 23–29
Arrhythmia-conduction disturbance type of cardiomyopathy, 497
Arrhythmias
abnormal conduction tissue and, 536
amiodarone and, 369, 557
antiarrhythmic agents and, 527
benign, 683
calcium antagonists and, 403, 404
calcium channel blockers and, 410
cardiac, 372
cardiovascular disease treatment changes, 189–191
cardiovascular safety of nicotine patches, 179–183
diltiazem in supraventricular tachyarrhythmias, 11, 12
epinephrine effects on heart function after food restriction, 240, 241, 243, 244, 245
epinephrine-induced, 674
HRV and, 677, 679, 682
intravenous propafenone for recent onset atrial fibrillation, 153–156
and isoproterenol use, 39
magnesium in acute myocardial infarction, 297, 298
malignant, 527
ouabaine-induced, 674
potassium-shift related ischemic, 303
propafenone treatment, 145
reentrant, 528
respiratory, HRV and, 678
sinus, 532
smoking as cause of, 179, 663
supraventricular, 557
symptomatic, and amiodarone treatment, 714
thromboxane effect on, 728
tilisolol in canine coronary circulation, 28
treatment costs, 789
ventricular, 373–376, 527–529, 549, 557, 621, 674, 762
ventricular, ACE inhibitors effect on, 519, 640
ventricular, amiodarone suppressing of, 714
ventricular, epinephrine injections and diet restrictions, 239, 243
ventricular, HRV and, 680
ventricular, ischemia-induced, 728–730
ventricular, LVH and, 399
ventricular malignant, and cardiac sarcoidosis, 497, 501, 502, 503
ventricular, PDE inhibitors and, 704

ventricular, reperfusion-induced, 730, 776
ventricular, spontaneous Lown grade IVa, 551
ventricular, symptomatic, 714
Arrhythmic death, amiodarone treatment endpoint in trial, 714
Arrhythmic events, 549, 552, 553, 555
prevention of, 549
Arrhythmogenesis, 369, 374, 400, 545
Arrhythmogenic effects, 704
Arterial baroreceptor reflex, 283, 284, 285
Arterial baroreflex, 400
Arterial distensibility, aorta, pressure standardized index of, 49–56
Arterial injury, intimal proliferation and hypertrophy, 633–634
Arterial lesions, 451
Arterial mean pressure (MAP), 805
aortic stiffness and antihypertensive therapy, 51, 52, 54, 55
Arterial permeability, 633
Arterial pressure, bosentan effect, 720, 722, 723
Arterial vasodilation mechanisms therapy (book review), 599
Arterial wall inflammatory response, 746
Arteriolar compliance, 513
Arteriolar constriction, efferent, 513
Arteriolar dilation, 632
Arteriolar resistance, efferent, 804
Arterioles, afferent, 807
Arteritis, 501
ASIST study. *See* Atenolol Silent Ischemia study
Aspirin, 299, 405, 747
cumulative mortality and reinfarction rate after MI, 731
low-dose, for prevention of myocardial infarction, 727–733
mortality/morbidity and, 519, 524
pharmacokinetic effects, 729
risk indicators for death after AMI, 485, 486, 487, 489
risk involved in use of, 751, 756
treatment for unstable angina, 739
vs. clopidogrel, 760
with captopril, 76
Aspirin Myocardial Infarction Study (AMIS) Research Group, 760
Assessment of Treatment with Lisinopril And Survival Trial (ATLAS), 619
ASSET study, 759
Atenolol, 398, 400, 689, 805
after MI, 95% confidence intervals and point estimates for relative risk reduction, early-entry trials, 762, 763
aortic stiffness and, 54, 56
effect on Ca^{2+}-activated contractions in skinned fibers, 581, 583, 585
vs. nifedipine for effort angina, 455, 456
with amlodipine, 411
with hydrochlorothiazide, 411
with nifedipine, 411
Atenolol Silent Ischemia Study (ASIST), 456
Atherectomy, 642, 643
Atherogenesis, 634, 663
Atheroma, 610, 611
Atherosclerosis, 17, 73, 663, 743–747, 795, 800
angiotensin-converting enzyme genotype and, 631–636
angiotensin-converting enzyme inhibition, 609–611
ACE inhibitor cardioprotective effect, 639, 641
ACE inhibitor studies, 642
aortic stiffness, 50
beta blockers and, 67
calcium-channel blockers and LDL, 417–422
as common factor in CAPRIE trial, 760
coronary, calcium antagonists and, 404
coronary, gemfibrozil therapy effect, 792
endothelin role in, 445
LDL oxidation and, 567
and low-dose aspirin therapy, 728, 729, 731
progression studied in PREVENT study, 411
promoted by sympathetic activation, 219
regression, as mechanism, 481
renin-angiotensin system influence on process, 614
short-acting dihydropyridines and, 398
stages, 743, 745
TREND and ACE inhibitors, 469, 470, 471
vascular alterations, produced by cyclosporine similar to, 379, 384
Atherosclerosis Risk in the Communities, 747
Atherosclerotic plaque formation, 634
Atherosclerotic process, 631
Atherosclerotic stenosis, 23
Atherothrombosis, 747
ATLAS trial. *See* Assessment of Treatment with Lisinopril and Survival Trial
Atomic absorption spectroscopy (AAS), vitamin D_3-induced calcium overload, 185
Atrial effective refractory period (A-ERP), 532–537
Atrial fibrillation, 403, 528
anticoagulant treatment recommended, 715
and cardiac sarcoidosis, 498
digoxin as initial agent, 711
diltiazem in supraventricular tachyarrhythmias, 11–15
intermittent, 410
intravenous propafenone for recent onset, 153–156
propafenone and ventricular rate, 148–149
propafenone vs. disopyramide for sinus rhythm maintenance, 145–151
quinidine therapy, 151
Atrial Fibrillation for the Clinician (book review), 90
Atrial Fibrillation. Mechanisms and Therapeutic Strategies (book review), 90
Atrial fibrillation: State of the Art (book review), 90
Atrial flutter
diltiazem in supraventricular tachyarrhythmias, 12
propafenone vs. disopyramide for prevention of arrhythmia relapses, 145
Atrial natriuretic factor, neutral endopeptidase prolonged inhibition effect, 593–596
Atrial natriuretic peptide (ANP), 502, 564
activated in heart failure, 623–624, 626
CHF and, 561
degradation inhibitors, 693, 697, 698
enoximone effect on renal and systemic hemodynamics, 81–82, 85–86
Atrial pacing, 31
Atrial receptors, 678, 683
Atrial stimulation, 528
Atrial tachycardia, diltiazem in supraventricular tachyarrhythmias, 12, 13
Atrioventricular block. *See* Heart block
Atrioventricular (AV) conduction disturbances, 11
Atrioventricular conduction time (AVCT), 531–537
Atrioventricular effective refractory period (AVN-ERP), 532–536
Atrioventricular nodal conduction, 532, 533, 535, 537
Atrioventricular nodal refractory period, 691
Atrioventricular node, 531, 537
re-entrant tachycardia, 527, 529
Atrioventricular pathways, 527, 528, 529
Atrioventricular reentrant tachycardia (AVRT), class I drugs adverse effects, 159–165
Atropine
added for dobutamine stress echocardiography, 37
as anticholinergic agent, 687, 691
aortic stiffness and, 50
heart rate and, 678, 680–682
to suppress early insulin response, 265
Atypical protein kinase C isotypes (aPKC's), 778
Autoantibodies, 704, 743
Autocoids, 728
antiproliferative, 514

nitric oxide, 439, 442
Automatic implantable cardiovascular defibrillator (AICD), 501
Automaticity, 705
Autonomic dysfunction, 705
Autonomic nervous system (ANS)
autonomic functioning, and metabolic consequences in hyperphagic rats, 267–270
disorders, 681, 682
energy substrate homeostasis, 264–266, 270
neurons, 658
obesity and autonomic regulation, 263–271
role of and HRV, 678–680
suppression of reflex tachycardia triggered by vasodilation, 283, 284
Autonomic tone, 405, 691
digitalis effect, 618
AWD 23–111[N-(dicyclohexyl-carbamoylmethyl)-N-(3-diethylamino-propyl)-4nitrobenzamid hydrochloride], electrocardiological effects of, 531–537

Bacterial toxins, 743
Balloon injury, 631, 633, 634
myointimal proliferation reduced by calcium channel blockers, 417
Bamiphylline, 770
Baroreceptor reflexes, 513, 679
Baroreceptor reflex mechanism, cardiac glycosides and, 695
Baroreceptor reflex tachycardia, 288
Baroreceptors, arterial and atrial, 624, 626
Baroreflex, 678
HRV and, 678, 679
Basal lamina layering (BLL), 499–500
Basal metabolic rate, and skeletal muscle metabolism, 220
Basic fibroblast growth factor (bFGF), 798
Basophils, 421
Bazett's formula, 154
BE-2254, 133
Bedfont Model EC50 microsmokerlyzer, 180
Behavioral supportive therapy, cardiovascular safety of nicotine patches, 179–183
Belladona, 687
Benazepril, 696
Benzimidazole pyridazine, 706
Benzothiazepines, 404, 439
controversies, 410
Bepridil, 404, 581, 585
vs. felodipine, 174, 175–176
Beta-adrenergic agonists, 561, 624
Beta adrenergic alteration, 374, 376
Beta-adrenergic drugs, 590
Beta-adrenergic receptor agonist, 704
Beta-adrenergic receptors
adrenergic mechanisms and food restriction, 239–246
arbutamine as cardiac stress agent, 37–38
endothelin-1 response in failing myocardium, 107
inotropic agents in heart failure, 703–707
Beta-adrenergic signal transduction pathway, 133
Beta-adrenoceptor agonists, drug treatment of heart failure, 693–696
Beta-adrenoceptor antagonists, 697, 700; *see also* Beta-blockers
Beta-adrenoceptor mechanisms, 264, 270
Beta-adrenoceptors
drug treatment of heart failure, 693–700
mediated heart rate increase, 657, 663
Beta agonists, isoproterenol, and excess catecholamine damage, 231
Beta-blockers, 298, 376, 502, 624, 697, 752, 806; *see also* Beta-adrenoceptor antagonists
after myocardial infarction, 759–761
after myocardial infarction, 95% confidence intervals for early-entry trials, 762
angiotensin mechanisms, 514–515
antiarrhythmic agents and, 543, 545
antihypertensive treatment effect on fibrinolysis and platelet functions, 119, 122
captopril test exclusion, 561
cardiovascular disease treatment changes, 189–191
CCB controversy and, 410
concomitant antianginal therapy with nitroglycerin patches, 5, 7
diastolic function indices improved, 328
diuretics with calcium antagonists, 464, 466
drug treatment of heart failure, 693, 700
effects on HMGCoA reductase, 67–73
esmolol, 15
for angina pectoris, 414, 574
for effort angina, 456
for elderly, 455
for end-stage heart failure, 617, 620
for heart failure therapy, 711, 713–715
for unstable angina, 455
heart rate and, 678
in pravastatin study, 477
"late" blockade, 761
metoprolol and quality of life in heart failure, 361–367
metoprolol vs. carvedilol in hypertensive patients, 113–117
mortality/morbidity and, 519, 523
postinfarct, not cost-effective, 455
programmed ventricular stimulation and, 550–554
renal hemodynamics and, 804, 805, 807
risk indicators for death after AMI, 485–489
tilisolol in canine coronary circulation, 23–29
vs. calcium antagonists, 464, 466
vs. calcium antagonists for cardiovascular disease, 455–459
vs. calcium channel blockers, 414
vs. 1,4-dihydropyridines for hypertension, 397–401
vs. nifedipine, 464
with amlodipine, 411
with nifedipine, 413
with nitroglycerin patches, 740
Beta-blocker therapy, alternatives to, 687, 688, 691, 692
Beta-blocker withdrawal syndrome, 400
Beta-carotene
/cholesterol ratio, 569, 570
as lipophilic antioxidant, 567–570
17 ß-estradiol, 745
Beta low density lipoproteins, 634
1–(ß-mercapto-ß,ß-cyclopentamethylenepropionic acid)-D-tyrosine-(Oethyl)-4-valine AVP[d(CH_2)-DTyr(Et)VAVP], 699
1–(ß-mercapto-ß,ß-cyclopentamethylenepropionic acid)-2-O-methylthyrosineAVP(d(CH_2)$_5$-Tyr(Me)-AVP], 699
Beta-neoendorphin, 514
Beta-nicotinamide adenosine dinucleotide phosphate, 68
Beta-receptors, 400, 624
effects of beta-blockers on HMGCoA receptors, 67, 72
$Beta_1$-adrenergic receptors, 677, 679, 683
arbutamine, adrenergic activities of, 39, 41–46
$ß_1$-AR, 678, 679
$Beta_1$-adrenoceptor, 695, 696, 805
increase in density (upregulation), 697
$Beta_1$-adrenoceptor agonist, 700
$Beta_1$-adrenoceptor antagonist, bisoprolol, 50, 55, 56
$Beta_1$-selective blockers, 804, 805
$Beta_1$-selectivity, effects of beta blockers on HMGCoA reductase, 67–73
$Beta_2$-adrenergic receptors
arbutamine, adrenergic activities of, 39, 42, 45, 46
$ß_2$-AR, 679
$Beta_2$-adrenoceptor, 695, 696
$Beta_2$-stimulant, 70, 72
Salbutamol as, 72
$Beta_3$-adrenergic receptors, arbutamine, adrenrgic activities of, 39, 42–46
Betaxolol
beta-antagonists and Ca^{2+} sensitivity, 581–586
concentration-response curves, 585
effect on Ca^{2+}-activated contractions in skinned fibers, 581–586
effects of beta-blockers on HMGCoA receptors, 67–73

vs. diltiazem, 581
vs. propranolol, 581–586
Bezafibrate, cost effectiveness in hyperlipidemia, 787, 790, 791
BHAT, 761
Big endothelin-1, bosentan effect, 718, 719, 720, 721
Bilateral hilar lymphadenopathy (BHL), in cardiac sarcoidosis, 497
Biogel P-6, 68
Bisindolylmaleimide (BIM)
preconditioning effectiveness in rat heart, 125–132, 134
as protein kinase C inhibitor, 779, 780, 782
Bisoprolol, 697, 805
aortic stiffness and antihypertensive therapy, 50
for heart failure treatment, CIBIS study outcome, 713
Black patients
antihypertensive responsiveness to RAAS inhibition, 313, 314
calcium antagonists for cardiovascular disease, 455–459
thiazide preferred to diltiazem to reduce blood pressure, 459
Blood, amiodarone concentration in, 559
Blood-brain barrier, 515
Blood coagulability, as risk factor for hyperlipidemia, 793
Blood flow, 635
coronary, in total myocardial ischemia, 662, 663
myocardial, 706
renal (RBF), 803, 804, 805, 806
Blood group A, 746
Blood group O, 746
Blood pressure (BP)
ACE inhibitors and, 635
actual, vascular elastic properties and, 54, 55
amlodipine and, 447, 452, 453
antihypertensive drugs and, 511, 513, 514, 803–807
aortic stiffness and hypertensive therapy, 49–56
arbutamine as cardiac stress agent, 35
arterial, 550, 562, 687, 688, 690, 798
arterial, hypothyroidism and ventricular fibrillation, 370, 371
brachial, vascular elastic properties and, 54–55
calcium channel antagonists and, 405
cardiovascular safety of nicotine patches, 179, 181, 182
cromakalim (CR) and, 590
diastolic, 545, 697–699, 704, 788–789
diastolic, ischemic ventricular fibrillation and, 449, 451
elevated, renin-angiotensin system and, 513, 515, 516
endothelins and, 797, 799
excessive fall, 522
heart rate and, 677, 678, 682
hypertension and, 67
increase in CHF, 694, 695, 697
in postmenopausal women, 387
long-acting drugs and, 397, 399
long-term safety of vasodilators, 410
mean arterial, 448, 449
nicotine and, 657
peripheral, aortic stiffness and antihypertensive treatment, 55
pranidipine in hypertension dose-finding study, 59–66
rapid and short-acting drugs and, 398, 399
reduction, and hyperlipidemia, 792
renal impairment and captopril test, 75, 76, 78
systemic, 520, 524, 527, 528
systolic, 704, 706, 711–715, 737, 744
systolic, captopril and inhibition of renin-angiotensin system, 561, 562, 563, 564
tilisolol in canine coronary circulation, 25–26, 28, 29
Blood pressure monitoring, 50, 51
Blood vessel walls, acetylcholine and, 691
Blurred vision, as side effect, 691
BM 13177, 729
B max (maximal receptor density), 240–241, 243
BMS 182874, 799
Body mass index, 632
correlated to arterial pressure, 219
Boehringer Mannheim Diagnostica UV test, 588
Borg-perceived exercise scale, 362
Born turbidimetric technique, 120
Borrelia burgdorferi
cardiac symptom duration, 354–355
diagnosis of, 357
diagnostic criteria, 352–353
immunological reactivity, 353
involvement in dilated cardiomyopathy development, 357
NYHA staging, 354, 355, 358
reversal by antibiotics, 351–358
Bosentan, 796, 797, 799
acute and short-term effects in humans, 717–724
BQ 123, 718, 722, 796, 799
Bradyarrhythmias, 495, 501
Bradycardia, 13, 239, 241, 298, 303, 410, 452
almokalant and, 543
hyperphagia and overfeeding, 268
intravenous propafenone for recent onset atrial fibrillation, 154
long-term dietary restriction effect in rats, 247, 249
magnesium supplementation, 307
rebound after clonidine withdrawal, 259, 260
sinus, elgodipine effect, 573–574
symptomatic, 687, 690, 691
Bradycardic agents
heart rate, apharmacological tool, 677–684
subclass 1, 682
subclass 2, 682–683
Bradykinin, 514, 631–633, 698, 730, 776, 778, 806
ACE-induced degradation of, 640, 641
breakdown inhibited by kininase II, 609, 610
cyclosporine and coronary endothelial function, 17, 18, 19, 21
degradation prevented by ACE inhibitors, 470
and endothelin-1 release, 723
and ischemic preconditioning, 767–768, 771
preload reduction as result of breakdown inhibition, 328
renin inhibitors, 309–310, 313
system, 625
Brain
AI conversion to A1–7, 511
angiotensin receptors and, 512
ET_B receptors in, 795
sympathetic outflow as determinant of primary hypertension, 251
underperfusion, 619
Brain natriuretic peptide, 626
Brain renin-angiotensin system, 445
Brain stem, 280
centrally acting antihypertensives and sympathetic outflow, 283, 284, 288
8Br-cAMP, 706
Brij 96, 68
BRL-37344, glycerol release stimulated in rat white adipocytes, 39, 41, 43, 44, 45
8-bromo cyclic GMP (BrcGMP), 440–442
Bronchitis, chronic, 745
Bronchoalveolar fluid, 559
Bronchoalveolar lavage fluid, 559
Bronchopulmonary infections, 618
Bronchospasm, 410
Bucindolol, 697
Bumethanide, drug treatment of heart failure, 694
Bundle-branch block, left, 497, 499
Bundle-branch block, right, 497–499
Bunitrolol, effect on Ca^{2+}-activated contractions in skinned fibers, 581, 583, 585
2-butyl-4-chloro-1-[*p*-(*o*-1*H*-tetrazol-5ylphenyl) benzyl] limidazole-5-methanol monopotassium salt, 514
Bypass surgery, 528, 752

Cachexia, 626
Cadmium chloride, 660
Caerphilly Prospective Heart Disease Study, 632
Caffeine, 799
CAGE, 512
Calan. *See* Verapamil
Calcification, necrotic, 587, 588, 589

Calcitonin gene-related peptide (CGRP), 624
Calcium
  blockade, 410
  content, effect of felodipine and cardiac protection, 425, 427
  cytosolic, 704
  and disorders, disease states, 406
  endothelin and vascular hypertrophy, 795–800
  extracellular, C_x exposure and, 384
  free cytosolic, increased by depression of contractile function, 347
  in tissues, felodipine effect, 425, 427, 429–432, 434, 435
  intracellular, 403, 404, 564
  intracellular, C_x exposure and, 384
  intracellular increase, and mibefradil, 104
  intracellular release, 20, 21
  in urine and blood, as cardiac sarcoidosis diagnostic indicator, 497
  myocardium and, 403
  nicotine and intracellular transmission, 657–663
  overload, 452, 453
Calcium antagonists. *See* Calcium channel blockers
Calcium channel blockers (CCBs), 374, 475, 477, 514, 550, 561, 587
  amlodipine and ischemic ventricular fibrillation, 447–453
  answers to arguments against use in cardiovascular diseases, 459
  AWD 23–111 comparison, 537
  calcium antagonists and endothelial function, 439–445
  calcium blocker benefits, detriments, 403–406
  captopril and renal impairment, 76
  cardiovascular disease treatment changes, 189–191
  concomitant antianginal therapy with nitroglycerin patches, 5
  controversies, 409–411
  coronary artery disease and, 397–400
  cost effectiveness, 464–465
  dihydropyridine, 796, 797, 798
  drug treatment of heart failure, 693–700
  effect on fibrinolysis and platelet functions, 122
  and endothelial function, 439–445
  felodipine and cardiac protection, 425–435
  felodipine and stunning, 347–349
  felodipine in myocardial ischemia, 167–176
  as first-line agents, 463–466
  for cardiovascular disease, 455–459
  for systolic left ventricular dysfunction, 711, 712–713, 715
  immediate-release vs. long-acting slowrelease formulations, 463–466
  interaction with endothelin on vascular tone in arteries and veins, 442
  interaction with nitric oxide, 440–442
  intracellular, 667
  ischemic ventricular fibrillation and, 447, 449, 451, 452, 453
  isradipine sustained release effects in hypertension, 119–122
  and LDL oxidation by oxygen radicals, 417–422
  mibefradil antiproliferative effect, 101–104
  mibefradil effect on neointima formation, 101–104
  myocardial protection, vitamin D_3 and calcium overload, 185–187
  negative inotropic effect, 414
  nifedipine, STONE study, 467–468
  pranidipine in hypertension, 59–66
  risk indicators for death after AMI, 486, 487
  risk of myocardial infarction in hypertension, 413–414
  sarcolemmal, 667, 672, 674
  vs. elgodipine hemodynamics during exercise, 573, 577–580
  vs. fish oil enhancement of immunosuppressive effects of cyclosporine, 384
Calcium channel gene type 2 (CaCh2), 440
Calcium channels, 403, 453, 537, 703
  angiotensin II receptors and, 513
  calcium blocker insensitive, 678
  L-type voltage-operated, 104, 405, 590
  T-type voltage-operated, 104, 405
  voltage-dependent, 796, 797
  voltage-dependent, nicotine and sympathetic neurotransmission, 657–663
  voltage-dependent N-type, 657, 658
Calcium dobesilate, 745
Calcium entry blockers (CEB), 804
  renal hemodynamics and, 804–807
Calcium influx, transmembrane, 796, 798, 800
Calcium ionophore-induced relaxations, 17, 21
Calcium ions (Ca^{2+}), 660, 776–778, 782
  activating isozymes, 779
  cardiac contractility and, 703, 705
  cellular homeostasis, 590
  concentration, 662
  cytosolic accumulation, 587, 795, 796, 797, 800
  efflux, 590, 672
  electrolyte, 370, 371, 374, 375, 376
  entry, 587
  intracellular, 404
  intracellular concentrations, 512
  inrtacellular release, 705
  loads, 587
  overload during reperfusion, 769
  permeability, 657, 658, 660, 661
  selectivity, 657
  sensitivity, betaxolol vs. propranolol effects in skinned fibers, 581–586
  sensitization of, 706
  transport systems, and excess catecholamines, 231–237
  -uptake mechanism, 672, 674
Calcium ion (Ca^{2+})-calmodulin dependent protein kinase (CaM-PK), 776, 778, 779
Calcium ion (Ca^{2+}) channel blockers, KT-362 and, 667, 670, 671, 672, 674
Calcium ion channels, L-type voltagedependent, 797
Calcium ion (Ca^{2+})-dependent protein kinase C isotypes, 778, 781, 782
Calcium ion (Ca^{2+})-independent isotype protein kinase C-ε, 782
Calcium ion (Ca^{2+})-independent isotypes, 782
Calcium ion (Ca^{2+}) influx, 672
Calcium ion (Ca^{2+}) release channels, sarcoplasmic, 667
Calcium ion/sodium ion exchange, 590
Calcium ion (Ca^{2+}) transients, KT-362 and, 667–674
Calcium sensitization, nanterinone hemodynamic effects in heart failure, 138–143
Calcium sensitizers, 703
  drug treatment of heart failure, 693, 699
Calcium-sensitizing effect, 706
Calmidazolium, anti-ischemic protection of, 175
Calmodulin, 581
  activation, 405
  felodipine as antagonist, 175, 176
Calphostin-C, as protein kinase C inhibitor, 779, 780
CAMIAT trial. *See* Canadian Amiodarone Myocardial Infarction Arrhythmia Trial
Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT), 714
Canadian Cardiovascular Society's (CCS) Consensus Conference, 711–715
Canadian Council on Animal Care, 587
Canadian Heart Health Surveys, 1992, 788
Canadian Hypertension Society, 400
Canadian Journal of Cardiology, Diagnosis and Management of Heart Failure (1993 consensus conference report), 711
Canadian Life Tables, 1986, 789
Candesartan, 514
Candoxatril, 596, 698
Candoxatrilat, 596
CAPE II study, 411
Capillary muscle networks, 527, 528
Capillary pressure, intraglomerular, 513

CAPRIE trial. *See* Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Events
Captopril (C), 561–564, 610, 633–635, 695, 696
  ACE inhibitors and, 520, 521, 522, 523
  and cardiac dilatation, 614
  cardioprotective effect in coronary heart disease, 639–643
  effect on platelet and fibrinolytic parameters, 119
  for congestive heart failure, 619, 620
  hypertension with endothelial dysfunction studied, 469, 470
  in STONE study, 467–468
  isovolumetric relaxation time, lengthening, 328
  renal impairment and ACE inhibitors, 75–78
  vs. tilisolol in dogs, 29
  with aspirin, 76
  with digoxin, 76
  with nitrates, 76
Captopril and Thrombolysis Study, CATS, 614
Captopril-Digoxin Multicenter Research Group study, 711
Captopril test, renal impairment and ACE inhibitors, 75–78
Carbohydrate metabolism, effect of beta blockers on, 71
Carbon dioxide (CO_2) chemoreceptor, 678
Carbon monoxide (CO), 559, 743
Cardene. *See* Nicardipine
Cardiac arrest, 527
  beta-blockers and, 458
  nicotine and previous, 663
  primary, 399
Cardiac arrhythmias
  beta blockers and, 688
  Electrophysiologic Basis of ECG and Cardiac Arrhythmias (book review), 89
  malignant, arbutamine vs. isoproterenol as cardiac stress agents, 38
Cardiac Arrhythmia Suppression Trial (CAST), 151, 536, 550, 552, 555, 752, 762
Cardiac $beta_1$-adrenergic receptors, 39, 41–46
Cardiac Ca^{2+} transport, systems of, and excess catecholamines, 231–237
Cardiac cells, 795
  endothelin formation, 795
Cardiac conduction system, 531, 532, 536, 537
Cardiac death (CD), 550, 552, 553
  after acute myocardial infarction, 486
Cardiac disease
  decreased HRV and, 681, 683
  exercise and heart rate and, 545, 546
Cardiac energy depletion, 657, 660
  nicotine and, 662–663
Cardiac events
  antiarrhythmic drugs and, 549, 552–554
  calcium channel blockers and, 410
Cardiac failure
  endothelin and, 800
  heart rate variability and, 677, 679, 683
Cardiac function, depressed, and cardiac sarcoidosis, 497
Cardiac graft vasculopathy, 17, 21
Cardiac hypertrophy
  inhibited by lacidipine, 443, 444, 445
  neutral endopeptidase prolonged inhibition effect, 593–596
Cardiac hypothyroidism, 369, 370, 376
Cardiac index, 698
  bosentan effect on, 718, 719, 721, 722, 723
  nanterinone hemodynamic effects, 139–143
Cardiac index basal value, enoximone and systemic and renal hemodynamics, 81, 83, 84, 86
Cardiac inotropism, 15
Cardiac insufficiency, HRV and, 680
Cardiac Insufficiency Bisoprolol Study (CIBIS), 713
Cardiac load, 451, 453
Cardiac membranes, calcium transport systems and excess catecholamines, 231–237
Cardiac metabolism, 451, 452
Cardiac mortality, 552–555
Cardiac muscle
  betaxolol vs. propranolol effect on Ca^{2+}-activated contractions, 581–586
  KT-362 and Ca^{2+} transients, 672
Cardiac myocytes, 674
Cardiac myxedema, 376
Cardiac output, 694, 696, 699; *see also* Inotropic action
  beta blockade and, 804, 806
Cardiac pacing, 730, 731
Cardiac protection, angiotensin-converting enzyme inhibitors for coronary heart disease, 639–643
Cardiac rhythm, *History of the Disorders of Cardiac Rhythm* (book review), 89
Cardiac sarcoidosis, 495–503
  classification scheme for patients, 497
  clinical presentations, 502
  diagnosis and recognition of, 497–500
  epidemiology, 496
  microangiopathy, 500–501
  mortality and morbidity, 502
  nongranulomatous pathology of, 500
  racial incidence, 495, 496
  treatment, 501–502
  vascular disorders associated with, 500
Cardiac SPECT Imaging (book review), 91
Cardiac stroke volume (SV), 574–579
Cardiac surgery, drug therapy and, 699
Cardiac tamponade, after acute myocardial infarction, 486
Cardiac transplantation, 379, 552
Cardiac valves, surgical reconstruction of, 693
Cardiac weight, HRV and, 682, 683
Cardiodepressant activity, 697
Cardiogenic shock, 303, 307, 523
  after acute myocardial infarction, 486
Cardioinhibitory response, 687, 690
Cardiomegaly, 498
Cardiomyocytes, 590
  calcium deposits in, 589
Cardiomyopathy
  dilated (DCM), 561, 562
  idiopathic, 697, 698, 704
  idiopathic, and beta-blockers, 620
  ischemic, 697
  ischemic, and beta-blockers, 620
  nonischemic, 713, 714
  reversal of *Borrelia burgdorferi* by antibiotics, 351–358
Cardioprotection, by cromakalim, 587–590
Cardioselectivity, tilisolol vs. arotinolol or propranolol, 23, 29
Cardiothoracic surgery, 659
Cardiotonics, 502
Cardiovascular cells, excitability of, 514
Cardiovascular death, 643
Cardiovascular diseases
  alternatives to mega-trials, 759–764
  AII-specific receptor blockers and, 516
  LDL oxidation and, 567, 569, 570
Cardiovascular disorders, endothelin and, 800
Cardiovascular events, 634
  ACE inhibitors treatment, 521
  nicotine as trigger, 657, 663
  survival after, 693, 694
Cardiovascular function, angiotensin II and, 511
Cardiovascular system
  angiotensin II receptors, 513
  Ion Channels in the Cardiovascular System. Function and Dysfunction (book review), 89
Cardiovascular trials, alternatives to mega-trials, 759–764
Cardioversion
  direct-current, vs. antiarrhythmic agents, 153, 156
  propafenone vs. disopyramide for sinus rhythm maintenance, 145–151
Cardizem. *See* Diltiazem
Carotid arteries, 448
  atherosclerosis progression, 398
Carotid endoarterectomy, 747
Carotid sinus syncope, 687
Carvedilol, 697
  as heart failure treatment, 713
  hemodynamic effects in hypertensive patients, 113–117
CAS 90729-41-2. *See* Oxodipine
CAS 119413-55-7. *See* Elgodipine

CAST trial. *See* Cardiac Arrhythmia Suppression Trial
Catalase, displayed by EUK-8, 337–338
Catecholamine-diphenylborate complexes, 322
Catecholamine-induced cardiotoxicity, calcium transport, and excess catecholamines, 231–237
Catecholamine-O-quinone, 235
Catecholamine release, carrier-mediated, 662, 663
Catecholamines, 7–8, 400, 617, 620, 730
  ability of myocardium to respond to, 624, 625, 626
  and adenosine, 767–768
  arbutamine, adrenergic activities of, 45, 46
  and cAMP, 704
  CHF and, 561
  clearance, alterations in, 219
  depletion preventing preconditioning, 125, 133
  enhancing hepatic glucose production, 264, 270
  epinephrine injections and food restriction effects, 241–246
  heart rate variability (HRV) and, 678, 679
  influence on membrane lipids: in vitro approach, 226
  long-term dietary restriction effects on heart function, 247, 248, 249, 250
  lowering of, after clonidine treatment, 285, 287
  nicotine stimulated release, 657–663
  overproduction and promotion of cardiovascular diseases, 275
  release and action promoted by angiotensin II, 321, 322, 324, 328
  release opposed by magnesium, 303
  sympathoadrenergic overactivity and lipid metabolism, 223–229
Cathepsin G, 512, 514
Catheter ablation, radiofrequency in patients with HCM, 527–529
Catheter mapping technique, 527, 528
Cation channels, nicotinic acetylcholine receptors and, 658
Cation gate, nicotinic acetylcholine receptor, 657, 659
Cation homeostasis, intracellular, 660
Cations, 658, 659, 660
  radiolabeled, 660, 661
CATS study. *See* Captopril and Thrombolysis Study
Caudal ventrolateral medulla (CVLM), 283–284
CCS-1 study. *See* Chinese Cardiac Study
Cedilanid, 694; *see also* Deslanoside
Ceftriaxone, for *Borrelia burgdorferi* cardiomyopathy, 351, 356, 357
Celiprolol, 550, 745
  for treatment of heart failure, 585
  vs. betaxolol, 585
Cell damage, 447, 452
  virus-induced, 705
Cell death, 557, 558–559
  myocardial, 705
Cell differentiation, 513
Cell growth/proliferation, 796, 797, 799, 800
Cell lysate, 558
Cell lysis, 559
Cell membranes, intracellular calcium, 403, 404
Cell migration
  inhibited by cilazapril, 101–104
  mibefradil and cilazapril effects on renin angiotensin system, 101–104
Cell necrosis, 587, 730
Cell proliferation, 744
  mibefradil and cilazapril effects on renin angiotensin system, 101–104
Cellular protein, 403
Cell vacuolization, 557, 558
Centrally acting antihypertensives
  general aspects, 284
  and sympathetic outflow, 283–288
Central nervous system (CNS)
  centrally acting antihypertensives and sympathetic outflow, 283–288
  drug penetration and, 691
  heart rate and, 678, 679
  long-term dietary restriction effects on heart function, 249
  nicotine and, 657
  nicotinic acetylcholine receptors and, 658
Centricon, 418
Cephalic insulin release, 268
Cerebral circulation, 796
  renin-angiotensin system and, 514
Cerebral embolism, 502
Cerebrovascular disease, 747
c-fos factor, 513
c-fos mRNA, 796, 797–798
c-fos protooncogene, 610, 796, 797, 800
CGP4122A. *See* Peptide antagonists
CGP-26505, as radiolabel ligand for beta$_1$-adrenergic receptors, 40–41, 43, 45
Channel blockers, open, 544
Channel gating, 678
  activating phase, 678
  inactivating phase, 678
Chaotic behavior, heart rate, a pharmacological tool, 677–684
CHD Prevention Model, 788–789, 792
Chelerythrine
  preconditioning effectiveness in rat heart, 125–132, 134
  as protein kinase C inhibitor, 779, 780
Chemoreceptors, HRV and, 678
Chemotactic peptide, 514
Chest discomfort, and cardiac sarcoidosis, 502
Chest pain, 527
  antecedent, 551
  nitroglycerin patch therapy, 6
  and removal from exposure to nitroglycerin, 736, 738, 739
  risk indicators for death after AMI, 485, 486
CHF-STAT trial. *See* Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy
Chinese Captopril Trial, 642
Chinese Cardiac Study (CCS-1), 520, 521, 522, 712, 713, 714, 715
Chi-square test, 563
Chloralose, 448
Chloride, distal tubular delivery of, 805
Chlorine ion (Cl^-) electrolyte, 370
Chlorisondamine, 276, 277
Chlorthalidone, with pravastatin, in ALLHAT study, 411
Cholecystokinin-8, 563
Cholesterol, 226, 229
  cellular levels, 69, 72, 73
  cost effectiveness of HMG-CoA reductase inhibitors and fibrates, 787–792
  high plasma level as hemostatic predictor, 744, 746
  moxonidine effect on, 275, 277, 278
  plasma concentrations, 380, 383, 384
  plasma levels, 72
  reduction of, 752–755, 757, 761, 762
  serum, 568, 569, 632, 634
  total, and hyperlipidemia, 788–793
Cholesterol metabolism, effects of beta blockers on HMGCoA receptors, 67, 68, 71
Cholesteryl esters, fatty acid profile of plasma lipids, 381
Cholestyramine, 570, 632, 761
  for hyperlipidemia therapy, 792
Choline, 778
Choline chloride, 661
Cholinergic nerve endings, 691
Cholinergic tone, 687
Chromosome 2, human, 512
Chromosome 17, human, 512
Chromosome 17q23, 631
Chromosome X, human, 512
Chronbach's alpha-coefficient, 362
Chronic atrial fibrillation, definition, 146
Chronic heart failure
  amiodarone treatment, 714
  clinical trials of ACE inhibitors, 761
  endothelin-1 plasma concentration, 717–721
  hemodynamic effects of short-term oral endothelin-receptor antagonist therapy, 721
  nitrates not used as first-line therapy, 735
Chronic obstructive pulmonary disease, 15
Chronotropic effects, 696
Chymase, 310, 511, 512, 514
Chymase pathway, 697, 698
Chymostatin-sensitive angiotensin-II generating enzyme (CAGE), 512, 564

Cibenzoline, adverse effects on induction of atrioventricular re-entrant tachycardia, 159–165
CIBIS study. *See* Cardiac Insufficiency Bisoprolol Study
Cilazapril, 633, 696
  antihypertensive therapy, and aortic stiffness, 49–56
  comparative effects with mibefradil in normotensive and DOCA hypertensive rats, 103
  direct antiatherogenic activity, 641
  effect on neointima formation, 101–104
  hypertension with endothelial dysfunction studied, 469, 470
  with mibefradil, 103–104
Cinevideodensitometric analyzer (Vanguard XR-70), 476, 482
Cinnarizine, 439, 581
Circadian rhythm, HRV and, 678, 680
Circulating hormones, 442
Circulation, 409
Circulatory insufficiency, 447
c-jun protooncogene, 641
Classical preconditioning period (CPP), 775, 776, 778, 783
Classical protein kinase C isotypes (cPKC's), 778, 782
Clinical anarchy, 752
Clinical descriptors, 757
"Clinical freedom," 759
Clinical tolerance data, 550, 551, 552
Clinical trials
  diltiazem in supraventricular tachyarrhythmias, 11–15
  inclusion criteria of new generation of, 751–757
  randomized, 752
Clofibrate, 761
Clonidine, 190, 214, 236
  chemical structure, 286
  diastolic function indices improved, 328
  rebound hypertension and, 251–261
  and sympathetic outflow, 283–288
  vs. moxonidine, 280
  withdrawal phenomenon, 286
Clonidine displacing substance (CDS), 286
Clopidogrel, 760
Clotting factor, 567
c-myc factor, 513
c-myc mRNA, 796, 798
c-myc protooncogene, 610, 641, 796, 797, 800
Coagulation necrosis, 588
Cocaine, 40, 41, 659, 663
Cod liver oil, 745
  in diet of rats, 225
Colchicine, as protein kinase C inhibitor, 779, 780
Cold, induced coronary constriction, 457
Cold pressor test (CPT), 322–328
Collagen, inducing thromboxane release, 732
Collagenase, 41
Collagenous proteins, 513
Collagen synthesis, 634
Comitogens, 798
Committee on Animal Care, 532
Compactin, 71
Complications
  calcium blocker benefits detriments, 403–406
  risk indicators for death after AMI, 485–489
Concentration-response curves
  Cx-induced vascular toxicity and fish oil, 380–384
  nicotine and, 657
Conditioning stimulus (S1), 531, 533–536
Conductance, bradycardic agents and, 682
Conduction, 528
  almokalant effects on, 539, 543, 545, 546
  anterograde, 529
  retrograde, 529
Conduction disturbances
  atrioventricular, 497
  and cardiac sarcoidosis, 497, 498
  intraventricular, 497
Conduction intervals, electrocardiological effects of AWD 23–111, 531–537
Conduction time, intraventricular, of amlodipine, 450, 451, 452, 453
Conduction velocity, 531
Confidence intervals, 542
  95%, 761, 762, 763–764
Congestive heart failure (CHF), 411, 550, 634, 640, 679
  ACE inhibitors and, 519–523
  age-adjusted incidence of, 703
  angiotensin-converting enzyme (ACE) inhibition in coronary artery disease, 609, 610, 611
  beneficial effects of diuretics, 752
  bosentan treatment for, trial results, 717–724
  calcium antagonists for, 403, 456, 458, 463, 464, 465
  calcium antagonist vs. beta-blocker risk, 464
  captopril plasma endothelin-1 concentration modulations, 561–564
  cardiac sarcoidosis, 495, 497, 501, 502
  cardiovascular disease treatment changes, 189–191
  cause of death in cardiac sarcoidosis, 495
  causes of ineffectiveness of medical therapy, 618
  cost of annual patient care, 299, 300
  diltiazem treatment of supraventricular arrhythmias, 13, 14
  and disopyramide therapy, 148, 150–151
  drug treatment of, 693–700
  endothelin-1 response in failing myocardium, 107–112
  end-stage heart failure medical treatment, 617–622
  enoximone effect on systemic and renal hemodynamics, 81–86
  felodipine in myocardial ischemia, 176
  and hyperlipidemia, 788
  median survival, 703
  neuroendocrine response in, 623–627
  neutral endopeptidase inhibition, 593
  and nitrate tolerance and rebound, 735–741
  renal impairment and ACE inhibitors, 75–78
  renin inhibitors and, 309, 311
  risk indicators for death after AMI, 485–489
  treatment costs, 789
Congestive heart failure syndrome, symptomatic treatment, 693
Congestive heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT), 714
CONSENSUS study. *See* Cooperative North Scandinavian Enalapril Survival Study
Continuous transdermal nitroglycerin, vs. intermittent transdermal nitroglycerin, 5–9
Contractile force, cardiac, 696, 699
Contractile proteins, 706
  betaxolol vs. propranolol effects on Ca^{2+}-activated contractions in skinned fibers, 581–586
Contractility
  beta-adrenoceptor-mediated increase, 657
  cardiac, 703, 705
  cell, 797, 800
  endothelin-1 response in failing myocardium, 107–112
  myocardial, 699, 706
  myocardial, depression of, 703
Contraction, KT-362 and, 667, 672
Converting enzyme inhibitor (CEI), 677, 682, 683, 704, 806
Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), 619, 625
  CONSENSUS I, 712, 761
  CONSENSUS II, 519–522, 642, 761
Copper, 567, 568, 569, 570
Corn oil, in diet of rats, 225
Coronary angiography, angina recurrence, 739
Coronary angioplasty, 633, 752, 756
  ACE inhibitors not showing preventive effect on restenosis after, 101, 104
  and hyperlipidemia, 788
  subcutaneous transluminal, 635
Coronary arterial spasm, 23
Coronary arteriolar system, 410

Coronary artery
AII and, 514
beta-antagonists and Ca^{2+} sensitivity, 581–586
cyclosporine and coronary endothelial function, 17–21
epicardial, 410
left circumflex, 783
occlusion, 372, 447, 449, 451
Coronary artery bypass grafting (CABG), 456, 477, 550, 551, 635
after AMI, 486, 487
ischemic preconditioning, 771
Coronary artery diameter, tilisolol in canine coronary circulation, 23–29
Coronary artery disease (CAD), 599, 744, 746
ACE inhibitors and, 609–611, 631–636
ACE inhibitors effect on endothelial dysfunction, 469–471
ACE inhibitor trials, 625
aspirin therapy, 728
associated with atrial fibrillation, 154
atherosclerotic, 631
calcium antagonist controversies, 409–411
cardioprotective effect of ACE inhibitors, 639–643
cost effectiveness in primary hyperlipidemia, 789, 793
1,4-dihydropyridine vs. beta blockers for hypertension, 397–401
elgodipine hemodynamics during exercise, 573–580
endothelin and, 800
nicotine and, 657, 663
pathogenesis of, 631, 632, 635
pathophysiology of, 519
pravastatin and restenosis, 475, 482
renin-angiotensin system role, 613–615
smoking and coronary vasoconstriction, 179, 183
vasodilatory effects of nitrates, 736
Coronary artery ligation, effect on rat body and tissue weights, 594, 595, 596
Coronary artery occlusion, 729, 730, 775, 779
Coronary artery occlusion-reperfusion, 775
Coronary artery perfusion, 405
Coronary atherosclerosis, 11
Coronary Balloon Angioplasty, Atlas of (book review), 92
Coronary blood flow, 447, 451, 452, 523, 796
felodipine effect, 170–172
tilisolol in canine coronary circulation, 23–29
Coronary bypass surgery, preconditioning during, 767
Coronary collateralization, 376
Coronary endothelial dysfunction, endothelin-1 role, 717
Coronary events, 632
beta-blockers and, 399, 400
beta-blocker treatment and, 397
1,4-dihydropyridines and, 397–399
thrombotic, 405
Coronary heart disease, 67, 610, 747
cardiovascular disease treatment changes, 189–191
deleterious influences, 223
HDL beneficial effects, 731
HMG-CoA reductase inhibitors and fibrates in hyperlipidemia, 787–789, 792, 793
LDL and, 567
medical care cost savings and those due to increased life expectancy, 789–790
nifedipine slowing appearance of new coronary lesions, 418, 422
risk factors, 223
vitamin E intake and risk of, 236
Coronary Heart Disease Policy Model, 299
Coronary hypoperfusion, 298
Coronary insufficiency, treatment costs, 789
Coronary occlusion, 244, 404, 447
ventricular fibrillation and, 447, 448, 449, 451, 452
Coronary perfusion, 403–404
Coronary reperfusion, 406
Coronary spasm, calcium antagonists for treatment, 455
"Coronary steal" phenomenon, 432, 471, 729
Coronary thrombus, 663
Coronary vascular disease, 745
Coronary vascular resistance (CVR), tilisolol in canine coronary circulation, 25–26, 27, 28
Coronary vasomotor response in cyclosporine-treated piglets, 17–21
Coronary vasospasm, 717
Cor pulmonale, 11, 12, 13
associated with atrial fibrillation, 154, 155
causing heart disease in sarcoidosis, 495, 499
Corticosteroid therapy, 475
to control cardiac sarcoidosis, 495–499, 501–503
Corticosterone, 40, 41
Cortisol, 795, 797
captopril and renal impairment, 78
COS cells, 776
Cost effectiveness
calcium antagonists as first-line agents, 463–466
of drug regimen, equation for calculating, 788
of HMG-CoA reductase inhibitors and fibrates in hyperlipidemia, 787–793
Cottbus study, 731–733
Cough, 410, 514, 515, 697, 698
dry, 695
Coumel, Philippe, 680
Coupling intervals, 542, 543, 544, 545
Cox hazard model, 467
Cox proportional hazards regression, 147
COX-2, 731
Craniofacial deformities, 799
C-reactive protein, 754
Creatine, decrease in, 704
Creatine kinase (CK), 533
serum activity, 588
Creatine kinase-MB, 771
Creatine kinase isoenzyme, 704
Creatine phosphate
amiodarone effect on, 376
felodipine and cardiac protection, 425, 428, 430–431, 432, 434
isoproterenol injection effect on heart, 234
Creatine phosphokinase (CPK), felodipine and cardiac protection, 426, 429, 433
Creatinine, bosentan effect, 722
Creatinine plasma, and congestive heart failure, 619
Creatinine clearance, renal impairment and captopril test, 75, 77, 78
Cr-labeled target cells, 705
Cromaffin cells, adrenal, 658, 660–662
Cromakalim (CR)
cardioprotection by, 587–590
spasmolytic effect in animals, 28, 29
Cultured rat ventricular cells, KT-362 and Ca^{2+} transients, 667–674
Cyanide, 660, 662
Cyanosis, 448, 449
Cycle lengths (CL), paced
almokalant and, 539, 540, 542–545
Cyclic adenosine monophosphate (cAMP), 134, 699, 730, 776
-dependent protein kinases, 703, 776, 779
increasing agents, 703–705
inotropic agents in heart failure, 703–707
intracellular, 405
Cyclic guanine monophosphate (c-GMP), 440, 441, 514, 523, 564, 632
preconditioning, 345
Cyclooxygenase, 727, 729, 731
Cyclo-oxygenase inhibitors, 729, 731
cardiovascular disease treatment changes, 189–191
Cyclooxygenase pathway, 18
Cyclosporin, inducing renin-dependent hypertension, 311
Cyclosporine (Cx)
and coronary endothelial function, 17–21
-induced vascular toxicity and fish oil, 379–384
Cyclosporine A, 17
Cysteine residues, 795
Cytokine inhibitors, 703
Cytokine-inhibitory effects, 706
Cytokines, 623, 626–627, 746
inducing NO synthase, 442

inotropic agents in heart failure, 703–707
Cytoplasma, 797
Cytoplasmic inclusions, 559
Cytoplasmic remodeling, 559
Cytoskeletal proteins, 403
Cytosol, 782
Cytosolic calcium, 405
Cytosol marker, 557
Cytotoxicity, 705

D-600. *See* Gallopamil
D allele, 632
Danish Verapamil Infarction Trial (DAVIT), 457
verapamil safety/efficacy, 455
Dataquest 4 program, 252
DATA trial. *See* Diet and Antioxidant Trial on Atherosclerosis
DAVIT studies. *See* Danish Verapamil Infarction Trial
Dazmegrel, 729
Dazoxiben, 729
DDD mode pacemakers, 529
DD genotype (ACE gene), 613–615, 631–633
Deacylation-acylation pathway, 229
Death (D)
after acute myocardial infarction, 486, 487, 488
AMI and, 519, 522, 523
cardiac, beta-blockers and, 398, 400
cardiovascular, 635
endpoint of, 634, 635
as study endpoint, 550, 552, 553
Declaration of Helsinki, 540
Decompensated heart failure, captopril and renal impairment, 75
Decosapentaenoic acid, 380
De-endothelialization, 559
DEFIANT studies, 458
Defibrillation, 448
Defibrillator, 552
implantable, 545
implantable automatic, 621
Defibrotide, 745
Delapril, 464
Dense granules, 404
Dense tubular system, 404
Deoxycorticosterone acetate (DOCA)-salt hypertension, endothelin and vascular hypertrophy, 795–800
Deoxycorticosterone acetate (DOCA)-salt SHR, 799
2-deoxy-D-glucose (2-DG), 265
Deoxyribonucleic acid (DNA), 796, 797
synthesis, 513, 798
Dephosphorylation, 783
Depolarization
atrial premature, 528
cyclosporine effect, 383
diastolic, 537
intracellular calcium and, 403, 404
ischemic, 447, 449, 452, 453
potassium, 662
spontaneous diastolic, 678, 682
of sympathetic nerve endings, 657, 658, 660, 661
Depolarizations-induced contractions, 17, 20, 384
Depressor response, 283–284
Deacetyldiltiazem, 14
Desensitization, 659
Desferrioxamine, 338
Desipramine, 659
Deslanoside, 694
Detajmium, 531
Device therapy, 549, 555
Dextran-sulphate, 567, 570
Dextran sulphate cellulose (DSC) column, 568
Diabetes/insulin resistance, with hypertension, 287
Diabetes mellitus, 405, 743, 744, 745
basal lamina layering, 500
captopril and renal impairment, 75, 76
in hyperlipidemia study, 789
isradipine sustained release effects in hypertension, 119–122
non-insulin-dependent, 614
renin inhibition, 311
risk indicators for death after AMI, 485–489
type II (non-insulin-dependent), 745
with retinopathy, diuretic treatment, 458–459
Diabetic nephropathy, 311
Diabetics, in Cottbus study of aspirin therapy, 732
Diacylglycerol, 512
to stimulate PKC, 125
1,2-diacylglycerol (1,2-DAG), 776–779, 781, 782, 796, 797
-protein kinase C complex, 777
-stimulated histone III-S, 782–783
Dialysis, nephrosclerosis and, 803
Diaphragm tissue, 587, 588
Diastole, coronary perfusion during, 697, 698, 699
Diastolic blood pressure, 545, 697–699
amiodarone effect, 371
aortic stiffness and hypertensive therapy, 49–56
calcium antagonists and, 403, 405
cardiovascular safety of nicotine patches, 179
clonidine effect, 252–253, 255–257
elgodipine effect, 573, 574, 576–579
EUK-8 vs. DMTU cardioprotective effects, 333, 335
felodipine effect, 428, 429, 432
in hyperlipidemia study, 788–789
metoprolol vs. carvedilol in hypertensive patients, 114, 115, 116
moxonidine effect, 252, 254, 257
nifedipine SR effect, 467
pranidipine in hypertension, 59–66
sitting, isradipine sustained release effects in hypertension, 119–122
Diastolic [Ca^{2+}], (dCa), 667, 669, 670, 671, 672, 673, 674
Diastolic dysfunction, felodipine in myocardial ischemia, 167–176
Diastolic function, 704
and adrenergic stress, angiotensin II in hypertension, 321–328
Diazoxide, 805
Diet
atherosclerotic, 632
excess caloric intake and hypertension, 251
fat intake and hemostatic predictors, 746
fish oil supplement, 379–381, 383, 384
as hemostatic predictor of arterial thrombosis, 745
high fat, 570
high salt, 804
high-salt, and endothelin production, 439, 443–444
hypercaloric, and rebound hypertension, 255–256, 259, 260, 261
low-fat, 570
low protein, 244
low sodium intake, 804, 806
n-3 polyunsaturated fatty acid (PUFA)rich oil, 223
nonatherogenic, 632
plasma LDL and, 567, 568, 570
and postmenopausal women, 387
sympathoadrenergic overactivity and lipid metabolism, 223–229
Diet restriction
adrenergic mechanisms and, 239–246
cardiovascular function and long-term food restriction, 247–250
Digitalis, 694–695
ACE inhibitor sympathetic activity, 640
cardiovascular disease treatment changes, 189–191
as CHF treatment, 561, 562
continued after cardioversion, propafenone vs. disopyramide for prevention of arrhythmia relapses, 146, 147
drug treatment of heart failure, 693–696, 700
effectiveness in conversion to SR, 156
for atrial fibrillation, 711–712
for dilated cardiomyopathy, 354
for end-stage heart failure, 617, 618
for left ventricular failure, 712
as inotropic agent, 703, 705
nanterinone hemodynamic effects in heart failure, 137–143
and nitrate tolerance, 741
risk indicators for death after AMI, 486, 487, 489
therapeutic index, 618
with bosentan, 717, 722, 723
with captopril, 76

with diltiazem, 14, 15
with propafenone or disopyramide, 149
Digitalis glycoside, 705
Digitalis glycoside ouabain, 662
Digitalis Investigation Group (DIG), 694, 711, 712
Digoxin. *See* Digitalis
Digoxin Investigators Group (DIG) Study, 618
DIG study. *See* Digoxin Investigators Group Study
DI heterozygotes, 614, 615
Dihydralazine, 561
Dihydropyridine derivative, pranidipine in hypertension, 59–66
Dihydropyridines, 439–440, 442, 445, 698, 752, 796–798, 805
amlodipine and ischemic ventricular fibrillation, 447–453
calcium antagonists controversies, 409, 410
calcium antagonists as first-line agents, 463–466
calcium channel antagonists for treatment, 456, 458
classification and physiologic properties, 404
elgodipine hemodynamics during exercise, 573–580
felodipine and cardiac protection, 425, 426, 432, 433, 435
isradipine effect in essential hypertension, 119–122
isradipine sustained release effects in hypertension, 119–122
long-acting, 398–399, 400
mibefradil prevention of neointima formation, 101–104
rapid-acting, 397–398, 399
vs. beta-blockers for mixed angina, 457
vs. elgodipine, 578–580
1,4-dihydropyridines, 439
vs. beta-blockers for hypertension, 397–401
Dilacor XR, safety documentation for SR in hypertension, 464
Dilatation, renal vascular, 695
Dilated cardiomyopathy, 497, 501; *see also* Cardiomyopathy
associated with atrial fibrillation, 154
idiopathic, 500
metoprolol and quality of life in heart failure, 361–367
reversal of *Borrelia burgdorferi*, 351–358
Dilated Cardiomyopathy Outpatient Clinic, 352
Dilators, 700
Diltiazem, 404–405, 410, 414, 417, 419–420, 422, 452, 698
alone or plus mononitrate, in CAPE II study, 411
AWD 23–111 comparison, 537
biological half-life, 11
calcium antagonists and endothelial function, 439–445
cardioprotection, 433, 435
congestive heart failure risk, 464
effects on ventricular rate and on systolic blood pressure, 13
efficacy according to type of arrhythmia, 12
for hypertensives or those who had non-Q-wave infarcts, 455, 457
for systolic left ventricular dysfunction, not recommended, 712
glomerular filtration rate, 15
inhibiting peroxidation of membrane lipids, 175
in supraventricular tachyarrhythmias, 11–15
intravenous, 15
long-acting formulations, 459
lupus-like skin lesions, 465
myocardial protection, vitamin D_3 and calcium overload, 185–187
negative inotropic effect, 14, 15
renal hemodynamics and, 805
side effects, 14, 459
studies on treatment of supraventricular arrhythmias, 14
vs. betaxolol, 581
vs. elgodipine, 573, 578–580
vs. nitroglycerin for unstable angina, 455, 457
"Dilution effect," 751, 753–754
5-[3-([2-(3,4-dimethoxyphenyl)-ethyl] amino)-1-oxopropyl]-2,3,4,5,-tetrahydro-1,5-benzothiazepine fumarate (KT-362), 667
Dimethylphenylpiperazine (DMPP), 658
Dimethylsulfoxide (DMSO), 587, 588, 590
Dimethylthiourea
protective effect minimal, 331
vs. EUK-8, cardioprotective effects, 331, 332, 333
2,3-dinor-6-keto-$PGF_1\alpha$, 729
2,5-dinor-6-keto-$PGF_1\alpha$, 729
1,2-dioctanoyl sn-glycerol (DOG), as protein kinase C activator, 779, 781
Diphenylpiperazines, 439
Dipyridamole, 31, 39, 770
Dipyridamole echocardiographic stress test, 470
Directional coronary atherectomy, 477
Disopyramide, 551, 555
anticholinergic effect and atrioventricular conduction, 150
adverse effects on induction of atrioventricular re-entrant tachycardia, 159–165
congestive heart failure development, 148, 150–151
negative inotropic effects, 150
previous studies compared, 149–150
safety, 150–151
side effects, 148–151
vs. propafenone, 149–151
vs. propafenone for sinus rhythm maintenance, 145–151
Distal tubule, 805, 806, 807
chloride delivery, 805
sodium delivery, 805, 806
Disulfide bonds, intrachain, 795
Dithiothreitol, 68, 512
Diuretics, 502, 515, 752
ACE inhibitor sympathetic activity, 640
antihypertensive drugs and aortic stiffness, 50, 51
captopril and renal impairment, 75
cardiovascular disease treatment changes, 189–191
CCB controversy and, 410, 411
as CHF treatment, 561, 562
contraindications, 459
coronary artery disease and, 397–399
effect of fibrinolysis and platelet functions, 122
end-stage heart failure medical treatment, 617–620
extracellular sodium reduction, 513
for anginal pain, 574
for black patients with high blood pressure, 459
for dilated cardiomyopathy, 354
for elderly with systolic hypertension, 455
hydrochlorothiazide as antihypertensive therapy, 49–56
hypertensive treatment and, 67
as monotherapy, 455, 458
nanterinone hemodynamic effects in heart failure, 137–143
and nitrate tolerance, 735, 741
not as first-line therapy, 458–459
not as single agent for heart failure, 711, 712
potassium-sparing, 694
renal hemodynamics and, 804–807
and renin-angiotensin-aldosterone system, 624, 625, 626
risk indicators for death after AMI, 486, 487, 489
risk of myocardial infarction and, 405
vs. calcium channel blockers, 414, 464–465, 466
with aldosterone drugs, 617, 618
with bosentan, 717, 722, 723
with calcium antagonists, 464
with nitroglycerin patch therapy, 7
with thiazides, 617, 618, 619
Diuretics, loop, drug treatment of heart failure, 693, 694, 696, 698
Dizziness, 515
DL-3-(glutaryl-3-^{14}C)-hydroxy-3-methylglutaryl CoA (51.6 mCi/mmol), 68
Dobutamine, 620, 693, 695, 704
chemical structure of, 32
heart failure treatment, 693

renal and systemic hemodynamics in heart failure, 86
vs. arbutamine, adrenergic activities of, 39–46
vs. arbutamine as pharmacological cardiac stress agent, 31–38
Docosahexaenoic acid, 223–227, 379, 380
Dofetilide, 543, 544, 776
Dogs
arbutamine as pharmacological cardiac stress agent, 31–38
arbutamine effect on hemodynamic functions blocked by propranolol, 45, 46
betaxolol vs. propranolol effects on Ca^{2+}-activated contractions in skinned fibers, 581–586
endothelin-1 response in failing myocardium, 107–112
protein kinase C inhibitors, 779, 780
protein kinase C isotypes, 778
protein kinase C translocation/activation, 779, 781
tilisolol in canine coronary circulation, 23–29
Dopamine, 31
cyclization of, 235
for end-stage heart failure, 620
heart failure treatment, 693, 695
renal and systemic hemodynamics in heart failure, 86
Dopamine-ß-hydroxylase (NPY), 662
Dopaminergic (DA_1) receptors, 695, 696
Dopaminergic (DA_2) receptors, 695, 696, 697
Doppler ultrasound, hypertensive therapy, 51, 55
Dosage, bosentan, 722
Dose-finding study, pranidipine in hypertension, 59–66
Dose-ratio (dr) values, 41
Downstream events, 796
Doxazosin, in ALLHAT study, 411
Draize rating scale, 180
Drive train beat, almokalant and, 543, 544
Droperidol, 448
Drosophila, *per* gene, 678
Drug classes
calcium channel antagonists, 403–406
long-acting, 397
short-acting, 397
Drug failure, propantheline bromide and, 691
Drug therapy
long-term, 527
myocardial infarction and, 519
Dry mouth side effect, 689, 690, 691
Duncan's multiple range test, 69, 669
Dunnett's test, 33
DuP-753, 698; *see also* Losartan
Dynacirc. *See* Isradipine
Dynorphin, 514
Dyslipidemia, 278, 788
cardiovascular disease treatment changes, 189–191
hypertensive drugs and, 67
Dyslipoproteinemia, 744
Dyspnea, 527
Dystrophic process, 588

E-3174. *See* Metabolites
E-4031, 543
Early growth and differentiation genes (Egr-1), 798
Early growth response gene, 798
Early insulin response (EIR), 265
ECAT Study. *See* European Concerted Action on Thrombolysis and Disabilities Angina Pectoris Study
Echocardiograms
almokalant study and, 540
ambulatory, cardiovascular safety of nicotine patches, 179–183
diastolic function, adrenergic stress, 322, 323, 328
Echocardiography, 528, 561, 704
of cardiac sarcoidosis, 498–499
transthoracic, 352, 353–354, 357
Echo-Doppler methods, elgodipine hemodynamic profile, 573, 574
Echographic ejection fraction, 561
Ecto-5'-nucleotidase, 776, 783
Ectopy, ventricular, frequency reduced by ACE inhibitors, 625
Edema
and CHF treatment, 694
interstitial, 499
Effective refractory period (ERP)
class I drugs adverse effects with manifest WPW syndrome, 161
right ventricular, 369, 371–373, 375, 376
Effective renal plasma flow (ERPF), enoximone and systemic and renal hemodynamics, 81–86
Effector cells, 705
Efficacy
calcium antagonists as first-line agents, 463–466
intermittent vs. continuous transdermal nitroglycerin, 5–9
surrogate vs. health, 463
Eicosanoids, 728, 731, 732, 733
Eicosapentaenoic acid, 224, 379
Elderly
beta-blocker therapy, 455, 458
diltiazem in supraventricular tachyarrhythmias, 11–15
diuretics for systolic hypertension, 455
efficacy of losartan and captopril in, 698
hemostatic predictors of thrombosis, 746
hypertensives and calcium antagonists, 465
incidence of CHF in, 693
propantheline bromide use and, 692
renal impairment and ACE inhibitors, 75–78
STOP study, 458
Electrical fibrillation threshold, 447, 451
Electrical field stimulation, 658, 662, 663
Electrical standstill, 621
Electric disturbance type cardiomyopathy (ECM), 497
Electrocardiograms (ECG), 370, 374, 532, 550, 551
abnormalities and cardiac sarcoidosis, 502
almokalant study and, 540
ambulatory, cardiovascular safety of nicotine patches, 179–183
antihypertensive therapy, 50
Borrelia burgdorferi cardiomyopathy, 355–357
cardiac sarcoidosis, 495, 497–498
cardioprotection by Cromakalim, 590
cardiovascular safety of nicotine patches, 180
diltiazem in supraventricular tachyarrhythmias, 12
Electrophysiologic Basis of ECG and Cardiac Arrhythmias (book review), 89
elgodipine hemodynamics during rest and exercise, 574
monitoring, 687
monitoring and HRV, 682
monitoring and ventricular fibrillation, 447, 449, 451
reperfusion intervals and preconditioning, 342
surface parameters, 371, 373
to display heart rate, arbutamine study, 32
use in AMI, 522
ventricular tachycardia and, 527, 528
Electrograms, epicardial, 370
Electrolytes
balance, angiotensin II and, 511
imbalance, inner cell, 587
loss of, 410
serum, 370, 371
serum, bosentan effect, 722
Electromechanical dissociation, 621
after acute myocardial infarction, 486
Electronic microscopy, 559
Electron spin resonance (ESR) spectroscopy, EUK-8 vs. DMTU effects, 332–334, 337, 338
Electrophoresis, 558
Electrophysiological disorders, 450
Electrophysiological parameters, 449, 450, 453, 531
Electrophysiological study, 549–552, 554, 555
antiarrhythmic drugs for supraventricular tachycardia, 159–165
ischemic changes, 551
Electrophysiologic measurements, 370–374, 376
Electrophysiology, cardiac
almokalant effect and, 539, 540

Electrophysiologic Basis of ECG and Cardiac Arrhythmias (book review), 89
Elgodipine
hemodynamics during exercise, 573–580
intravenous, hemodynamic effects, 578
maximal therapeutical effects, 578
side effects, 576
vs. dihydropyridines, 578–580
ELITE trial. *See* Evaluation of Losartan in the Elderly trial
Embolism, 528
Embolization, 622
Embryo, AT_2 receptor expression, 512
EMIAT trial. *See* European Myocardial Infarction Amiodarone Trial
Emotion, heart rate and, 677, 678
Enalapril, 564, 625, 634, 695, 696
cardioprotective effect in coronary heart disease, 639–643
CONSENSUS-2 trial, 761
cost-effective for severe heart failure, 455
for congestive heart failure, 619, 620
hypertension with endothelial dysfunction studied, 469, 470, 471
MI and, 519, 520, 522
nanterinone hemodynamic effects in heart failure, 138
renal hemodynamics and, 804, 805, 807
SOLVD trials, 613
vs. losartan safety and efficacy, 313–319
Enalaprilat, 564
Encainide, 555, 762
CAST results, patients with ventricular ectopy, 151
Encephalomyocarditis (EMC) virus, 704, 705
End-diastolic pressure, left ventricular, nitrates effect, 740
Endocardial fibroelastosis (EFE), 500, 501
Endocardial refractoriness, 452
Endocardium, 500, 501
ischemia and, 452
Endocrine system, AII and, 513
Endogenous fibrinolysis, 633
Endogenous fibrinolytic system, 633
Endomyocardial biopsy, 704
Konno's, and cardiac sarcoidosis, 495, 497, 499–500
Endomyocardium, 782
Endopeptidases, 511, 512
E.C.3.4.24.11, 512
E.C.3.4.24.15, 512
E.C.3.4.24.26, 512
Endoplasmic reticulum, 796, 797
Endothelial cell culture, 557, 558, 559
Endothelial cell injury, 743–746
Endothelial cells, 564, 778, 782
calcium channel blocker effects, 418
endothelin and, 795, 796, 798, 799
human umbilical cord, 706
modified, sympathetic overactivity and lipids, 224
vascular, 797, 798
vascular, ET_B receptors in, 795
Endothelial dysfunction, 632
ACE inhibitors effect on, 469–471
Endothelial function, angiotensin-converting enzyme inhibition in coronary artery disease, 609–611
Endothelial injury, 633, 634
Endothelial procoagulant, 745
Endothelin (ET), 623, 625, 626, 633, 778
angiotensin II-mediated production inhibited by ACE inhibition, 610
calcium antagonists and endothelial function, 439–445
hyperplastic response, 796
hypertrophic response, 796
immunoreactive, 797, 798, 799
plasma concentration and captopril in congestive heart failure, 561–564
released due to angiotensin II, 469–470
and vascular hypertrophy, 795–800
Endothelin antagonism in human heart failure, 717–724
Endothelin antagonists, 800
Endothelin-converting enzyme, 795
Endothelin receptor antagonists, 797, 798, 799
Ebndothelin receptors, 799, 800
Endothelin release, spillover, 799
Endothelin system, 795–796
Endothelin-1 (ET-1), 442–445, 561–564, 728, 731, 776, 778, 795–799
bosentan treatment for congestive heart failure, 717–724
mitogenic effects, 722
plasma irET-1 concentration, 563, 564
radioimmunoassay (RIA), 562–563
response altered in failing myocardium, 107–112
Endothelin-1 converting enzyme inhibitors, 719
Endothelin-1 gene
cardiac, 722
expression, 796, 797, 798, 799
Endothelin-1mRNA (prepro), 439, 797, 799
Endothelin type A/B($ET_{A/B}$)-receptor antagonism, bosentan treatment for congestive heart failure, 717–724
Endothelin-type A receptor (ET_A), 718, 722–724, 795, 796, 797, 798
antagonist, 796, 799
signal transduction pathway, 111
vasoconstrictor, 799
Endothelin-type B receptor (ET_B), 111, 718–720, 722–724, 795, 796, 797
antagonist, 796, 799
vasodilator, 799
Endothelin-2 (ET-2), 563, 795, 796, 799
murine form (ET-4) of, 795, 796
Endothelin-3 (ET-3), 563, 793, 795, 796
Endothelin-4 (ET-4), 795, 796
Endothelium, 379–384, 631–636
barrier effect of, 111
dysfunction, 379
endothelin-1 response in failing myocardium, 107–112
improved function, 631, 635
pulmonary vascular, damage, 557
toxicity of amiodarone for, 557–559
vascular, 511, 514, 795
vascular, angiotensin receptors, 512
Endothelium-dependent relaxations, 17–21, 381–384
Endothelium-derived nitric oxide (EDNO), 383, 384
Endothelium-derived relaxing factor (EDRF), 624, 626, 632, 633, 717, 723
and ACE inhibition, 641
cyclosporine and coronary endothelial function, 17–21
ET_B receptors responsible for, 111
mediating flow-dependent vasodilation in canine coronary circulation, 28, 29
Endothelium-independent responses, cyclosporine and coronary endothelial function, 18, 20
Endotoxemia, 706
Endotoxin, 730
Endpoint, 519, 523
of ablative procedure, 528
alternatives to death, 761–762
clinical cardiac, 634, 635
of controlled therapy, 550
of coronary heart disease, per Framingham Heart Study, 788–789
hard, 399
hard, for statistical analysis of clinical trials, 755
intermediate, 399
Metoprolol in Dilated Cardiomyopathy trial, 713
primary, death or heart transplant, 362
primary, MDC trial, 362
secondary, MDC trial, 361
soft, 399
surrogate, 399, 755–756
End-stage congestive heart failure, 626
End-stage heart disease, ACE inhibitor cardioprotective effects, 639–643
End-stage heart failure
additional therapeutic measures, 621–622
endothelin-1 response, 112
hemodynamically unstable patients, 620
medical treatment of, 617–622
End-stage refractory heart failure, definition, 618
Energy metabolism, effects of catecholamines, 228
Energy supply, ACE inhibitors effect, 640
Energy utilization, 590

myocardial, 703, 704, 705, 706
Enkephalin, 514
Enoximone, 620, 699, 762
and systemic and renal hemodynamics, 81–86
vs. nanterinone, 142
Enzymatic colorimetry, 380
Enzymes
angiotensin II (AII), 511, 514, 515
calcium antagonists and, 403, 404
ischemia and, 452
Epicardial coronary arteries, nitroglycerin effects, 739
Epicardium, ischemia and, 452
Epidemiological studies, lipophilic antioxidants and cardiovascular disease, 567
Epidermal growth factor (EGF), 798
Epimyocardium, 782
Epinephrine
cyclization of, 235
diet restriction and adrenergic mechanisms, 239–245
-induced arrhythmia, 674
in heart failure patients, 624
lisinopril effect on resting concentration, 323, 328
long-term dietary restriction effects, 247, 248, 249
nicotine and sympathetic neurotransmission, 657–663
obesity and autonomic regulation, 264–266, 268, 269
Epinephrine treatment, sympathetic overactivity and lipids, 225
Epinine, 696, 697; *see also* N-methyldopamine
Epoprostenol, 713; *see also* Prostacyclin
Equimolar amrinone, 706
Equivalence, as clinical and philosophical concept, 762–764
Equivalence trials, alternatives to mega-trials, 759–764
Ergomanomat, 50
Erythema chronicum migrans (ECM), and *Borrelia burgdorferi* cardiomyopathy, 351–353, 355, 357
Escape clause, 15
Esmolol, 15
Esophagus tissue, 514
Essential hypertension, 757, 799, 803, 804, 807
angiotensin mechanism and, 511–516
diastolic function, adrenergic stress and angiotensin II in, 321–328
isradipine sustained release effects, 119–122
mild to moderate, losartan vs. enalapril safety and efficacy, 313–319
pranidipine in hypertension, 59–66
Estimated odds ratio (OR), 298
Ethanol ingestion, food restriction and, 244
Ethics
almokalant study and, 540
plasma endothelin-1 and captopril study, 563
Ethmozime, 555
Euglobulin lysis time (ELT)
after standardized venous occlusion (ELT-VO), 120, 121
isradipine sustained release effects in hypertension, 120, 121
Euglycemic hyperinsulinemia, 217
Euinsulinemia, 215–217
EUK-8
cardioprotective effects of, 331–338
chemical structure, 333
European Association for Clinical Pharmacology and Therapy, 573
European Concerted Action Against Thrombosis, 747
European Concerted Action on Thrombosis and Disabilities Angina Pectoris (ECAT) Study, 754
European Myocardial Infarction Amiodarone Trial (EMIAT), 714
European Society of Cardiology in Amsterdam, August, 1995, 409
Euthyroid sick syndrome, 369, 371–374
Evaluation of Losartan in the Elderly (ELITE) trial, 698
Excess catecholamines, as drug targets, 236–237
Excess catecholamine syndrome, 231–237
Excitability, 452, 453
of cardiovascular cells, 514
myocardial, 534
Excitation, ventricular, almokalant and, 539, 545
Excitation-contraction coupling, 672, 703
Exercise, 745
antiarrhythmic drugs and, 545
arbutamine as pharmacological cardiac stress agent, 31, 37
and atherosclerotic stenosis, 23
bicycle protocol in European centers, 362
capacity, 699, 704, 705, 706, 707
digitalis and exercise capacity, 618, 619
diminished norepinephrine response, 263, 266, 270
elgodipine hemodynamics during, 573–580
HRV and, 678
-induced coronary spasm, 457
intermittent vs. continuous transdermal nitroglycerin, 5–9
neuroendocrine response, 623
oxygen, blood flow inadequacy and, 447
and postmenopausal women, 387
sympathoadrenergic overactivity and lipid metabolism, 223–229
tolerance, digitalis for heart failure, 711–712
tolerance, metoprolol and quality of life in heart failure, 361–367
Exercise capacity
calcium antagonists and, 403
nanterinone effects in mild heart failure, 143
Exercise performance, nitrate tolerance, 735–739
Exercise stress testing, 39
Exercise test, isometric handgrip stress, 50, 51, 52, 55
Exocytosis, 662
Exocytotic release mechanism, 660, 661, 662
Extracellular matrix, detachment, 557, 559
Extracellular protein, 633
Extracellular volume, 805
Extraneuronal uptake, 662
Extrasystoles, ventricular, almokalant and, 539, 542–545

Factor VII, 746
Factor VIII/von Willebrand factor complex, 746
Fagerstrom score, 180
Faintness, and cardiac sarcoidosis, 502
Fat, amiodarone concentration in, 559
Fatal myocardial sarcoidosis (FMS), 502, 503
incidence, 496
Fatty acid free bovine albumin, 41
Fatty acids
endogenous, 570
sympathoadrenergic overactivity and lipid metabolism, 223–229
Felodipine, 400, 404, 414, 698
ATP-sparing effect, 425
attenuation of regional myocardial stunning, 347–349
beneficial effects, 174–176
calmodulin-inhibiting effects, 175
and cardiac protection, 425–435
dosages and their effects, 429, 430
dose-response infusions during low-flow ischemia, 169–174, 176
dose-response infusions during normoxia, 169–170, 173, 174
extended-release, 459
for less severe heart failure, 713
in myocardial ischemia, 167–176
negative inotropic effect absent, 174, 175, 176
protection against ischemic reperfusion injury, 168, 175, 176
safety documentation for SR (plendil) in hypertension, 464
vs. bepridil, 174, 175–176
vs. elgodipine, 577
vs. W-7, 175
Felodipine, ER, 400
Femoral artery, 370
Femoral blood flow, formula, 114
Femoral vascular resistance (FVR)
formula, 114
metoprolol vs. carvedilol in hypertensive patients, 116
Femoral vein, 370
Fenfluramine, 280

Fenofibrate, cost effectiveness in hyperlipidemia, 787, 790, 791, 792–793
Fenton reaction, 331, 335
Fibrates, 745, 762
  cost effectiveness in primary hyperlipidemia, 787–793
  calcium antagonists vs. beta blockade, 457
Fibrin, 743, 744, 746
Fibrinogen, 663, 754
  plasma level as hemostatic predictor, 743, 744. 745, 746
Fibrinolysis, 744
  isradipine sustained release effects in hypertension, 119–122
Fibrinolytic drugs, 303, 523
Fibrinolytic potential, 405
Fibroblasts, 782, 798
  cardiac, endothelin-1 mitogenic effects, 722
  homogenized, 778
Fibronectin, 743
Fibrosis, 682, 683, 743
  interstitial, 498, 499, 500
  periarterial, 501
  perivascular, 499, 501
  periveneous, 501
Filtration fraction (FF), 803, 804
  enoximone effect on renal and systemic hemodynamics, 85, 86
FIRST trial. *See* Flolan International Randomized Survival Trial
Fisher's exact test for dichotomous variables, 486, 551, 563
Fisher's permutation test, 486
Fish oil (FO), C_x-induced vascular toxicity and fish oil, 379–384
Fixed effects model, 298
Flecainide, 536–537, 544–545, 550–555, 762
  CAST results, patients with ventricular ectopy, 151
  effects on accessory pathways, 163
  intravenous, for atrial fibrillation, 156
  maintenance rates of sinus rhythm in studies, 149–150
  vs. amiodarone negative inotropic effect, 156
Flesinoxan, 288
Flolan International Randomized Survival Trial (FIRST), 713
Flosequinan, 700, 713, 762
Flunitrazepam, 448
Fluorescein, 782
Fluorescence polarization immunoassay, 380
Flushing side effect, 691
Fluvastatin, cost effectiveness in hyperlipidemia, 787, 790–793
Foam cells, 417, 634
  formation, angiotensin II role, 469
Folate supplements, 757
Follow-up coronary arteriography, 477, 479, 481
Food and Drug Administration (FDA), 410
  safety documentation for SR calcium antagonists in hypertension, 464, 466
Food restriction, vs. caloric intake effect on rat hearts, 244–245
Fosinopril, 520, 564, 696
Fourier transformation, 677, 680, 682, 683
4S trial. *See* Scandinavian Simvastatin Survival Study Group trial
FR 139317, 799
Framingham Heart Study, 703, 754–755, 788–789, 792
  logistic equations for primary events, 789
  risk of cardiovascular events, 119
Free fatty acids
  activating isozymes, 779
  increased parasympathetic activity and, 263–265, 267, 269–271
  myocardial infarction, 297
Free l-thyroxine (FT_4), 370, 372
Free oxygen radicals, 745
Free radicals, 567
Free radical scavenging, 633
Frequency dependence, of almokalant, 539–546
Frequency-dependent depressant effect, of KT-362, 674
Frequency domain method, HRV and, 680, 681
Friedenwald formula, 476
Fura-2, KT-362 and Ca^{2+} transients, 667–674
  /AM, 668
  Ca^{2+} signals, 440–441
Furburg study, 409, 410
Furosemide, 550
  drug treatment in heart failure, 694, 695
  for congestive heart failure, 619

Gadolinium chloride, 660, 661
Gallium (67 GA), 499
Gallopamil (D-600), KT-362 and Ca^{2+} transients, 667–674
$G\alpha_i$ protein concentrations, 678
$G\alpha_{i2}$ proteins, 679
$G\alpha_s$ protein concentrations, 678
Gamma-aminobutyric acid (GABA), 658
Gammaglobulins, in blood, as cardiac sarcoidosis diagnostic indicators, 497
Gamma-^{32}P-labelled ATP, 778, 781
Ganglionic blockade, 691
Gas liquid chromatography, 380
Gastrointestinal bleeding, with calcium antagonists, 465
Gastrointestinal distress, 704
Gastrointestinal mucosal injury, aspirin therapy and, 727–733
Gastrointestinal toxicity, 515
Gemfibrozil, 761
  cost effectiveness in hyperlipidemia, 787, 790–793
  Helsinki Heart Study and reduction of atherosclerotic disease, 792
Gene polymorphism, 631
Genetics, coronary artery disease risk factors, 614
Genetics studies, 631–633, 636
Genotyping, 643
GESICA trial, 714. *See* Grupo de Estudio de la Sobrevida en la Insuficienca Cardiaca en Argentina trial
GF109203X, as protein kinase C inhibitor, 780
Giant cell myocarditis, vs. cardiac sarcoidosis, 500
Gingivitis, chronic, 745
GISSI trial. *See* Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto miocardico
GLANT project. *See* Study Group of Longterm Antihypertensive Therapy Project
Glaucoma, narrow-angle, 691
Glibenclamide, 590, 770, 771
  with tilisolol, in canine coronary circulation, 23–29
Global ischemia, 768
Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial, 756, 760, 762
  GUSTO-1, 413
  GUSTO-2a, 413
Glomerular basement membrane, 807
Glomerular damage, 806
Glomerular filtration rate, 697, 803, 804, 805, 807
  captopril and renal impairment, 75
  diltiazem, 15
  diuretics for congestive heart failure, 619
  enoximone and systemic and renal hemodynamics, 81, 83, 85, 86
Glomerular hemodynamics, 513
Glomerular-tubular balance, 513
Glomerulopathy with proteinuria, 276, 279
Glomerulosclerosis, moxonidine benefits for obese hypertension, 275–280
Glucagon, 245
Glucocorticoids, 245, 727
Gluconeogenesis, hepatic, 264
Glucose
  endothelin release and, 795
  high plasma level as hemostatic predictor, 744
  increased parasympathetic activity and, 263–265, 267, 268, 271
  intolerance and hypertensive drugs, 67
  intolerance in hyperlipidemia study, 789
  tolerance, moxonidine effect on, 277–279
  tolerance, reduced, 694
  withdrawal, 662
Glucose-6-phosphate dehydrogenase, 68
Glutathione, reduced GSH, felodipine and cardiac protection, 425, 426, 428, 431, 433, 434

Glutathione peroxidase, 567, 570
Glyceryl trinitrate, 729
Glycogen, depletion dissociated, 769
Glycogenolysis, hepatic, 264
Glycolysis, 660, 662
  and adenosine, 769
  role in preconditioning effect, 767–769
Glycolysis/glycogenolysis, 768
Glycoprotein IIb/IIIa, 405
Glycosaminoglycan, polyanionic, 569
Glycoside, cardiac, 694, 695, 696
Goteborg study, 744
G-proteins. *See* Guanine nucleotidebinding regulatory protein
Graft vasculopathy, 384
Granulocytes, 746
Group Health Cooperate of Puget Sound, 405
Growth factors, 445, 511, 513, 623, 633
  endothelin and vascular hypertrophy, 795–800
  vascular smooth muscle cell, 795
Grupo de Estudio de la Sobrevida en la Insuficienca Cardiaca en Argentina (GESICA) trial, 714
Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto miocardico (GISSI)
  GISSI-1, 754
  GISSI-2, 405, 759, 760
  GISSI-3, 520–523, 642, 712, 754
GTP-binding-protein-linked receptors, 776
Guanabenz, blood pressure rebound, 260
Guanfacine
  blood pressure rebound, 260
  chemical structure, 286
  onset of action and effect, 286
  and sympathetic outflow, 283–288
Guanine nucleotide-binding regulatory protein, 770, 796, 797
  pertussis toxin-sensitive, 770
Guanyl nucleotide binding protein (Gs), endothelin-1 response in failing myocardium, 107
Guanyl nucleotide proteins (G-proteins), 512
Guanylyl cyclase, 513
Guinea pigs
  arbutamine, adrenergic activities of, 39–46
  electrocardiological effects of AWD 23–111, 531–537
  nicotine effect on hearts, 657–662
GUSTO trial. *See* Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial
Gut, renin-angiotensin system and, 512, 514
Gynecomastia, 619

H-7. *See* 1–(5-isoquinolinesulfonyl)-2methylpiperazine
Haber-Weiss reaction, 331, 335
Haemodynamics, elgodipine effects during exercise, 573–580
Hamster
  arbutamine, adrenergic activites of, 39–46
Hamster cardiomyopathy (CM), cardioprotection by cromakalim, 587–590
[^{3}H]-clonidine, 286
Headaches, 515
Head-up tilting reflex, HRV and, 678
Health care economics
  and research funding, 757
  risk reduction and cost-effectiveness of clinical trials, 751–757
Healthy subjects, cardiovascular safety of nicotine patches, 179–183
Heart
  amiodarone concentration in, 559
  angiotensin receptors and, 512–514
  necrotizing process, 587–589
Heart aneurysms, 501
Heart block (atrioventricular block, AV), 298, 497, 621
  and cardiac sarcoidosis, 497
  diltiazem in supraventricular tachyarrhythmias, 12
Heart catecholamines
  adrenergic mechanisms and food restriction, 239–246
  cardiovascular function and food restriction, 247–250
Heart catheterization, right, 620
Heart disease
  chronic ischemic, 561
  organic, 527, 528
  ventricular paced QT intervals and, 545
Heart failure, 8, 13, 303, 307, 448, 452, 515
  ACE inhibition, 610
  ACE inhibitors and acute MI, 519–524
  activation of humoral adaptive responses, 623–624
  anticoagulant treatment recommended, 715
  betaxolol vs. celiprolol treatment, 585
  Borrelia burgdorferi cardiomyopathy, 351–358
  bosentan treatment for CHF, 717–724
  captopril and plasma endothelin-1, 564
  clinical, 550, 552
  diagnosis and management, 711–715
  disopyramide vs. propafenone for sinus rhythm maintenance, 145–151
  enalapril for treatment, 455
  endothelin-1 response in failing myocardium, 107–112
  enoximone and systemic and renal hemodynamics, 81–86
  LVH and, 399
  medical treatment suggested by Canadian Cardiovascular Society's Consensus Conference, 711–715
  metoprolol and quality of life, 361–367
  nanterinone hemodynamics effects, 137–143
  neuroendocrine response in, 623–627
  neutral endopeptidase prolonged inhibition effect on cardiac hypertrophy, 593–596
  and nitrate tolerance and rebound, 735–741
  NYHA class III, 712
  NYHA class IV, 712
  PRAISE study, 411
  progressive, 631, 634–636
  recurrent or refractory, 502
  severe decompensated, refractory to conventional treatment, 712
  survival, 695
Heart function
  adrenergic mechanisms and food restriction, 239–246
  cardiovascular function and food restriction, 247–250
Heart muscle, acetylcholine and, 691
Heart Outcomes Prevention Evaluation (HOPE) trial, 471, 635, 643
Heart rate, 448, 450, 453
  almokalant effects on, 539, 543–545
  AWD 23–111 effect on, 535–537
  basal, 681
  bosentan effect, for congestive heart failure, 717, 723
  bosentan effect on, 719, 722
  cardiovascular safety of nicotine patches, 179, 181, 182
  clonidine effect, 253–260
  cromakalim effect, 590
  during tilt-table testing, 687–689
  elgodipine hemodynamics during rest and exercise, 573–580
  EUK-8 vs. DMTU cardioprotective effects, 333, 335
  genetic component, 678
  increased and CHF, 694, 697–699
  ischemic preconditioning, 768
  isradipine in essential hypertension, 121
  metoprolol and carvedilol in hypertension, 115
  moxonidine effect, 252, 254, 255, 257–260
  nanterinone hemodynamic effects in heart failure, 139, 141, 143
  nicotine and, 657
  a pharmacological tool, 677–684
  propafenone vs. disopyramide effects before cardioversion and at arrhythmia relapse, 149, 150
  regulation of, 680, 681, 682
  resting, 688

sympathoadrenergic overactivity and lipid metabolism, 223–229
tilisolol in canine coronary circulation, 25–26, 28
Heart rate variability (HRV)
heart rate, a pharmacological tool, 677–684
high frequency, 681, 682, 683
low frequency, 681, 682, 683
measuring, 680
reflexes controlling, 678
Heart size, food restriction effect, 242
Heat-shock proteins, 771, 775, 776
Heat shock/stress proteins, 783
Heat stress, 730
Helsinki Heart Study, 67, 792
Hemangioendotheliomas, 799
Hematocrit, 7–8
and blood viscosity, 745
Hemodilution, 745
Hemodynamic benefit, 519, 521, 524
Hemodynamic compromise, 551
Hemodynamic effects
drug therapy and, 697–700
inotropic agents and, 703–707
Hemodynamic overload, 796
Hemodynamics, 631, 635
ACE inhibitors in CAD patients, 640
arbutamine as pharmacological cardiac stress agent, 33, 34, 35
bosentan treatment for CHF, 717–724
enoximone and systemic and renal hemodynamics, 81–86
felodipine and stunning, 348
glibenclamide with tilisolol in canine coronary circulation, 25, 27
intrarenal, 807
long-term dietary restriction in rats, 247–249
metoprolol vs. carvedilol in hypertensive patients, 113–117
nanterinone hemodynamic effects in heart failure, 137–143
nitrate tolerance, 735
rebound hypertension and central acting drugs, 251–261
renal, antihypertensive drugs and renal function, 803–807
reperfusion intervals and preconditioning, 343–344
stability, 549, 550
systemic, 806
tolerance, 449
Hemofiltration, 619
Hemoglobin, 757
Hemorrhage, 640
calcium blocker benefits, detriments, 403–406
as complication in routine use of aspirin, 727
neuroendocrine response, 623
Hemostasis, 406, 631–636
calcium and, 404
Hemostatic abnormality, 743
Hemostatic predictors, 743, 744
Heparin, 405, 528, 532, 570, 760
treatment for unstable angina, 739
Hepatic microsomal systems, calcium channel blocker effects, 418
HEPES [N-(2-hydroxy-ethyl)-piperazine-n2-ethane-sulfonic acid], 68, 69
n-heptane, 322
Heptapeptide angiotensin-(1–7), 511
Herxheimer-Jarisch reaction, 356–358
Heterotopic heart transplant model, 384
Hexamethonium, 659, 660, 662
Hexapeptide, 563
[^{3}H]-idazoxan, 286
High-affinity intracellular receptors, 776
High-density lipoprotein (HDL), 731
cost-effectiveness in hyperlipidemia, 787, 788
effects of beta blockers on HMG-CoA receptors, 67, 68
High-density lipoprotein cholesterol, 569, 747
beta blockers and, 68
pravastatin study, 476, 477, 478
raised levels by HMG-CoA reductase inhibitors, 787–793
High-density lipoprotein-3 (HDL-3), 731
High-energy phosphates, 297, 768
felodipine and cardiac protection, 425, 427–428, 433
isoproterenol-induced alterations, 234–235
High performance liquid chromatography (HPLC), 240, 322, 426, 428, 568
High-pressure liquid chromatography (HPLC), 235, 370
HINT study. *See* Holland Interuniversity Nifedipine/Metoprolol Trial Research Group
His bundle, 550
His bundle conduction time, 531–534, 536
His potential, almokalant and, 540
His Purkinje system, 531
Histamine, 41, 43, 380, 381, 382, 728
Histamine-induced relaxations, 379, 381, 382, 383
Histone III-S, 778, 781, 782
[^{3}H]-mevalonolactin, 68
HOE 140, 768
Holland Interuniversity Nifedipine/Metoprolol (HINT) Trial Research Group, 398, 457
Holter monitoring, 6, 551, 555, 677, 680, 682, 691, 705
and cardiac sarcoidosis, 498
HOPE trial. *See* Heart Outcome Prevention Evaluation trial
Hormonal activation, enoximone and systemic and renal hemodynamics, 81–86
Hormone replacement therapy, in postmenopausal women, 387
Hormones
bosentan effect, 718, 719
endothelin release, 795, 797
neuroendocrine response in heart failure, 623–627
Horn rating scale, modified, 180
Hospitalization, cardiovascular disease treatment changes, 189–191
^{3}H-thymidine, 796
Human atrial tissue, cardiac norepinephrine release and, 659–660
Human coronary artery, calcium antagonists and endothelial function, 439–445
Human coronary vein, calcium antagonists and endothelial function, 439–445
Humans, nanterinone hemodynamic effects in heart failure, 137–143
Human skin fibroblasts, effects of beta blockers on HMGCoA reductase, 67–73
Human syndrome X, resembling obese hypertension in rats, 275–276, 278–280
HV intervals, 528
AWD 23–111 effect on, 532–534
Hydralazine, 695, 805
for end-stage heart failure, 617, 619, 620
with isosorbide dinitrate, 735, 740–741
with nitrates for heart failure, 712
Hydrochlorothiazide (HCTZ), 311, 398, 694, 698, 803, 804
antihypertensive therapy and aortic stiffness, 49–56
in INSIGHT study, 411
in MIDAS, 464
Hydrogen peroxide, 235, 338
Hydrolases, 768
Hydrophilic molecules, 691
Hydroquinidine, 550
6-hydroxydopamine, effect on preconditioning of rat heart, 133
15-hydroxy-5,8,11,13-eicosatetraenoic acid (15-HETE), 727
3-hydroxy-e-methylglutaryl coenzyme A (HMG CoA) reductase, 68
beta-blockers and, 67–73
mRNA, 71
HMG CoA-reductase inhibitors, 643
cost effectiveness in primary hyperlipidemia, 787–793
lovastatin, to prevent restenosis after PTCA, 475, 481
pravastatin and restenosis, 475–482
Hydroxylapatite high-pressure-liquidchromatography, 778
Hydroxyl radicals, 331–335, 337, 338
Hydroxyproline level, neutral endopeptidase prolonged inhibition effect, 593, 594, 595
5-hydroxytryptamine, 728
5-hydroxytryptamine maleate, 380
Hyperaldosteronism, secondary, 619
Hyperalimentation, obesity and autonomic regulation, 263–271
Hyperangiotensinemia, 515
Hypercapnia, 13

Hypercholesterolemia, 17, 21, 384, 481, 610, 717, 744–745, 756
antioxidants and LDL apheresis, 567–571
cost effectiveness of treatment, 787
diet induced, 632
familial, 567, 568
familial, heterozygous form, 568
familial, homozygous form, 568, 569
mega-trials, 759
Hyperfiltration, 807
Hyperglycemia, 213, 245, 265, 280
renin profile and myocardial infarction, 613
Hyperglyceridemea, 266
Hyperhomocysteinemia, 746
Hyperinsulinemia, 213, 215–220, 275–276, 278, 280, 744
inducing hypofibrinolysis, 122
obesity and autonomic regulation, 263, 266–268, 270
Hyperinsulinemic euglycemic clamp, body fat and sympathetic nerve activity studies, 215–217, 218
Hyperkalemia, extracellular, 662
Hyperlipidemia, 459, 611, 746
costs (Montreal-based) of physicians visits, blood test, lipid profiles, and biochemical profiles, 788
familial combined, 790–791
familial heterozygous and polygenic, 790
in advanced CHF, 694
moxonidine benefits for obese hypertension, 275–280
primary, cost effectiveness of HMG-CoA reductase inhibitors and fibrates, 787–793
renin profile and myocardial infarction, 613
requiring chronic drug therapy, 191
Hyperlipoproteinemia, 275–276
Helsinki Heart Study, 792
Hyperperfusion, 807
Hyperphagia, animal models for, obesity and autonomic regulation, 266–270
Hyperphasia
vascular, 513, 515
vascular smooth muscle cell, 798
Hyperpolarization
acetylcholine and, 691
HRV and, 678, 679, 682
Hyperpolarization-activated current (I_f), 678
Hyper-reninemia, 806
Hypertension, 13, 561–562, 564, 631, 634, 717; *see also* Essential hypertension
ACE inhibitors effect on endothelial dysfunction, 469–471
ACE synthesis, 640, 641
angiotensin-converting enzyme (ACE) inhibition in coronary artery disease, 609, 610, 611
arterial, 745, 746, 800
arterial, calcium channel blockers for, 713
associated wtih obesity, 215, 219
calcium antagonism and ACE inhibition effects on neointima formation, 101–104
calcium antagonist controversies, 409–411
calcium antagonists and endothelial function, 439–445
calcium antagonists, 464
calcium antagonists for cardiovascular disease, 455–459
cardiovascular disease and, 67
cardiovascular disease treatment changes, 189–191
as cause of ineffectiveness of medical therapy for congestive heart failure, 618, 620
cilazapril and hydrochlorothiazide therapy, 49–56
cyclosporine and coronary endothelial function, 21
1,4-dihydropyridine vs. beta-blockers, 397–401
diltiazem or verapamil treatment in post-MI phase, 455
DOCA salt, 103, 104
drug costs for prevention of clinical event, 465
drugs inhibiting catecholamine release, 236
effect of beta blockers on, 71, 73
endothelin and vascular hypertrophy, 795–800
endothelin-1 role in, 717, 721
felodipine treatment, 167
and food restriction, 244, 246
hemorrhage and, 405
as hemostatic predictor, 743, 746, 747
incidence correlated with age, 213, 214
in Cottbus study of aspirin therapy, 732
in postmenopausal women, 387
isradipine sustained release effects, 119–122
L-NAME, 798
losartan vs. enalapril safety and efficacy, 313–319
malignant, 798, 799
mega-trials, 759, 762
metoprolol vs. carvedilol hemodynamic effects, 113–117
mineralocorticoid-induced, 719
moxonidine benefits for obese hypertension, 275–280
nonmodulating, 804
prevention of secondary complications, 442
primary, 795
primary pulmonary, and vasodilator treatment, 713
primary pulmonary, calcium channel antagonists for, 455, 456
pulmonary, 620, 800
pulmonary, and endothelin-1 role, 717, 721
pulmonary, bosentan effect, 719
rebound hypertension and central acting drugs, 251–261
renin-angiotensin system role in myocardial infarction pathogenesis, 613
renin inhibitors, 309–312
renovascular, 104
requiring chronic drug therapy, 191
risk indicators for death after AMI, 485, 487
risk of myocardial infarction, and calcium channel blockers, 413
role of kidney in, 803, 804, 805, 807
salt-sensitive, 804
spontaneous, 515
STONE Study report, 467–468
sympathoadrenergic overactivity and lipid metabolism, 229
treatment of, 693, 698
with diabetes/insulin resistance, 287
Hypertensive heart disease, associated with atrial fibrillation, 154
Hypertensive renal disease, 275
Hyperthyroidism, 550, 552
Hypertriglyceridemia, 267, 744
Hypertrophic cardiomyopathy, 403, 497
catheter ablation in patients with HCM, 527–529
Hypertrophy
cAMP and, 704
cardiac, 513, 515
cardiac, heart rate, a pharmacological tool, 677–684
cell, 797
endothelin-induced, 797, 798, 799
left ventricular (LVH), 286–287, 321–322, 328, 499, 613, 746
left ventricular, and ACE gene polymorphism, 614
left ventricular, ACE inhibitors and, 687
left ventricular, calcium antagonists and, 403
left ventricular, 1,4-dihydropyridine vs. beta-blockers for hypertension, 397–401
left ventricular, in hyperlipidemia study, 789
myocardial, endothelin responses and, 796–799
myocyte, 499
vascular, 513, 697
vascular, ACE inhibitor effect, 639–641
vascular, endothelin and, 795–800
vascular, hypertensive, 800
ventricular, 624, 625
Hyperuricemia, hypertensive drugs and, 67
Hypervagotonia syndrome, 687
Hypofibrinolysis, 122
Hypoglycemia

neuroendocrine response, 623
Hypokalemia, 12, 410, 458
diltiazem in supraventricular tachyarrhythmias, 15
magnesium supplementation, 307
provoked by digitalis, 618
Hypokinesis, 619
Hypolipidemic drugs, 568, 570
Hypomagnesemia, 304, 641
magnesium supplementation for acute myocardial infarction, 303–304
Hyponatremia
captopril and renal impairment, 75, 78
dilutional, 699
Hypo-osmolality, 699
Hypotension, 298, 303, 307, 619, 640, 690
ACE inhibitors and CHF, 695
after acute myocardial infarction, 486, 488
captopril and renal impairment, 75
diltiazem in supraventricular tachyarrhythmias, 11–14
from dipyridamole, 39
isosorbide-induced, 398
long-term dietary restriction effect in rats, 247
myocardial ischemia and, 449
observed with isoproterenol, 31, 38
systemic, 520, 523
tilisolol in canine coronary circulation, 28
vasodilating drugs and, 405
Hypotensive action, 635
Hypotensive drugs, 803, 805
Hypothalamus, 280
coordinating sympathoadrenal outflow and energy homeostasis, 266
idaxozane binding sites, 261
Hypothyroidism, and ventricular fibrillation, 369–376
Hypovolemia, 640
Hypoxanthine, 770
Hypoxanthine oxidase, 333
Hypoxanthine-xanthine oxidase, 338
Hypoxemia, 12
diltiazem in supraventricular tachyarrhythmias, 15
Hypoxia, 13, 795, 797
preconditioning rabbit myocardium via adenosine and catecholamine release, 767, 769

I_1-agonists, nutritional disorders, 213–214
I_f blocker, 682–683
Ibopamine, 713, 762
drug treatment of heart failure, 693–700
Idazoxan, 285, 287
ID genotype, 632, 633, 634
Idiopathic dilated cardiomyopathy (IDC)
Borrelia burgdorferi reversal by antibodies, 351–358
metoprolol and quality of life in heart failure, 361–367
II homozygotes, 614, 615
I-iodine, 68
^{125}I-iothalamate, 807
I-LDL, 71
Imidazoles, 514
I_1-imidazoline agonists, 229
Imidazoline (I_1) receptors, 213–214, 229, 236
located in neuronal networks, 283, 284, 286–288
moxonidine benefits for obese hypertension, 275–280
rebound hypertension and central acting drugs, 251–261
Immune disorders, 743
Immune mechanisms, 704, 707
Immunoblot analysis, 778, 781
Immunohistochemistry, 778
Immunohistofluorescence analysis, 778, 781, 783
Immunomodulation, inotropic agents in heart failure, 703–707
Immunosuppressive drugs, cyclosporine as, 379, 384
Immunosuppressive effects, 706
Implantable defibrillators, 754
Inclusion criteria, clinical trials, 751, 752
Individual stratification of absolute risk, clinical trials, 751–757
Indomethacin, 380, 382–384, 729
cyclosporine and coronary endothelial function, 17–21
Infarct, amiodarone and, 376
Infarction, 632
anterior, 519, 522, 524
index, 519
Q-wave, 519
Infarct location, 522
Infarct size, 298, 522
calcium effects on, 403
CCBs and, 410
as endpoint of ischemic preconditioning, 775, 776, 779, 781
not limited in rabbit hearts by ischemic preconditioning, 767
preconditoning protection afforded, 341, 343
prostacyclin effect on, 730
Infarct survivors, 554
Infarct to risk-zone ratio, reperfusion intervals and preconditioning, 343–345
Infarct volume, reperfusion intervals and preconditioning, 343–344
Infections, low-grade, 745
Infusion, duration of, amlodipine, 449, 450
Inhibitory muscarinic acetylcholine receptors, 662
INJECT. *See* International Joint Efficacy Comparison of Thrombolytics
Inorganic phosphate (P_i), 771, 778
Inositol 1,4,5-trisphosphate (IP_3), ($Ins(1,4,5)P_3$), 512, 777, 778, 796, 797
Inotropes, 619
Inotropic action, 694–700
Inotropic agents, 631
drug treatment of heart failure, 693–696, 700
for heart failure, 711–712
in heart failure, 703–707
KT-362 as, 674
Inotropic effects, 410
Inotropism, amlodipine and, 447, 448
Inotropy, 403, 404
Inpatient trial, losartan vs. enalapril safety and efficacy, 313–319
Insertion/deletion (I/D) polymorphism, 631, 632
INSIGHT clinical trial, 399, 410, 411
Insulin
circulating, progressive decrease in, 242, 245
levels after moxonidine therapy, 275, 277, 278, 280
release inhibited by link to norepinephrine, 261
resistance, and role in parasympathetic nervous system, 213, 214
secretion during hyperglycemia, 265
stimulating uptake, storage and utilization of glucose, 264, 267–271
vascular and sympathetic actions in insulin-resistant states, 217–219
vascular and sympathetic actions in lean subjects, 215–217
Insulin hypothesis of hypertension, 215
Insulin-like growth factors (ILGF), 795, 797, 798
Insulin resistance, 459
body fat and sympathetic nerve activity, 215, 217–219, 220
as metabolic element of Zucker syndrome, 266, 270
moxonidine benefits for obese hypertension, 275–280
INTACT study. *See* International Nifedipine Trial on Antiatherosclerotic Therapy
Intention-to-treat principle, 409
Interbeat intervals, cardiac, 677, 681, 683, 684
Interleukin-1 (IL-1), 731
Intermittent transdermal nitroglycerin, vs. continuous transdermal nitroglycerin, 5–9
Internal consistency reliability, 362
International Joint Efficacy Comparison of Thrombolytics (INJECT), 762–764
International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT), 398, 409, 410
follow-up study, 410
International Society of Federation of Cardiology, 747
International Society for Molecular Nutrition and Therapy, 211
International Society of Cardiovascular Pharmacotherapy (I.S.C.P.), 656

International Society of Thrombosis and Hemostasis, Scientific and Standardization Committee, 747
International Study of Infarct Survival (ISIS)
ISIS-1, 761
ISIS-3, 759, 760
ISIS-4, 297, 299–300, 303, 307, 520–523, 642, 712, 754, 760–761
Interstimulus interval (S1-S1), 531, 533
Intervention studies, 397
Intestinal contractor, vasoactive, 795, 796
murine (ET-4), 796
Intimal thickening, 632, 633
Intra-aortic balloon pump (IABP), 621
Intracellular calcium
nicotine and intracellular transmission, 657–663
renal hemodynamics and, 805
Intracellular calcium ions, 699
concentration, 797, 798
inotropic agents in heart failure, 703–707
overload, calcium transport, and excess catecholamines, 231–237
Intracellular free calcium concentration ($[Ca^{2+}]_i$), 667, 668, 672, 674
Intracellular ion concentrations, 452
Intracellular signalling pathway, 778
Intracellular sodium, nicotine and sympathetic neurotransmission, 657–663
Intracellular sodium ions, 699
Intracerebral hemorrhage, 405
Intraglomerular pressure, 806, 807
Intraventricular conduction, 376
Intraventricular conduction time (QRS). AWD 23–111 effect, 531–537
Intraventricular septum, 498–499
Intrinsic sympathomimetic activity (ISA), 700
of tilisolol, 23
Intron 16, 631
In vitro, arbutamine, adrenergic activities of, 39–46
"In vitro" calibration method, 668–670
In vitro phosphorylation assays, 783
Iodo-gen (1,3,4,6-tetrachloro-3a-5adiphenyl-glycuril), 68
Ion channels, 512
HRV and, 678
inotropic agents and, 705, 706
membrane, 587
Ion channels in the Cardiovascular System. Function and Dysfunction (book review), 89
Ion flux, transmembrane, 587
Ionic calcium, 303
Ionic currents, myocardium
time-dependent currents, 679
time-independent currents, 679
Ion permeability, 658
Ion selectivity, 659
Iopanoic acid, 369
IP_3 receptor (IP_3R), 797
Irbesartan, 514
Iron chelators, 338
Iron dextran, 335, 338
Iron deficiency, 752, 757
Iron overload, cardioprotective effects of EUK-8, 331–338
Iron oxidoreduction cycle, 335
Ischaemic heart disease (book review), 599
Ischemia. *See* Myocardial ischemia
Ischemia-reperfusion, 590
cardioprotective effects of EUK-8, 331–338
oxygen free radical formation, 419–422
Ischemic preconditioning, 587, 590
controversies in, 767–771
current state of knowledge of molecular mechanisms, 776
infarct size-limiting effect, 771
protein kinase C role, 775–783
Ischemic stroke, CAPRIE trial, 760
Ischemic ventricular fibrillation, amlodipine and, 447–453
ISIS trial. *See* International Study of Infarct Survival
Iso-channels, 440
Isometric handgrip stress test, 50–52, 55
Isoprenaline, to stimulate adenylcyclase, 624
Isoproterenol, 527, 587, 679, 688, 689
chemical structure of, 32
concentration-response curves, 42
inducing a biphasic change in cardiac Ca^{2+} transport, 231–236
sympathoadrenergic overactivity and lipid metabolism, 223, 226, 227
vs. arbutamine adrenergic activities of, 39–46
vs. arbutamine as pharmacological cardiac stress agent, 31–38
Isoproterenol hydrochloride, in tilisolol canine coronary circulation study, 24
Isoproterenol injections, diet restriction and, 244
Isoptin. *See* Verapamil
1–(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7), as protein kinase C inhibitor, 779, 780
Isosorbide, 695
Isosorbide dinitrate (ISDN)
vasodilatory effects, 736, 737, 738, 740–741
with hydralazine, 735, 740–741
Isosorbide mononitrate, 8
and nitroglycerin patch therapy, 8
Isosorbide-5-mononitrate, nitrate tolerance, 735, 738, 739, 740
Isradipine, 398, 404
calcium antagonists and endothelial function, 439–445
effects in essential hypertension, 119–122
in MIDAS, 464
side effects, 121
vs. elgodipine, 577, 580
Japanese, cardiac sarcoidosis incidence, 496
JNC-V guidelines, 400
Journal of the American Medical Association, 405
JT interval, AWD 23–111 effect on, 531, 532, 534, 535, 537
Jubilee message, 656
Jukat T-cell line, 706
Juxtaglomerular cells, 805
Kallikrein, 514, 624, 632
Kallikrein-kinin system, 610
Kaplan-Meier life-table analysis, 147, 148, 149
Kaplan-Meier product-limit method, 551
Karolinska Institute, Stockholm, ethics committee of, 540
Kd (dissociation constant), 240–241, 243, 244
120-KDa protein, 798
75-KDa protein, 798
Ketanserin, 284, 288, 475
cyclosporine and coronary endothelial function, 18, 19
PACK study, 762
renal hemodynamics and, 805
Ketanserin tartrate, 18
ketonemia, 242
6-keto-$PGF_{1\alpha}$, 728, 729, 731
6-keto-$PGF_{2\alpha}$, 732, 733
Kidney damage, 803, 807
accelerated by dietary salt and reduced by moxonidine, 275, 277, 279
Kidney disease, 788
Kidney dysfunction, 805
Kidney failure, 717
chronic, 746
endothelin and, 800
Kidney function
antihypertensive drugs and, 803–807
dopamine and, 695
perfusion, 696, 697
Kidney replacement therapy, 803
Kidneys
ET_B receptors in, 795
hypertension and, 803
ischemic preconditioning, 775
renin-angiotensin system and, 511, 514
Killip class 1, 522
Kininase II, 514, 633
inhibition by ACE inhibitors, 609, 610
Kinin degradation, 564
Kinin-kallikrein system, 632
Kininogen, 632
Kinins, 514
Koletsky rat, 275, 276
Kruskal-Wallis test, 588
KT-362, and calcium (Ca^{2+}) transients, 667–674
Labetalol

effect on Ca^{2+}-activated contractions in skinned fibers, 581, 583, 585
renal hemodynamics and, 805
Lacidipine, 698
and endothelial function, 439–445
inhibition of preproendothelin-1 mRNA expression, 442–445
lactate, 332, 662, 768–771
reduced accumulation of, 134
Lactate consumption and production, felodipine in myocardial ischemia, 173–175
Lactate dehydrogenase (LDH) isoenzymes, and toxicity of amiodarone for endothelial cells, 557–559
isoenzyme 3 (LDH-3), 557, 559
isoenzyme 4 (LDH-4), 557, 559
isoenzyme 5 (LDH-5), 559
Lamellar inclusions, intracytoplasmic, 557, 559
Langendorff, electrocardiological effects of AWD 23–111, 531–537
Large epicardial coronary artery, nitrate tolerance, 738
L-arginine, 798
L-arginine nitric oxide pathway, insulin's vascular effects mediated by, 215, 217, 220
Lateral hypothalamic area (LHA), electrical stimulation of, 267
Left cardiopathy, 12
Left circumflex coronary artery (LCx) occlusion, felodipine and stunning, 347–348
Left ventricle, poor performance as hemostatic predictor, 744
Left ventricular developed pressure (LVDP), EUK-8 cardioprotective effect, 332, 337
Left ventricular developed pressure (LVDP)
EUK-8 vs. DMTU cardioprotective effects, 335
felodipine effect, 170–172
Left ventricular dysfunction, 15
Borrelia burgdorferi dilated cardiomyopathy, 358
calcium channel blockers harmful, 413, 414
Left ventricular end-diastolic pressure (LVEDP)
dobutamine effect, 37
felodipine beneficial effects at end of low-flow ischemia, 167, 168, 172–175
neutral endopeptidase prolonged inhibition effect, 593, 596
Left ventricular function. *See* Ventricular function, left
Left ventricular hypertrophy. *See* Hypertrophy, left ventricular
Left ventricular (LV) mass, 397, 399
Left ventricular pressure with respect to time (LV dP/dt max), 448–450, 453
Leicester Intravenous Magnesium Intervention Trial-2 (LIMIT-2), 298, 760
Length-tension relations, 380
Leukocyte count, 744–745
Leukotrienes, 728
L-glutamate, 283–284
Life expectancy, 751
normal life span and HRV, 679
Ligand, 512
Ligand-gated cation channel, 657, 659
Ligand-gated ion channels, 658, 661
Ligand-gated receptors, 658
Likert scale, six grade, 362
LIMIT-2 trial. *See* Leicester Intravenous Magnesium Intervention Trial-2
Linear regression model, almokalant study and, 539
Linoleate, 380
Linoleic acid, sympathoadrenergic overactivity and lipid metabolism, 223–227
Lipid A, 730, 731
nontoxic derivatives of, 730
Lipid-lowering drugs
cardiovascular disease treatment changes, 189–191
risk indicators for death after AMI, 486, 487, 489
Lipid metabolism, beta blockers and, 67, 71
Lipid peroxidase, 469
Lipid Research Clinic Follow-up Cohort, 789
Lipid Research Clinics Coronary Primary Prevention Trial, 792
Lipid Research Clinics Intervention Trial, 67
Lipid Research Clinics trials, 792
Lipids
blood, 743, 745
cost effectiveness of treating hyperlipidemia, 787–793
extracellular, 634
intracellular, 634
serum, 568
sympathoadrenergic overactivity and lipid metabolism, 223–229
Lipolysis, 264
Lipopolysaccharide (LPS), 706
Lipoprotein, 731, 743, 744, 745
atherogenic, 634
Lipoprotein (a) [Lp(a)], 744, 745
Lipoprotein deficient serum (LPDS), 68
Lipoprotein lipase activity, 67
Lipoprotein metabolism, beta blockers and, 67
Liposomes, calcium channel blocker effects, 418
Lisinopril, 520, 521, 523, 695, 696, 698, 761
diastolic function, adrenergic stress, and angiotensin II in hypertension, 321–328
for congestive heart failure, 619, 620
in ALLHAT study, 411
Liver, 514
amiodarone concentration in, 559
angiotensin receptors and, 512
diltiazem metabolism, 14
ischemic preconditioning, 775
Liver disease, 745, 788
Liver enzymes, bosentan effect, 722
Living with Heart Failure questionnaire, 366
L-NMMA, 627
LNNA (NO synthase inhibitor), 441
Losartan, 310, 698
adverse events, 317–319
angiotensin mechanisms in hypertension, 511–516
multiple dosing safety, 313–319
renal hemodynamics and, 804
vs. enalapril safety and efficacy, 313–319
Losartan potassium, 512
Lovastatin, 475, 481
cost effectiveness in hyperlipidemia, 787, 788, 790–793
for heart failure prevention, 455
Low-density lipoprotein (LDL), 632
and aspirin therapy, 731
calcium-channel blockers and LDL oxidation by oxygen radicals, 417–422
native LDL (n-LDL), 417
oxidized, 567, 634
Low density lipoprotein 2 (LDL2), 731
Low-density lipoprotein 3 (LDL3), 731
Low-density lipoprotein apheresis, 745
antioxidants and, 567–571
Low-density lipoprotein (LDL) cholesterol, 68, 569, 611, 746, 747
beta-blockers and, 68, 70, 71
endothelin release and, 795, 797
HMG-CoA reductase inhibitors and fibrates for decreasing levels, 787–789, 792, 793
macrophage-mediated oxidation of, 469–471
pravastatin study, 476, 478, 481
Low density lipoprotein receptors, 567, 569
effects of beta-blockers on HMG CoA receptors, 67–73
mRNA, 71, 73
Low-flow ischemia, ischemic preconditoning, 769
Low-molecular-weight protein kinase effectors, 776
LPS, inducing NO synthase, 442
L-type calcium channels, 439–440, 445
Lumen, 799
Luminal diameter, 634
Lung
amiodarone concentration in, 559
AII and, 514
diffusion capacity, 559
fibrosis, 559
toxicity, of amiodarone for endothelial cells, 557–559

Lupus erythematosus, 459
Luteinizing-hormone-releasing hormone, 514
Lyapounov exponents, 680, 681
Lyme *borreliosis*, *Borelia burgdorferi* reversal by antibiotics, 351–358
Lyme disease, *Borrelia burgdorferi* cardiomyopathy, 351–358
Lysozyme, in blood, as cardiac sarcoidosis diagnostic indicator, 497

M2
  muscarinic receptor density, 678, 679
  -receptors mRNA, 679
  transmembrane alpha-helix, 658, 659
Macrophages, 417, 421
MAGIC (Magnesium in Coronaries), 297, 300
Magnesium
  in acute myocardial infarction, 297–300
  incremental cost effectiveness (ICE) for MI, 299, 300
  supplements for acute myocardial infarction, 303–304
Magnesium deficiency, 297, 304
Magnesium in Coronaries (MAGIC), 297, 300
Magnesium ion electrolyte (Mg^{2+}), 370
Magnesium supplementation, 304, 307
  negative potential of, 304, 307
  positive role for myocardial infarction treatment, 307
Magnetic resonance imaging (MRI), 528
Malondialdehyde formation, 234
Malonyldihaldehyde (MDA) production, 417, 418, 419, 421
Manidipine, 797
  in GLANT, 464
Mann-Whitney test, 114
Mann-Whitney U-test, 558
MAPHY study, 73, 399
MARCKS. *See* Myristoylated-alanine-richC-kinase-substrate
Markov model, 299, 300
Mast cells, 514
Maximal response (EC_{50}), 41
MDC trial. *See* Metoprolol in Dilated Cardiomyopathy trial
Mean arterial pressure (MAP), nanterinone hemodynamic effects in heart failure, 139, 141
Mean blood pressure (MBP), pressor effect of dietary salt, 277
Mean pulmonary arterial pressure (MPAP)
  enoximone and systemic and renal hemodynamics, 81, 83, 84
  nanterinone hemodynamic effects in heart failure, 139, 141, 142
Mean pulmonary pressure (PAM), nanterinone hemodynamic effects in heart failure, 139, 141, 142
Media, smooth muscle cell migration, 101, 104
Medical Research Council (MRC) trial, 458
  vs. STONE study, 468
Medical treatment, of heart failure, as suggested by Canadian Cardiovascular Society's Consensus Conference, 711–715
Medication, prescribed at discharge, risk indicators for death after AMI, 485–489
MEDLINE, search done of HMG-CoA reductase inhibitors and fibrates studies, 788
Mega-trial, defined, 759
Membrane-bound protein kinase *C-DAG*(Ca^{2+})-membrane complex, 777
Membrane-stabilizing activity, of tilisolol, 23
Men, cost effectiveness of drug therapy for hyperlipidemia, 791, 792, 793
Menopause, hypertension in postmenopausal women, 387
MERCATOR trial. *See* Multicentre European Research Trial with Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis
Mesangial cells, 798
  endothelin-1 mitogenic effects, 722
Mesenteric artery, endothelial cells, 798, 799
Mesenteric artery occlusion-reperfusion, 775
Messenger ribonucleic acid (mRNA), 679, 778
  endothelin and, 796, 798
  vascular endothelin, 798
Meta-analysis
  alternatives to mega-trials, 759–761
  risk/benefit ratio of drugs, 760
Metabolic factors, endothelin release and, 795
Metabolism, 515
Metabolites, 515, 662
Metalloprothease, 718
Meta-regression, 298
Methane sulfonanilide compounds, 543–544
Methantheline bromide, 691
Methyldopa, 190, 806
Metolazone, 619
Metoprolol, 697
  after MI, 95% confidence intervals and point estimates for relative risk reduction, early-entry and late-entry trials, 762, 763
  dihydropyridines vs. beta-blockers, 398, 400
  effect of beta-blockers on HMG CoA receptors, 67–73
  effect on isoproterenol and arbutamine concentration-effect curves, 39–42, 45
  for congestive heart failure, 620
  for heart failure therapy, 713
  hemodynamic effects in hypertensive patients, 113–117
  and quality of life in heart failure, 361–367
  vs. verapamil for effort angina, 455, 456
Metoprolol in Acute Myocardial Infarction (MIAMI) trial, 761
Metoprolol in Dilated Cardiomyopathy (MDC) trial, 713
  quality of life in heart failure, 361–367
Mevalonate synthesis, inhibition in cultured cells, 482
Mevalonic acid, 68
Mevalonolactin, 68
Mevinolin, 71
Mexiletine, 551, 555
MIAMI trial. *See* Metoprolol in Acute Myocardial Infarction trial
Mibefradil, 442, 698
  comparative effects with cilazapril in normotensive and DOCA hypertensive rats, 103
  effect on neointima formation, 101–104
  time of administration influence on effects in normotensive rats, 103
  with cilazapril, 103–104
Microalbuminuria, 746
  antihypertensive drugs and renal function, 803–807
Microangiopathy, 500–501
Microcirculation, 706
  defective, 590
Microelectrode
  PVC ETH-123, calcium antagonists, vitamin D_3 and calcium overload, 185–187
  to study hyperinsulinemia and sympathetic nerve activity, 215–216
Microfluorimetry, 661
Microneurography, 219
Microvascular disease, 513
Microvascular spasm, 590
MIDAS study. *See* Multicenter Isradipine Diuretic Atherosclerosis study
Milrinone, 699, 704, 706, 762
  effect on renal function or hemodynamics, 81, 86
  vs. nanterinone, 142, 143
Minoxidil, 713
Mioflazine, protecting mitochondria against calcium deposition, 175
Mitochondria, 404
  ATPase and preconditioning, 768
  Ca^{2+} transport, 233–234
  calcium transport and felodipine effect, 426–427, 429–432, 434–435
  energy-regenerating, 704
  EUK-8 vs. DMTU cardioprotective effects, 335, 337

modulation of K^+_{ATP} channels in, 776–778
Mitochondrial dysfunction, 587
Mitochondrial respiration, oxygen free radical formation, 419–421
Mitogen-activated protein (MAP) kinases, 796–798
Mitogens, polypeptide, 798
Mitral regurgitation. *See* Mitral valve insufficiency
Mitral valve insufficiency, 498, 528, 619
MK-945. *See* Losartan potassium
Molecular biology
AII-receptor subtypes and, 512
role in biomedical research, 677
Molecular Cardiology for the Cardiologist (book review), 91
Molecular markers, 511
Molecular Nutrition and Therapy, International Society for, 211
"Monday head," 735
Monoclonal antibodies, 496
Monocyte macrophage, 634
Monocytes, 744
Mononitrates, 6
with diltiazem, 411
Mononuclear cells, human peripheral blood, 706
Monophasic action potential (MAP), 449
frequency-dependent effects of almokalant, 539–546
hypothyroidism and ventricular fibrillation, 369–376
Monophasic action potential dispersion (MAP_d), 371, 372, 374, 376
Monophasic action potential duration (MAP_D), 449–452, 539–546
Monotherapy, 805
Montreal General Hospital, 788
Mood Adjective Check List, 362
Morbidity
ACE inhibitors and acute MI, 519, 522
angiotensin mechanisms in hypertension, 516
cardiovascular, age distribution and, 397
cardiovascular, beta-blockers and, 399
cardiovascular, long-acting dihydropyridines, 399
PDE inhibitors and, 704, 706
Mortality, 634, 635
ACE inhibitors and acute MI, 519–523
angiotensin mechanisms in hypertension, 516
calcium channel blockers and, 409, 410
cardiac, 376
cardiovascular, 397, 398
cardiovascular, age distribution, 397
cardiovascular, beta-blockers and, 399
cardiovascular, effect of calcium in, 403, 404, 405
cardiovascular, long-acting dihydropyridines, 399
classification, 450–451
CHF drug therapy and, 693, 697–700
drug therapy and, 704–706
MI and, 536
"premature," 397
Motility
clonidine effect, 253–257, 259
moxonidine effect, 252, 254, 257
Moxonidine, 214, 236, 237
benefits for obese hypertension, 275–280
chemical relationship with clonidine, 287
and hypercaloric nutrition, 255–256
rebound hypertension and central acting drugs, 251–261
and sympathetic outflow, 283–288
vs. clonidine, 280
M(r)20,000. *See* Myosin light chain
M(r)57,000. *See* Vimentin
M(r)76,000. *See* PKC substrate
MRC trial. *See* Medical Research Council trial
Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR), 633, 634, 635
Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS), 398, 464
Multifocal premature ventricular contractions, epinephrine-induced arrhythmias, 243
Multiple logistic regression analysis, pravastatin study, 479
Multiple-vessel coronary artery disease, 744
Multivariate one-way analysis of variance (MANOVA), 575
Murine heart, 705
encephalomyocarditis (EMC) virus and, 705, 706
Muscarinic agonists, 778
Muscarinic receptors, 20
M_2-subtype, 691
Muscarinic transduction system myocardial, 677–680, 683
Muscle blood flow, body fat and sympathetic nerve activity studies, 215–219
Muscle cell, membrane potential, 590
Muscle foci, necrotic, 588
Muscle, smooth cells, 778, 782
endothelins and, 795
proliferation and inflammation, 743
Muscle, smooth, vascular-cell receptor, 796, 797
Muscle, smooth, vascular cells
endothelin-1 mitogenic effects, 722–723
growth factor, 795, 796, 799, 800
KT-362 and, 667, 672
Muscle sympathetic nerve activity (MSNA), 217, 218, 219
Muscular dystrophy (MD), human, 590
Muscular work, 451
Musculature, skeletal muscle changes, 588
Mydriasis, 692
Myocardial, atrial, 533
Myocardial contractility, 303, 447, 450
nicotine and, 657
Myocardial damage, 587
calcific degeneration, 589, 590
Myocardial fibers, depolarization, 452
Myocardial fibroblasts, 514
Myocardial infarction (MI), 398, 447, 452, 599, 631–635
ACE inhibition and risk of, 610
ACE inhibitors and acute, 519–524
acute, 657
acute, calcium antagonist controversies, 409, 410
acute, programmed ventricular stimulation and, 549, 552
anterior, 521, 522, 524
antihypertensive agents and, 399, 400
AWD 23–111 and, 536
beta-blockers and, 399, 400, 759
beta-blockers after, 95% confidence intervals for early-entry trials, 762
calcium antagonists and risk of, 464
CAPRIE trial, 760
determining endpoints in clinical trials, 761
d-sotalol therapy, 714
effects of calcium in, 403–406
effect of digitalis on mortality, 705
EUK-8 cardioprotective effects, 331
following sudden withdrawal of nitrates, 736, 738
heart rate variability and, 677, 680, 683
and hyperlipidemia, 788
INJECT study, 763–764
low-dose aspirin for prevention of, 727–733
magnesium in, 297–300
magnesium supplementation for, 303–304, 307
mega-trials, 759–761
neutral endopeptidase prolonged inhibition effect on cardiac hypertrophy in rats, 593–596
new generation of clinical trials, 752, 754, 756, 757
nicotine and, 663
non-fatal, total drug costs, 465
programmed ventricular stimulation, 549–555
recurrence and antiplatelet therapy, 743–747
recurrent, 634, 635
renin-angiotensin system role in pathogenesis of, 613–615
risk indicators for death after, 485–489

risk in hypertensive patients, and calcium channel blockers, 413
secondary prevention post, 399
site of, 549, 551, 553
survival after, 693, 695
treatment costs, 789
Myocardial ischemia, 409–411, 447, 471, 520, 631–634, 745–746, 762, 768, 771
ACE inhibitor effect, 639–641
acute, 532, 533, 552
amiodarone treatment, 557
arbutamine as pharmacological cardiac stress agent, 31–38
associated with obesity, 215, 219
bradycardic agents and, 682
calcium antagonists and, 405, 698
calcium channel blockers and mortality risk, 413, 414
caused by beta-adrenergic agents, 45
chronic ischemic heart disease (IHD), 561, 562
clinical trials, 751, 752, 755–757
cytosolic calcium ion accumulation, 587
dobutamine vs. arbutamine as cardiac stress agents, 37, 38
episodes, 7
factors influencing, 614
felodipine and stunning, 347–349
felodipine beneficial effects, 167–176, 425–435
global, 662
hypertension and, 449, 452
juvenile, 744
KT-362 and, 667, 674
long-acting dihydropyridines and, 398
low-dose aspirin for prevention of, 728, 729, 730, 733
LVH and, 399
nicotine and sympathetic neurotransmission, 119, 657–663
nitrate tolerance, 735, 739, 740
nitroglycerin patch therapy, 6, 7, 8
PDE inhibitors and, 704
preconditioning mediation in rat heart, 125–134
protein kinase role in ischemic preconditioning, 775–783
reperfusion intervals and preconditioning, 341–345
serotonin role in, 442
silent, 456, 471
ventricular fibrillation during, 369, 371–376
Myocardial oxygen consumption
elgodipine hemodynamics during rest and exercise, 573
pranidipine in hypertension, 59–66
Myocardial oxygen demand, 746, 754
exercise stress testing, 39, 45
tilisolol in canine coronary circulation, 23–29
Myocardial protection, protein kinase C role in ischemic preconditioning, 775–783
Myocardial reinfarction, 447, 745
ACE inhibitors and, 519
calcium and rate of, 403
nicardipine and, 398
Myocardial reperfusion, 448
KT-362 and, 667
Myocardial salvage, 522
Myocardial stunning, 298, 522
felodipine and, 347–349
nisoldipine and, 347
Myocarditis
Borrelia burgdorferi cardiomyopathy, 351–358
energy metabolism, 704
murine model of, 705, 706
Myocardium
atrioventricular, 533
calcium and, 403
calcium antagonists, vitamin D_3 and calcium overload, 185–187
endothelium receptors in, 795, 798
energy-use, 704, 705, 706
normal, ischemic ventricular fibrillation, 449–451
thyroid hormone and, 369, 376
ventricular, 533
Myocytes, 782
cardiac, endothelin-1 mitogenic effects, 722
cardiac, endothelin responses, 796, 798
homogenized, 778
ischemic preconditioning, 771
murine, 705
ventricular, 667, 668
Myofibrillar calcium sensitivity, endothelin-1 response, 111
Myofibrillar elements, Ca^{2+} delivery, 704
Myofibrils, 776–778
energy-consuming, 704
Myofilaments, 699
Myointimal proliferation, 631
Myointimal thickening, 634, 636
Myolysis, 588
Myolytic lesions, 587, 588, 589
Myometrium, endothelium receptors in, 795
Myopathy, 587–589
Myosin isozymes
redistribution of, 224
V_1, increased due to hypercaloric diet, 256
Myosin light chain, 796
Myosin VI, 224
Myristoylated-alanine-rich-C-kinasesubstrate (MARCKS), 783
binding protein, 777

N-acetylcystein, 7
Nadolol, 400, 550
effect on concentration-response curves of arbutamine and isoproterenol, 40–46
Nafazatrom, 729
Nanterinone
hemodynamic effects in heart failure, 137–143
long-term hemodynamic effects, 140, 143
preload-dependent effect of, 139–140
preload-dependent hemodynamic effects, 143
systemic hemodynamic profile, 142–143
NASPE survey, 529
National Heart Lung and Blood Institute, 366
criterion 4, 476
National Registry of Myocardial Infarction, 406
Native low-density lipoprotein (n-LDL), 417
Natriuresis, 698
nocturnal, 806
Natriuretic agents, 694
Natriuretic/diuretic agents, 694
Natural killer (NK) cell activity, 705, 706
Necrosis, myocardial, 705
Necrotizing process
heart, 587–590
tongue, 587, 588, 590
Negative inotropic agents, betaxolol effect in skinned fibers, 584, 585
Neointima, smooth muscle cell migration, 101, 104
Neointimal formation, 633, 634
prevention by mibefradil after vascular injury, 101–104
NEP-ACE inhibitors (mixed), 596
Nephritis, 279
Nephron heterogeneity, 513
Nephrons, ischemic, 807
Nephropathy, 279, 745
Nephrosclerosis, 279, 803, 804, 807
Neprilysin, 593
Neurocardiogenic presyncope, 687, 691
Neurocardiogenic reflex, 687
Neurocardiogenic syncope, propantheline bromide in, 687–692
Neuroendocrine, 627
Neuroendocrine compensatory mechanisms, drug treatment of heart failure, 693–700
Neuroendocrine response, ACE inhibitors effect, 640
Neurohormonal disorders, 703
inotropic agents and, 703, 705
Neurohormones, 624
activation with nitrate tolerance, 738
Neuromuscular (vascular) terminals, 691
Neuronal catecholamine reuptake, 662–663
Neuronal cell membrane, nicotinic acetylcholine receptor and, 658
Neuropeptide Y (NPY), nicotine and sympathetic neurotransmission, 657–663
Neurotensin, 514
Neurotransmitter-gated ion channels, 658
Neurotransmitters, 283–284, 678
release, prejunctional modulation, 219

Neutral endopeptidase, effect of prolonged inhibition on cardiac hypertrophy, 593–596
Neutropenia, 515, 705
Neutrophils, 421, 610, 744–745
New York heart Association (NYHA) classification, 362, 363, 365, 367
class II, 561, 562
class II/IV, 694, 695, 697–699
class III, 561, 562, 722
class III/IV, 694, 697, 698, 700
Niacin, 745
Nicardipine, 398, 404, 807
safety documentation (Cardene) for SR in hypertension, 464
vs. elgodipine, 577, 578, 580
Niceritrol, 745
Nicotine, 743
and sympathetic neurotransmission, 657–663
Nicotine binding sites, 659, 661
Nicotine chewing gum, 180, 657
Nicotine nasal spray, 180
Nicotine patches
cardiovascular safety of, 179–183
side effects, 182
withdrawal symptoms, 182
Nicotinic acetylcholine receptors
muscle type receptor subtype, and their subunits, 658
neuronal type receptor subtype, and their subunits, 658, 659, 661
nicotine and sympathetic neurotransmission, 657–663
NIDDM, 213
Nifedipine, 404, 417, 590, 698
aortic stiffness and, 50
calcium antagonist controversies, 409–411
cardioprotection, 433, 435
congestive heart failure risk, 464
contraindicated for acute myocardial infarction, 455
contraindicated in unstable angina, 455
effect on platelet aggregation, 122
effect on platelet and fibrinolytic parameters, 119
for systolic left ventricular dysfunction, not recommended, 712
in GLANT, 464
inhibiting peroxidation of membrane lipids, 175
long-acting formulations, 459
long-term safety, STONE study, 467–468
protecting mitochondria against calcium deposition, 175
SA, contraindications, 459
short-acting safety problems, 465
slow-release, STONE study, 467–468
to slow progression of atherosclerosis in humans, 417–420
vs. atenolol for effort angina, 455–456
vs. beta-blockers, 464
vs. elgodipine, 578
with beta-blockers, 413
with unstable angina, 413
Nifedipine capsules, 397, 398, 401, 409
controversies, 409, 410
Nifedipine (GITS), 397–400, 410, 411
Nifedipine-induced angina, 398
Nifedipine SR, 398, 399
Nimodipine, 404
Nimotop. *See* Nimodipine
Nisoldipine, 414, 433, 458, 797
and endothelial function, 439–445
stunning and, 347, 348
vs. elgodipine, 578
Nitrates, 413, 414, 523
arterial effects, 739
cardiovascular disease treatment changes, 189–191
as CHF treatment, 561, 562
for angina pectoris, 466
for effort angina, 456, 457
for end-stage heart failure, 617, 619–620
in acute myocardial infarction, 754
intermittent vs. continuous transdermal nitroglycerin, 5–9
in vitro tolerance of vascular effects, 736
in vivo tolerance of vascular effects, 736
long-acting, risk indicators for death after AMI, 486, 487, 489
tolerance, and angina and heart failure, 735–741
to relieve anginal pain, 573, 574
vasodepressor effects, 735–736
venodilatory effects, 736, 738, 739
with captopril, 76
with diltiazem vs. amlodipine, 411
with hydralazine for heart failure, 712
Nitrate sensitivity, 8
Nitrate tolerance, and stable angina pectoris, unstable angina, and heart failure, 735–741
Nitrendipine, 459, 807
vs. elgodipine, 577, 580
Nitric oxide (NO), 17, 523, 624, 626–627
and ACE inhibitor effect on endothelial function, 469, 470
AII and, 511, 513, 514
calcium antagonists and endothelial function, 439–445
contribution to insulin induced vasodilation, 216–217, 220
cyclosporine and, 379
endogenous bradykinin cardioprotective effect, 640, 641
endothelin and vascular hypertrophy, 795–900
endothelium-derived, 717, 723, 728–731, 733
nitrate conversion to, 735, 736, 738
preconditioning, 345
release from endothelial cell stimulated by bradykinin, 609, 610
Nitric oxide synthase (iNOS), 442, 627, 706, 728, 730–731, 798
Nitric oxide synthase inhibitor, 798
Nitroglycerin
aortic stiffness and, 50
effect on brachial blood pressure or wave form, 599
inducing coronary "steal," 471
intravenous, 735, 736, 738–740
noxious effects, 735, 736, 740
sublingual, 5–7, 9
vasodilator response to, 470
vs. diltiazem for unstable angina, 455, 457
Nitroglycerin patches, 5–9
and nitrate tolerance, 735–740
zero hour effect, 738–739
Nitroprusside, 470
Nitrosothiols, 523
nitrate conversion to, 735, 736, 738
N-methyldopamine, 696
N^G-monomethyl-L-arginine (L-NMMA), 217
Nocturnal dyspnea, and nitrates therapy, 740
Nodal tachycardia, diltiazem in supraventricular tachyarrhythmias, 12
N omega-nitro-L-arginine methyl ester (L-NAME), 798
Non-CHD diseases, treatment costs, 789–790
Noncompliance
neurocardiogenic syncope trials, 691
therapeutic, 515
Nonfatal myocardial infarction, 643
Non-insulin-dependent diabetes mellitus, pravastatin study, 477, 478
Noninvasive investigation, 683
Nonpeptide antagonists, 512
Nonpeptide receptor-selective antagonists, 795, 800
Non-Q-wave myocardial infarction
diltiazem or verapamil therapy, 455–458
pravastatin study, 477, 478
Nonspectral power analysis, 680–681
Nonsteroidal antiinflammatory drugs (NSAIDs), 727, 729, 731
Nonsulfhydryl, enalapril as, 564
Noradrenaline, 729, 776, 778
bosentan effect, 718
captopril and renal impairment, 78
eliciting preconditioning, 133–134
evoking Ca_o-dependent contraction, 439
-induced tachycardia, 697
and ischemic preconditioning, 767, 771
-mediated afferent vasoconstriction, 805
plasma, ACE inhibitor effects, 640
plasma levels in CHF, 694, 695, 697

release and felodipine cardiac protection, 425, 426, 429, 435
release of, 696
Noradrenaline/adrenaline plasma, 698
No-reflow phenomenon, 298
felodipine in myocardial ischemia, 175
Norepinephrine, 767, 768
bosentan effect, 719, 723
concentration-effect curves, 40, 41, 45
cyclization of, 235
dietary salt effect, 279, 280
diet restriction and adrenergic mechanisms, 239–242, 244
increased in heart failure patients, 624, 626
-linked inhibition of insulin release, 261
linoleic acid and arachidonic acid affected in rats, 223, 224, 225
lisinopril effect on resting concentration, 323
long-term dietary restriction effects, 247, 248, 249
nicotine and sympathetic neurotransmission, 657–663
not mimicking protective effect of preconditioning, 133
obesity and autonomic regulation, 263–271
plasma levels, 705, 799
release of, 691
release stimulated and accompanied by muscle blood flow, 217
release suppressed by preconditioning, 767–768
Norepinephrine/Na^+ cotransport, 662
Normocholesterolemic subjects, 567–570
Normoglycemia, 214, 261, 266–267
Normolipidemic subjects, 568
Normothermic ischemic cardiac arrest (NICA), ischemic preconditioning, 126
Norvasc. *See* Amlodipine
Norwegian Timolol Trial, 759, 761
Novel protein kinase C isotypes (nPKC's), 778, 782
n-3 polyunsaturated fatty acid (PUFA)rich oil diet, 223–227
n-6 polyunsaturated fatty acid (PUFA)rich oil diet, 224, 226–227
NS, 549
Nuclear magnetic resonance studies, preconditioning in stop-flow ischemia, 769
Nuclear proteins, 796
5'-nucleotidase, regulation of enzyme producing this during preconditioning, 767, 768, 771
Nucleus, 776
Nucleus reticularis lateralis, 286
Nucleus tractus solitarii (NTS), 283, 284, 285
Nutrition, disorders, I_1-agonists, 213–214

Obese spontaneously hypertensive rats (SHROB), moxonidine benefits for obese hypertension, 275–280
Obesity
and autonomic regulation, 263–271
body fat and sympathetic nerve activity, 215–220
and effectiveness of medical therapy in congestive heart failure, 618
as hemostatic predictor, 744, 745, 746
moxonidine benefits for obese hypertension, 275–280
Occlusion, 298
Occlusion-reperfusion, 782
sequences, 779
Occult sinus node disease, 14
Ocular fundus, periphlebitis in, 500
Oleic acid, 225
Oleyl acetylglycerol (OAG), 779
as protein kinase C activator, 779, 781
Oligomycin, 768
Omega-6 fatty acids, 380
Omega-3 fatty acids, 380, 475
Omnifluor, 68
Oncogenes, regulation of cellular, 511
OPC-8212, 699; *see also* Vesnarinone
Open heart surgery,for supraventricular tachycardias, 527
Ophthalmologic manifestations, with cardiac sarcoidosis, 495
Opiates, 776, 778
Optic microscopy, 557
Organ damage, obesity and overweight, 223
Orthostatic tachycardia, 317
Oscillators, biological, 680, 681, 683, 684
Oscilloscope
multiple channel, 550
ventricular fibrillation threshold (VFT), 371
Osteoporosis, in postmenopausal women, 387
Ouabain, 729
intoxication, 730
Ouabaine-induced arrhythmia, 674
Outcome, cardiac, 1,4-dihydropyridine vs. beta-blockers for hypertension, 397–401
Overfeeding, obesity and autonomic regulation, 263–271
Oxidative processes, 570
Oxidative stress
felodipine and cardiac protection, 425, 426, 431, 433, 435
mechanisms of damage, 235–236
sensitivity of calcium transport systems, and excess catecholamines, 231–237
Oxidized GSSG glutathione, felodipine and cardiac protection, 425, 426, 428, 431, 433, 434
Oxodipine, 574–575
7-oxo-prostacyclin, 730
Oxprenolol
after MI, 95% confidence intervals and point estimates for relative risk reduction, early-entry and late-entry trials, 762, 763
effect on Ca^{2+}-activated contractions in skinned fibers, 581, 583
Oxygen
cardiac consumption, 697
chemoreceptor, 678
Oxygen consumption, 706
felodipine and cardiac protection, 426
felodipine in myocardial ischemia, 173, 174, 175
Oxygen demand, 635
nicotine and, 657, 663
Oxygen free radical injury, and nitrate tolerance, 736, 738
Oxygen free radicals
EUK-8 cardioprotective effects, 331–338
felodipine effect, 433, 434, 435
Oxygen need, myocardial requirements, 447, 451, 453
Oxygen radicals, 235, 303, 331
calcium-channel blockers inhibiting human HDL oxidation by, 417–422
Oxygen supply, nicotine and, 663

Pacemakers
current, 678
HRV and, 678
implantation, 529
multiprogrammable pulse generator, 108
permanent cardiac, 501, 502
ventricular paced QT intervals and, 545
Pacemaker system, AWD 23–111 effects, 531
Pacemaker tissues, cardiac, 678
Pacing
atrial, 528, 533
cycle length, 373, 375, 376
cycle length, and almokalant, 540, 541, 543, 545
ventricular, 528
Pacing cycle, AWD 23–111 effect, 531–537
Pacing-overdrive model, dogs tested for endothelin-1 response in failing myocardium, 108–112
Pacing protocol, 550
PACK Study, of ketanserin, 762
P. acnes, 496
Pain, exercise-induced anginal symptoms and elgodipine, 573, 574, 575
Palmitoleic acid, 225
Palpitations, 527, 528
intravenous propafenone for recent onset atrial fibrillation, 153–156
Pancreas, 280
AT_2 receptor expression, 512
Pancreatic ß-cells, increased outflow of insulin by, 263–264
Papaverine, vasodilator alkaloid, 403
Papillary muscles

endothelin-1 response in failing myocardium, 107–112
rupture after acute myocardial infarction, 486
Paracrine action, 631
Paracrine release, 799
Parasympathetic nervous system, 265, 268–270
heart rate, 678, 679, 682
Parasympathetic tone, 687, 691
Partial agonistic activity (PAA), betablockers and, 67
Partial left anterior descending coronary artery occlusion, arbutamine effect, 33, 35, 36, 37
Pasteur effect, 769
Pathophysiological changes, protection against, 587
Pathophysiological characteristics, 523
PCR technique, 679
PD 123177. *See* Nonpeptide antagonists
pD_2 values, 41, 42, 43, 44
PEACE, 471
Peak and trough method of analysis, HRV and, 680–682
Penicillin, 68
Penta-acetoxymethyl ester fura-2 (fura2/AM), 668
Pentoxifylline, 20–21, 745
Peptide antagonists, 512, 514
Peptide-ε, 781–783
Peptides, 564
antiproliferative, 515
calcitonin gene-related, 563
production of, 439, 442, 443
regulatory, role in ANS, 678, 679
Peptide serotonin, 623
Peptide systems, 631
renin-angiotensin system and, 511
Percutaneous transluminal coronary angioplasty (PTCA), 101, 104, 551, 633, 635, 642–643, 756
after AMI, 486, 487
ischemic preconditioning, 770
pravastatin to reduce restenosis, 475–482
preconditioning during, 767
Perfusion
coronary, 697
renal, 804, 805
Perfusion rate, 532, 533
AWD 23–111 effect, 532, 533
per gene, 678
Perhexiline, 581, 585
Pericarditis
acute, 12
constrictive, 497
w/wo cardiac tamponade, 497
Perindopril, 634, 695, 696
Perindoprilat, 634
Peripheral artery disease, 663
Peripheral blood vessels, 625
Peripheral coronary resistance, 410
Peripheral dilators, 590
Peripheral energy substrate homeostasis, 264
Peripheral nervous system, nicotinic acetylcholine receptors and, 658
Peripheral sympathetic nervous system, 285
cardiac glycosides and, 695
Peripheral sympathoinhibition, 283–288
Peripheral vascular disease, 745
CAPRIE trial, 760
Peripheral vascular resistance, 694, 698
arbutamine as cardiac stress agent, 35, 37
Periphlebitis in ocular fundus, 500
Peroxidation, calcium-channel blockers and LDL oxidation by oxygen radicals, 417–422
Pertussis-sensitive Gi proteins, preconditioning, 345
Pertussis toxin-sensitive G protein function, 17, 21
PGHS-1 (COX 1)(isoenzyme), 727
inhibited by aspirin, 727, 728
PGHS-2 (COX 2)(isoenzyme), 727, 728
pH, intracellular, 796
Pharmacokinetics
elgodipine hemodynamics during exercise, 573–580
intermittent vs. continuous transdermal nitroglycerin, 5–9
Pharmacological treatment, AMI and, 519, 523
Pharmacology, heart rate and heart rate variability, 677
Phase contrast microscopy, 557
pH chemoreceptor, 678
Phentolamine, 41, 45, 133, 624
Phenylalkylamines, 439, 440
controversies, 410
Phenylephrine, 380, 381, 382
alpha$_1$-adrenergic stimulation on myocardial recovery, 126, 127, 129, 130, 133
protein kinase C translocation/activation and protection by ischemic preconditioning, 779, 781
Phenylephrine hydrochloride, 380
Phenylethanolamine, methylation, and SR Ca^{2+} pump, 233
Phlebitis, 500, 501
Phlebotomy, 745
Phorbol esters, 776, 778, 779, 781
to stimulate PKC, 125
Phorbol-12-myristate-13-acetate (PMA), 778
as protein kinase C activator, 779, 781
protein kinase C translocation/activation and protection by ischemic preconditioning, 779, 781
Phosphatase, 768
Phosphates, 453
depletion of, 403, 404
Phosphatidic acid (PtdOH), 778
Phosphatidic acid hydrolase, 778
Phosphatidylcholine (PtdCho), 225, 227, 778
fatty acid composition, 227
sarcolemmal Ca^{2+} transport, 232
Phosphatidylethanolamine, 225, 227
fatty acid composition, chronic stimulation influence, 228
methylation, sarcolemmal Ca^{2+} transport, 232
methylation, sarcoplasmic reticular Ca^{2+} transport, 233
Phosphatidylinositol, 226, 227
fatty acid composition, chronic stimulation influence, 228
Phosphatidylinositol-4,5-biophosphate (PtdIns(4,5)P_2), 777, 778
Phosphatidylinositol bisphosphate (PIP_2), 796, 797
Phosphatidylserine (PtdSer-), 226, 776–779, 782
Phosphocreatine, 704
Phosphodiesterase (PDE), 706
Phosphodiesterase (PDE) inhibitors, 502, 561, 617, 620, 694, 699
inotropic agents in heart failure, 703–707
nanterinone hemodynamic effects in heart failure, 137–143
not recommended for heart failure treatment, 712
Phosphodiesterase III inhibitors, effect on renal function or hemodynamics, 81, 86
Phosphodiesterase (PDE) isoforms, 730
Phosphoesters, 703
Phospholamban, phosphorylation of, 233
Phospholipase A, 405
Phospholipase C (PLC), 404, 405, 796–797
activating protein kinase C in ischemic preconditioning, 775–778
"cross talk" mechanism, 778
Phospholipase D (PLD), activating protein kinase C in ischemic preconditioning, 775, 776, 778, 797
Phospholipids, 512
fatty acid profile of plasma lipids, 381
increase in content in mitochondria after isoproterenol injection, 233–234
sympathetic overactivity and lipids, 223–229
Phosphorylation, 782, 783
enzyme activity of protein kinase C, 779
protein, 796, 798
Phosphorylation process, 587
oxidative, 403
Physicians' Health Study, 614
Pig heart
cyclosporine and coronary endothelial function, 17–21
protein kinase C activators and myocardial infarct size, 779, 781
protein kinase C inhibitors, 779, 780

protein kinase C
translocation/activation, 779, 781, 783
Pilsicainide, adverse effects on induction of atrioventricular re-entrant tachycardia, 159–165
Pimobendan, 699, 706–707
vs. nanterinone, 138
Pinacidil, 28
^{32}P incorporation assays, 782, 783
Pindolol, effect on Ca^{2+}-activated contractions in skinned fibers, 581, 583, 584, 585
Piretanide, 696
Pituitary gland, vasopressin released from, 624
Placebo controlled, pranidipine in hypertension dose-finding study, 59–66
Plaque fissuring, 745, 746
Plaque instability, 405
Plaque rupture, 745
Plasma atrial natriuretic factor (ANF), enoximone and systemic and renal hemodynamics, 81, 86
Plasma beta-thromboglobulin (BTG), 119–122
Plasma catecholamines
adrenergic mechanisms and food restriction, 239–246
cardiovascular function and food restriction, 247–250
Plasma concentration of amlodipine, 449
Plasma concentration levels (Cpl), of almokalant, 540, 542–545
Plasma creatinine, renal impairment and captopril test, 75, 77, 78
Plasma drug concentration, 400
of dihydropyridines, 399, 400
Plasma flow, renal, 804
Plasma hormones, heart rate and, 678–679
Plasma levels, timing of nitroglycerin efficacy, 6, 8
Plasma lipids
beta-blocker effect on, 67, 68
and CHF treatment, 694
fatty acid profile, 380, 381, 384
Plasma membrane, calcium ions and, 404
Plasma renin activity (PRA), 7–8, 561–564, 694, 695, 697–698, 745
bosentan effect, 718, 719
enoximone and systemic and renal hemodynamics, 81, 83, 85–86
in heart failure, 625
renal impairment and ACE inhibitors, 75–78
Plasma sodium, captopril and renal impairment, 76, 77
Plasma viscosity, 744, 745, 746
Plasma volume expansion, 7–8
Plasminogen, 744
Plasminogen activator inhibitor (PAI), 522, 745
gene, 745
Plasminogen activator inhibitor-1 (PAI-1), 405, 610, 633, 641, 744–747
isradipine effects on, 119–122
Platelet activating factor (PAF), 405, 728, 731
Platelet activation, 746
Platelet aggregation, 405, 744, 745
and nitrate tolerance, 739
thromboxane effect on, 728–729, 732–733
Platelet agonists, 405
Platelet-derived growth factor (PDGF), 610, 798
Platelet factor-4 (PF4), isradipine effect, 119–122
Platelet functions, 635
adhesion, 632
aggregation, 631, 632, 633
isradipine sustained release effects, 119–122
Platelets
calcium ions and, 404
nicotine activation of, 663
PLC-IP_3-DAG transduction pathway, 795, 800
Plendil. *See* Felodipine
PMA. *See* Phorbol-12-myristate-13-acetate
P nuclear magentic resonance spectroscopy, 704
Polyanions, 569
Polymixin B, 134, 660
as protein kinase C inhibitor, 779, 780
Polymorphonuclear leukocytes, 235
Polypeptide chains, L-type calcium channel, 439–440
Polyphosphatidylinositol, 512
Polysaccharides, sulphated, 570
Polyunsaturated fatty acids, 223–229
n-3 polyunsaturated fatty acid (PUFA)rich oil diet, 223–227
n-6 polyunsaturated fatty acid (PUFA)rich oil diet, 224, 226–227
Positive inotrope, nanterinone hemodynamic effects in heart failure, 137–143
Positive inotropic agonists, in congestive heart failure, 111–112
Positive inotropic effect, mediated by catecholamines, 625
Postexertional syncope, 687
Postganglionic sympathetic nerve terminals, 691
Postgraduate Medical Institute in Chandigarh (India), neuroendocrine response in untreated patients, 624
Post-infarct therapy, calcium antagonists for cardiovascular disease, 455–459
Postmenopause, hypertension and, 387
Postreceptor events, 662
Potassium antagonist, AWD 23–111 effect, 531, 532, 537
Potassium canrenoate, 619
Potassium channel blockers, almokalant and, 543, 544
Potassium channels
AWD 23–111 effect on, 531, 537
tilisolol in canine coronary circulation, 23–29
voltage-gated, 706
Potassium chloride, 380
Potassium currents, 699
I_k, 539, 540
I_{kr}, 543, 544
I_{ks}, 544
and sodium mix, 678
Potassium depletion, 452, 453
cardiac arrhythmias, 399
Potassium ion electrolyte, 370
Potassium ions (K^+), 662, 674
and antihypertensive therapy, 399
loss of, 694, 696
Potassium$_{ATP}$ (K^+_{ATP}) channel blocker, 771
Potassium$_{ATP}$ (K^+_{ATP}) channels, 770, 775, 776, 779, 783
cardioprotection by cromakalim, 587–590
intracellular level, 590
preconditioning, 345
Potassium ions-ATPase, 662
inhibition, 705
Potassium phosphate, 68
Practolol, after MI, 95% confidence intervals and point estimates for relative risk reduction, early-entry and late-entry trials, 762, 763
PRAISE study. *See* Prospective Randomized Amlodipine Survival Evaluation study
Pranidipine
adverse events possible, 60, 64, 65–66
dosage, 66
mean plasma concentrations of responders and nonresponders, 64
mean plasma values, 63, 64
safety and tolerability, 59, 60
Pravastatin
cost effectiveness in hyperlipidemia, 787, 790–792
and restenosis, 475–482
with chlorthalidone, in ALLHAT study, 411
Prazosin, 590, 655, 713
preconditioning effectiveness in rat heart, 125–134
vs. isosorbide dinitrate with hydralazine for CHF, 740
Precapillary resistance arteries, 513
Preconditioning; *see also* Ischemic preconditioning
alpha$_1$-adrenergic signal transduction, 125–134
controversies in, 767–771
evidence in human heart, 770–771
ischemic, 587, 590, 730
reperfusion intervals and preconditioning, 341–345
Precordial lead V2, 540–543, 545, 546
Precordial lead V_3, 451
Precordial lead V5, 540, 541, 542, 546
predonisolone, 501

Preexcitation syndrome, 528
Preganglionic splanchnic nerve, 264
Pregnancy, α-methyl-DOPA safety, 286
Preload, 635
Premature beats
  benign, 682
  ventricular, 555, 677
  ventricular, amiodarone treatment, 714
Premature ventricular contraction (PVC), and cardiac sarcoidosis, 497, 498, 499
Prenalterol, 704
Preproendothelin-1 mRNA, 564
  inhibition of expression by lacidipine, 442–445
Pressor effect of insulin, 280
Pressor responses, 313
Presynaptic receptors, 659, 662
Presyncope, 527
Prevention of Atherosclerosis with Ramipril Therapy (PART) trial, 643
PREVENT study, 410, 411
Primary asystole, after acute myocardial infarction, 486
PRIME-2 trial. *See* Prospective Randomized Study of Ibopamine on Mortality and Efficacy in Heart Failure
PR intervals, 371, 373, 529
  prolongation of, 59
prinzmetal's angina, calcium antagonists as first-line therapy, 455, 456
Proarrhythmia, 527
  almokalant and, 543
  excluded from propafenone vs. disopyramide study, 151
Proarrhythmic effects, 550
  of antiarrhythmic drugs, 621
  AWD 23–111, 537
Proarrhythmogenic activity, 697, 699
Pro-Banthine, 688, 690, 691
Probucol, 421
Procainamide
  adverse effects on induction of atrioventricular re-entrant tachycardia, 159–165
Procardia/Adalat. *See* Nifedipine
Procardia XL, safety documentation for SR in hypertension, 464
Proendothelin, 795
PROFILE study. *See* Prospective Randomized Flosequinan Longevity Evaluation study
Prognosis, risk indicators for death after AMI, 485–489
Programmed ventricular stimulation, 549–555
pro-hANF cleavage peptide, 596
Prolongation of life, digoxin and, 694
Prolyl endopeptidase, 512, 515
PROMISE trial. *See* Prospective Randomized Minrinone Suvival
Propafenone, 536, 550, 551
  beta-adrenergic actions, 150
  intravenous, for recent onset atrial fibrillation, 153–156
  previous studies, 149–150
  safety, 150–151
  side effects, 148–151
  toleration better than that of disopyramide, 151
  vs. amiodarone negative inotropic effect, 156
  vs. disopyramide, 149–151
  vs. disopyramide for sinus rhythm maintenance, 145–151
Propafenone/disopyramide hazard ratio for treatment, 147, 148
Propantheline bromide, in neurocardiogenic syncope, 687–692
Propranolol, 400
  after MI, 95% confidence intervals and point estimates for relative risk reduction, early-entry and late-entry trials, 762, 763
  beta-antagonists and Ca^{2+} sensitivity, 581–586
  as beta blocker, 67, 71, 73
  BHAT study, 761
  blocking a concentration-dependent relaxation of arbutamine and isoproterenol, 39, 41, 42, 43, 45
  concentration-response curves, 585
  contractile response in arbutamine study, 33–35, 36–37
  effect on Ca^{2+}-activated contractions in skinned fibers, 581–586
  heart rate and, 678–679, 681–682
  renal hemodynamics and, 804, 806
  vs. betaxolol, 581–586
  vs. tilisolol, in canine coronary circulation, 23–29
d-propranolol, effects of beta-blockers on HMG CoA receptors, 67–73
L-propranolol, effects of beta-blockers on HMG CoA receptors, 67–73
Prospective Randomized Amlodipine Survival Evaluation (PRAISE) study, 411, 712
  PRAISE-I trial, 698
Prospective Randomized Flosequinan Longevity Evaluation (PROFILE) study, 670, 713, 762
Prospective Randomized Minrinone Survival Evaluation (PROMISE), 699, 704, 706, 762
Prospective Randomized Study of Ibopamine on Mortality and Efficacy in Heart Failure (PRIME-2), 713, 762
Prospective Randomized study of Ventricular failure and the Efficacy of Digoxin (PROVED), 711
Prostacyclin (PGI_2), 663, 713, 797; *see also* Epoprostenol
  ACE inhibition and, 641
  antiplatelet effect and LDL, 731
  breakdown inhibited by ACE inhibition of kininase II, 609, 610
  delayed cardioprotection by, 730–731, 733
  ET_B receptors responsible for, 111
  production maintenance by endothelial cells and aspirin therapy, 727–733
  release, 795
  stable derivatives, delayed cardioprotection by, 730
Prostacyclin analogs, 475
Prostacyclin-stabilizing factors, 731
Prostaglandin-endoperoxide synthase, vasoactive cyclooxygenase, 384
Prostaglandin endoperoxide H synthase, 727
Prostaglandin $F_{2\alpha}$, cyclosporine and coronary endothelial function, 17–20
Prostaglandin metabolism, oxygen free radical formation, 419–421
Prostaglandin peroxide $H_2(PGH_2)$, 727
Prostaglandins (PGs), 512–513, 624, 727–731
  release and endogenous bradykinin, 640
  as vasodilators, 511, 805, 806
Prostanoids, 729
  preconditioning, 345
  vasodilator, 564
Prostatism, 691
Protection, reperfusion intervals and preconditioning, 341–345
Protein, 557
Protein kinase A (PKA), 706, 776, 797
Protein kinase C (PKC), 405, 564, 795–798, 800
  activation, 779, 781
  activation triggered by adenosine, 767–768, 771
  -ε immunoreactivity measurements, 782
  evidence for role in ischemic preconditioning, 779
  general biochemical properties, 776–778
  in coupling phospholipase C- to phospholipase D-activation, 778
  inhibition of, 779
  inhibitors, 125–134
  measurements of translocation (activation), 781–783
  M(r) 76,000 substrate, 796
  nicotine and intracellular transmission, 657–663
  processes regulated by, 776
  role in protection of functional recovery by ischemic preconditioning in rat heart, 125–134
  role in ischemic preconditioning, 775–783
  substrate phosphorylation, 798
  target proteins of, 776, 778, 779, 783
  translocation from cytoplasm to membrane, preconditioning, 345
Protein kinase C antagonist, 771
Protein kinase C isotypes, 776–778, 781–783

Protein kinase C (PKC)-MAP kinase pathway, 796
Protein kinase C signal transduction pathway, 445
Protein kinase D, 776
Protein kinases, cAMP-dependent, 703
Protein S, 746
Proteins, 679
  contractile, 703, 704, 796
  polyanion binding, 569
Protein Serine/Threonine (Ser/Thr) kinases, 776
Protein sulfydryl (SH) groups, 428, 434
Protein synthesis, 797
Protein-Tyr kinases, 779
Proteinuria, 276, 277, 279, 515, 807
Proteinuria/microalbuminuria, 745
Proteolytic cascade, 512
Protons, 662
Protooncogenes, 610
  cellular, 796, 797, 798
PROVED study. *See* Prospective Randomized study of Ventricular Failures and the Efficacy of Digoxin
Proximal coronary resistance, 410
Psaty and Pahor case control studies, 401, 409, 410
Pseudo-Wigner-Ville transformation, 677, 679–681
Psychosocial stress, hypertension and, 251
Psychosomatic diseases, 271
Psychotropics, risk indicators for death after AMI, 486, 487
Public health, calcium antagonists as first-line agents, 463–466
Pulmonary artery, porcine, 559
Pulmonary artery, endothelial cells, bovine, 559
Pulmonary artery pressure, mean, bosentan effect on, 718–719, 720, 722
Pulmonary artery wedge pressure, bosentan effect on, 718–719, 720, 722
Pulmonary capillary wedge pressure
  bosentan effect, 722
  nitrates effect on, 740
Pulmonary circulation, 796
Pulmonary congestion, 698
Pulmonary edema, acute, 13
Pulmonary embolism, 621
Pulmonary fibrosis, 495, 497
Pulmonary gas excahnge, diltiazem in supraventricular tachyarrhythmia, 14
Pulmonary hypertension, diltiazem in supraventricular tachyarrhythmia, 14
Pulmonary infarction, 559
Pulmonary infections, intercurrent, 618
Pulmonary sarcoidosis, in Afro-Americans, 496
Pulmonary vascular resistance
  bosentan effect, 719, 721
  enoximone effect with heart failure, 81–86
  nanterinone hemodynamic effects, 139, 141
Pulmonary wedge pressure, 362, 698
  enoximone effect with heart failure, 81, 83, 84, 86
  nanterinone hemodynamic effects in heart failure, 139, 141, 142
Pulse pressure/storage volume ratio, aortic stiffness and hypertensive therapy, 53
Pulse pressure/stroke dimension ratio, aortic stiffness and hypertensive therapy, 53
Pulse rate, pranidipine in hypertension, 59–66
Pulse wave velocity, antihypertensive therapy and aortic stiffness, 49–56
Purkinje strands, 672
p values, 362, 363, 551

QRS complex, 12, 239
  prolongation of, due to food restriction, 239, 241, 244
QRS duration, 371, 373, 376, 551
QRS interval
  analyzed in trial of IV propafenone for recent onset atrial fibrillation, 154
  AWD 23–111 effect, 531–536
QRS waves, 528
QT intervals, 369, 371, 373, 374, 376
  almokalant effects on, 539–543, 545
  end of T wave and (QT_{END}), 540–543, 545
  precordial lead V2, 540–543, 545, 546
  precordial lead V5, 540–542, 546
  prolongation of, due to food restriction, 239, 241, 244
  tangential of T wave (QT_{TANG}), 540–543
  ventricular paced, 545, 546
QT_C interval
  analyzed in trial of IV propafenone for recent onset atrial fibrillation, 154, 155
  prolongation of, 590
Quality of life
  CHF, drug therapy and, 699
  metoprolol treatment and heart failure, 361–367
  pimobendan, 706
  and risk of correcting the risk, 751–753, 755, 756
Quality of Life in Heart Failure Questionnaire (QLQ-CHF), 361, 362, 366
Quantascope, 573, 574
QUIET trial. *See* Quinapril Ischaemic Event Trial
Quinapril, 564, 610–611, 633, 635, 642–643, 695–696, 807
  cardioprotective effect in coronary heart disease, 639–643
  TREND, 469, 470, 471
Quinapril Ischaemic Event Trial (QUIET), 471, 611, 635, 636, 642, 643
Quinidine, 539, 551–555
  for atrial fibrillation, 151
  maintenance rates of sinus rhythm in studies, 149–150
Quinolinon derivative, 705
Q-wave myocardial infarction, 519
  pravastatin study, 477, 478, 479
Q waves, and cardiac sarcoidosis, 497

Rabbit hearts protein kinase C activators and myocardial infarct size, 779, 781
  protein kinase C inhibitors, 779, 780
  protein kinase C translocation/activation, 783
Racial difference, cardiac sarcoidosis incidence, 495, 496
RADIANCE trial. *See* Randomized Assessment of Digoxin in Inhibitors of the Angiotensin-Converting Enzyme
Radioimmunoassay (RIA) method, 370
  Ang-II plasma concentration, 564
  ET-1, 562–563
Radioligand binding competition study, 41
Radionuclide studies, cardiac sarcoidosis, 495, 499
Radionuclide ventriculography, 76
Radio telemetry, to record cardiovascular parameters of rebound hypertension, 251, 252, 256–257, 261
Raftery, Edward Bernard (obituary), 193
Ramipril, 20–21, 471, 520–521, 632, 635, 695–696, 761
Randomized Assessment of Digoxin on Inhibitors of the Angiotensin-Converting Enzyme (RADIANCE), 711
Random effects model, 298–299
RAPID study, 762
Rat aorta, Cx-induced vascular toxicity and fish oil, 379–384
Rate dependency, electrocardiological effects of AWD 23–111, 531–537
Rate-dependent effect, AWD 23–111, 535–536
Rate-pressure product (RPP), 575, 576, 578
Rat heart
  $alpha_1$-adrenergic signal transduction, 125–134
  arbutamine, adrenergic activities of, 39–46
  cyclosporine and coronary endothelial function, 17
  EUK-8 cardioprotective effects, 331–338
  moxonidine benefits for obese hypertension, 275–280
  neointima formation prevention by mibefradil after vascular injury, 101–104
  neutral endopeptidase prolonged inhibition effect on cardiac hypertrophy, 593–596
  obesity and autonomic regulation, 263–271
  protein kinase C activators and myocardial infarct size, 779, 781
  protein kinase C inhibitors, 779–780

protein kinase C translocation/activation, 779, 781
tilisolol producing vasodilation, 23, 27
ventricular myocytes, 778
Rauwolscine, 285
Raynaud's phenomenon, calcium antagonists as first-line therapy, 455–457
Reactivation, reperfusion intervals and preconditioning, 345
Reactive oxygen species (ROS), inducing heart damage, 331–333, 335, 338
Rebound
hypertension, and central acting drugs, 251–261
nitrate tolerance, and clinical relevance in stable angina pectoris, unstable angina, and heart failure, 735–741
Rebound hypertension, losartan therapy, 318
Rebound phenomena, intermittent vs. continuous transdermal nitroglycerin, 5–9
Receptor function, 679–680
Receptor-G-protein, 778
Receptors, high-affinity, 796
Receptors for activated C kinase (RACK), 776, 777, 783
Receptor subtype-selective antagonists, 795, 799
Reflex, baroceptors, 678
Reflex sympathetic activity, 520
Reflex tachycardia, 640
Reflex vasodilation, 691
Refractoriness, 543
almokalant and, 543, 544, 545
electrocardiological effects of AWD 23–111, 531–537
Refractory periods, almokalant and, 539, 544
Regression lines, almokalant and, 543, 544, 545
Regulation, biological, 680
Rehabilitation, 752
Reinfarction, 550
low-dose aspirin for prevention of myocardial infarction, 727–733
Reintroduction, reperfusion intervals and preconditioning, 341–345
Remodeling of the heart, 695
cytoplasmic, 559
left ventricular, 614–615, 635, 636
theory, 521
vascular, 634, 635, 796, 797, 799
Renal artery stenosis, 804
Renal blood flow, 513
A1–7 and, 511
Renal disease, 515
renin inhibitors, 309–312
Renal dysfunction, calcium antagonists for, 464
Renal failure, 443, 444, 561
Renal function
enoximone and systemic and renal hemodynamics, 81–86
impairment, and ACE inhibitors, 75–78
Renal hemodynamics, enoximone effect in heart failure, 81–86
Renal resistance (RR), enoximone effect on renal and systemic hemodynamics, 85, 86
Renal transplantation, 379
Renal tubule cells, endothelin formation, 795
Renin, 310–311, 511, 512, 514, 561, 632
antihypertensive drugs and renal function, 803–807
CHF and, 561, 564
endothelin and vascular hypertrophy, 795–800
plasma, 513, 515
RAS as risk factor, 613–615
renal, 515
Renin-angiotensin-aldosterone (RAAS) system. *See* Renin-angiotensin system
Renin-angiotensin system (RAS), 405, 445, 519, 631–632, 635, 798, 800
ACE inhibitors effect, 620
ACE levels regulating, 640, 641
activated in heart failure, 623–627
activation of, 693–694, 697–698, 700, 705
AMI and, 519, 522
angiotensin mechanisms and hypertension, 511–516
antihypertensive drugs and, 803–806
blockade, 561, 564
captopril and renal impairment, 75, 76, 78
catecholamines-stimulating effects, 213–214
diastolic function, adrenergic stress, and angiotensin II in hypertension, 321–328
digitalis effect, 618
effects of mibefradil and cilazapril on neointima formation, 101–104
endothelin-1 and bosentan relationship, 718, 723
enoximone effect on systemic and renal hemodynamics, 81–82, 86
influence on process of atherosclerosis, 614
losartan vs. enalapril safety and efficacy, 313–319
mediating ACE inhibition, 610
neutral endopeptidase prolonged inhibition effect, 594, 595, 596
nifedipine effect, 413
renin inhibitors, 309–312
role as risk factor for coronary artery disease, 613–615
stimulation and sympathetic activation, 215
Renin-angiotensin system genes, 516
Renin inhibitors
vs. ACE inhibitors, 310
vs. ACE inhibitors as cardiovascular drugs, 309–312
vs. angiotensin II antagonists, 310
Reocclusion, 298
Reperfusion, 298, 299, 300
alpha$_1$-adrenergic signal transduction pathway and ischemic preconditioning, 125–134
effect of calcium following, 403, 404
felodipine and cardiac protection, 425–435
felodipine beneficial effects, 167–176
felodipine and stunning, 347–349
intervals of, and preconditioning, 341–345
ischemic preconditioning and, 768, 769, 770–771
and platelet activating factor, 728, 730
ventricular fibrillation during, 369, 372, 374, 375
Reperfusion arrhythmias, 640
Reperfusion injury, 303, 304
EUK-8 cardioprotective effects, 331–338
magnesium in acute myocardial infarction, 298, 300
Replacement therapy, 752
Repolarization, 449, 452
ventricular, almokalant and, 539, 540, 544, 545, 546
Repolarization period, electrocardiological effects of AWD 23–111, 531–537
Reproductive organs, angiotensin receptors and, 512
Reserpine, 190
effect on guinea pig catecholamines, 40
effect on preconditoning of rat heart, 133
Respiration, heart rate and, 677, 678
Respiratory arrhythmia amplitude, cosinor analysis of, 692
Respiratory control index (RCI), mitochondrial function and felodipine, 426
Respiratory distress, acute, 12, 13
Respiratory failure, acute, 15
Rest, unloading the heart and, 693
Rest angina, 23, 735, 736, 738
Restenosis, 101, 104, 633, 634, 636, 756, 757
after vascular injury, bradykinin cardioprotective effect, 640
incidence reduced by aspirin therapy, 733
reduced by pravastatin after PTCA, 475–482
Resting membrane potential, 451–453
Resting muscle metabolism, 220
Restitution curves, 545, 546
Resuscitation, in CAMIAT, 714
Reteplase, 762
in INJECT study, 763–764
Retinol, plasma levels, 570
Retinol binding protein (RBP), 567, 570

Retinol dehydrogenase, zinc-dependent hepatic, 570
Revascularization
coronary, 634, 635
procedures, 519
Reverse frequency dependence, 539, 543
Reverse use-dependent effect, AWD 23–111, 531, 532, 536, 537
Right atrial pressure (RAP)
bosentan effect on, 718–720, 722
enoximone and systemic and renal hemodynamics, 81, 83, 84, 86
nanterinone hemodynamic effects in heart failure, 139, 141, 142
Right ventricles
apex (RV_{APEX}), 550
apical region stimulation (RV_{APEX}), 539–543, 545, 546
outflow (RV_{OT}), 550
outflow tract of (RV_{OT}), 539–543, 545, 546
Right ventricular disease, 545
Rilmenidine
chemical relationship with clonidine, 287
for hypertension, 251, 261
and sympathetic outflow, 283–288
Risk area, reperfusion intervals and preconditioning, 343–344
Roentgenogram, 527
Rostral ventral medulla, 284
Rostral ventrolateral medulla (RVM), 283–285, 288
Rostral ventromedial medulla, 284, 285
Roxithromycin, for *Borrelia burgdorferi*associated dilated cardiomyopathy, 358
R-R intervals, 680, 681, 683
HRV and, 680, 681
RS-[5–^{3}H(N)] mevalonacton (28.4Ci m mol), 68
rtPA treatment, *See* Alteplase
R-waves, 527
Ryanodine, KT-362 and Ca^{2+} transients, 667–674

S-16257, 682, 683
S1-S1 interval, 531, 533–536
AWD 23–111, 531, 533–536
S1-S2 interval, AWD 23–111, 533, 534
Safety
calcium antagonists as first-line agents, 463–466
Safety checkups, antihypertensive therapy and, 50
Salbutamol, effects of beta-blockers on HMG CoA reductase, 68, 70, 72
Salen-manganese complexes, synthetic, 331–332, 338
Saline infusion, hyperosmatic, 806
SAG. *See* 1-stearoyl-2-arachidonoyl glycerol
Salt sensitivity, moxonidine benefits for obese hypertension, 275–280
Saralasin, 318
Sarcoid granuloma, 495, 497, 499–501
Sarcoid heart disease, cardiac sarcoidosis, 495–503
Sarcoidosis, cardiac, 495–503
Sarcoidosis Research Committee of Japan, 500
Sarcolemma, 231, 776, 777, 782, 783
Ca^{2+} channels activated, calcium ion transport, 231–235
calcium transport, and felodipine effect, 426, 427, 430, 432, 435
trigger calcium ions, 703
Sarcolemmal Ca^{2+} pump, 672
Sarcomeres, EUK-8 vs. DMTU cardioprotective effects, 335, 337
Sarcoplasma, Ca^{2+} release channels, 667
Sarcoplasmic reticulum (SR), 703, 776–778
Ca^{2+} transport, 231, 233–235
felodipine effect, 432–433
KT-362 and Ca^{2+} transients, 667–674
SAVE study. *See* Survival and Ventricular Enlargement study
Scandinavian Simvastatin Survival Study Group (4S) trial, 754, 760
Scarring, 588
Scatchard analysis, 69, 70, 71, 73
SCH 34826, 596
SCH 39370, 596
Schild plots, 41, 42, 45
Scleroderma, with Raynaud's phenomenon, 457
Scopolamine, 691
SDS-polyacrylamide gel electrophoresis (PAGE), 418, 419, 422
Secondary Prevention Reinfarction Israeli Nifedipine Trials (SPRINT)-2, 398
Second messengers, 776
Second National Registry of Myocardial Infarction, 405
Second window of protection (SWOP), 775, 776, 783
SECURE study. *See* Study to Evaluate Carotid Ultrasound Changes with Ramipril and Vitamin E
Seldinger technique, 540
Selenium, 567–570
Selenium-carrier proteins, 570
Selenoprotein P, 570
Septal wall hypertrophy, 529
Septic shock, 627
Serine proteases, 514
Serotonergic $5HT_{1A}$-receptors, 283, 284, 288
Serotonin, 380, 381, 383, 405
cyclosporine and coronary endothelial function, 17, 18, 19, 21
role in ischemic heart disease, 442, 443
Serotonin-induced contractions, 379, 381, 383
Serotonin ($5\text{-}HT_3$) receptors, 658
Serotonin uptake blockers, 280
s-fos protooncogene, 641
Shanghai trial of hypertension in the elderly (STONE), report of, 467–468
Shear stress, 634, 743, 795, 797
-SH moiety, 523
Sialic acid, 232
Sickness Impact Profile, 362
Sick sinus syndrome, 11–14, 497–498
diltiazem in supraventricular tachyarrhythmias, 15
Signal transduction
cellular, 660, 661
endothelin-1 response, 111
mechanisms, 796, 798–800
Signal transduction pathways, 512, 590
Ca^{2+}-associated, 706
ET, 797, 800
Simultaneous vasodilatation, 116
Simvastatin, cost effectiveness in hyperlipidemia, 787, 788, 790–793
Simvastatin and Enalapril Coronary Atherosclerosis Trial (SCAT), 635, 643
Single photon emission computed tomography (SPECT), 499
Cardiac SPECT Imaging (book review), 91
Single-vessel disease, 633
Sinoatrial node inhibition, 403
Sinus arrest, 14
Sinus cycle length (SCL), 371, 373
Sinus node, HRV and, 678, 679, 682, 683
Sinus node cycle length, 531, 534, 535
AWD 23–111, 531, 534, 535
Sinus node dysfunction, 15, 497, 498
Sinus node inhibitor, 682–683
Sinus rate (SR), 448
electrocardiological effects of AWD 23–111, 531–537
Sinus rhythm, 528, 529, 550, 694
digoxin not used unless ACE inhibitors tolerated, 712
digoxin recommended to relieve symptoms, 711
intravenous propafenone for recent onset atrial fibrillation, 153–156
propafenone vs. disopyramide for maintenance after electrical cardioversion of chronic atrial fibrillation, 145–151
ventricular dysfunction in, 705
Sinus tachycardia, 298
Skeletal muscle
excitation-contraction coupling, 440
fatigue, 587
ischemic preconditioning, 775
Skeletal muscle changes, 588, 590
Skin, AII and, 514
Skinned fibers, betaxolol vs. propranolol on Ca^{2+}-activated contractions, 581–586
SMAC II multiparametric analyzer, 568
SMILE study. *See* Survival of Myocardial Infarction: Long-term Evalaution
Smoking, 717
acute cardiovascular effects of, 657, 663

cardiovascular safety of nicotine patches, 179–183
as hemostatic predictor for arterial thrombosis, 743, 744, 745, 747
-induced spasm, 457
in hyperlipidemia study, 789, 792
isradipine sustained release effects in hypertension, 119–122
risk indicators for death after AMI, 485
risk of cardiac events, 179
Smoking cessation, 663
cardiovascular safety of nicotine patches, 179–183
Smooth muscle; *see also* Vascular smooth muscle (VSM)
betaxolol vs. propranolol effects on Ca^{2+}-activated contractions, 581–586
Smooth muscle cells
antimigratory effects, 610
bradykinin effects, 610
calcium antagonism and ACE inhibition effects on neointima formation, 101–104
CCBs and, 410
Cx-induced vascular toxicity and fish oil, 379, 384
growth factor, 631, 634
mibefradil prevention of cell proliferation, 101–104
migration, 633, 634
proliferation, 632, 633
proliferative activity reduced by CCBs, 417
Smooth function, cyclosporine and coronary endothelial function, 20, 21
Smooth muscle receptors, 20
S-nitrosocaptopril, 599
SnoCap (S-nitrosocaptopril), 599
Sodium, 452, 453
antihypertensive drugs and renal function, 803–807
dietary, moxonidine benefits for obese hypertension, 275–280
excretory capacity, 803, 806
extracellular concentration, 660–662
intracellular, nicotine and intracellular transmission, 657–663
loss in CHF treatment, 694, 696
retention, 513, 806
urinary excretion, 513
Sodium antagonists, AWD 23–111, 531, 536, 537
sodium channel blockade, 674
Sodium channel blocker, 536, 537
Sodium channel potential, 453
Sodium channels
AWD 23–111, 531, 536, 537
drug therapy and, 699
Sodium chloride, 380, 799
Sodium current, and potassium mix, 678
Sodium excess, intake and congestive heart failure, 618, 619
Sodium intake, nutritional disorders and I_1-agonists, 213–214
Sodium ion/calcium ion exchanger, 590, 661, 679
Sodium ion electrolyte, 370
Sodium ion excretion, 745
Sodium ion/hydrogen ion exchange, 797
Sodium ions (Na^{2+})
inhibition of, 705
KT-362 and, 667
permeability, 657–661
selectivity, 657
Sodium meclofenamate, 729
Sodium mercaptoacetate (MA), 265
Sodium nitroprusside, 729
Sodium/potassium-ATPase, 730
Sodium pump, 679
SOLVD study. *See* Studies of Left Ventricular Dysfunction
Somatic symptoms, correlated with physical activity, 363–366
Sonomicrometry, 347
to monitor coronary artery diameter changes in dogs, 23, 29
Sotalol, 550, 551, 552, 554, 714
after MI, 95% confidence intervals and point estimates for relative risk reduction, late-entry trials, 763
for atrial fibrillation, 151
maintenance rates of sinus rhythm in studies, 149–150
d-sotalol, 714
Spastic colon side effect, 689, 690
Spectral power analysis, 680–682
Sphygmomanometer, 550
Spillover, 400
Spirochetosis, 356
Spironolactone, 619, 694
for congestive heart failure, 626
Spontaneously hypertensive rat (SHR)
endothelin and vascular hypertrophy, 795
heart rate, a pharmacological tool, 677–684
moxonidine benefits for obese hypertension, 275–280
SPRINT 2 study. *See* Secondary Prevention Reinfarction Israeli Nifedipine Trial-2
SQ 28,603, 593, 596; *see also* TM1
Standard deviation (SD) of the mean technique, HRV and, 677, 680
Standard errors of the mean (SEM), 449
Stanozolol, 745
Statins, 762
and hyperlipidemia therapy, 787–793
reducing fatality in a secondary prevention, 760
Statistica package, 252
Staurosporine
abolishing preconditioning as PKC antagonist, 134
as protein kinase C inhibitor, 779, 780
Stearic acid, 223, 225
1-stearoyl-2-arachidonoyl glycerol (SAG), as protein kinase C activator, 779, 781
Stenosis, 634
renal artery, 804
Steroids, 745
Stimulation protocols, 532, 533, 536
Stomach, ET_B receptors in, 795
Stomach tissue, 514
STONE study. *See* Shanghai Trial of Nifedipine in the Elderly Study
STOP study, 458
Stop-flow ischemia, ischemic preconditioning, 769
"Strange attractors," 680
Streptokinase, 759, 760
in INJECT study, 763–764
Streptomycin, 68
Stress
endothelin release and, 799
-induced heart disease, 231–237
mental, heart rate and, 678
shear, 634, 743, 795, 797
Stress testing
arbutamine, adrenergic activities of, 39–46
non-exercise, arbutamine as pharmacological cardiac stress agent, 31–38
Stretch receptors, preconditioning, 345
Stroke, 610, 635
associated with obesity, 215, 219
calcium antagonists for, 464
cardiovascular disease treatment changes, 191
correlated with arachidonic acid, 223
decrease in morbidity, 67
decrease in mortality, 67
diuretics and, 397
endothelin role in, 445
hemorrhagic, calcium channel antagonists and, 405
low-dose aspirin for protection, 727, 733
non-fatal, total drug costs, 465
prevention by calcium antagonists, 468
recurrence and antiplatelet drug therapy, 743–747
risk of clinical trials, 762
spontaneously hypertensive rats, 799
survival in, 515
Stroke volume (ejection fraction)
calcium channel blockers effect, 413
left ventricular (LVEF), 562
left ventricular, ACE inhibitors for treatment, 712
left ventricular, amiodarone effect in CHF-STAT trial, 714
left ventricular, *Borrelia burgdorferi* cardiomyopathy, 351–358
left ventricular, bosentan effect on, 718, 721, 722
left ventricular, and cardiac sarcoidosis, 497

left ventricular, GUSTO trial results, 756
metoprolol and quality of life in heart failure, 367
Stroke volume index
bosentan effect on, 719, 721, 722
nanterinone hemodynamic effects, 139–143
Stroke volume/pulse pressure ratio, 53–54
aortic stiffness and hypertensive therapy, 53–54
Stroke work index, nanterinone hemodynamic effects, 139–143
ST-segment
anterior elevation, 522
ischemia and, 447–449, 451, 452
nocturnal changes, 457
ST-segment deflections, arbutamine as pharmacological cardiac stress agent, 31, 35–38
ST-segment depression, transdermal nicotine patch trial, 180
Student-Newman-Keuls test, 108–109
Student's t-test, 551, 588
almokalant study and, 540
aortic stiffness and antihypertensive therapy, 51
for paired values, 449
for unpaired observations, 669–673
propantheline bromide dosage, 688
Studies of Left Ventricular Dysfunction (SOLVD), 366, 613, 625, 634–635, 695, 712
reduced left ventricular function, 642
Study Group of Long-term Antihypertensive Therapy (GLANT) project, 464
Study to Evaluate Carotid Ultrasound Changes with Ramipril and Vitamin E (SECURE), 643
Stunned myocardium, ACE inhibitors, 640
Stunning, 433
arbutamine as cardiac stress agent, 37
felodipine and, 347–349
Subconductance state, 672
Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP), 633
Subdiaphragmatic vagotomy, 265
Substance P, 309, 313, 514
cyclosporine and coronary endothelial function, 17–21
Sucrose, 661
Sudden cardiac death (SD), 244, 372
beta-blockers and, 397, 399, 458
calcium antagonist proarrhythmic effect, 463
calcium antagonists and, 447, 452
catheter ablation in patients with HCM, 527–529
cause of death in cardiac sarcoidosis, 495, 501, 502
causes, 621
diuretics and risk of, 458
following sudden withdrawal of nitrates, 736
HRV and, 680
LVH and, 399
low-dose aspirin therapy for protection, 727, 733
metoprolol, to reduce mortality in myocardial infarction, 361
programmed ventricular stimulation and, 549, 551–553, 555
risk of, 699
smoking and, 663
treatment costs, 789
Sugar, as glycolytic end product, 768
Sulfhydryl, captopril as, 564
Sulfhydryl donors, to counteract sulfhydryl group depletion with nitrates, 735, 738, 740
Sulfhydryl-group donors, with nitroglycerin patch therapy, 7
Sulfhydryl groups, depletion of, 735, 738
Sulfhydryl theory, 736
Sulmazole, 699
Superoxide dismutase (SOD), 331, 335, 337–338, 470, 567
Superoxide ions, 331, 334, 335, 337, 338, 469
Superoxide radical, 235
Supine diastolic blood pressure (SuDBP), losartan vs. enalapril safety and efficacy, 313–319
Supraventricular premature beats, 682
Supraventricular tachyarrhythmias, diltiazem for acute managment in elderly, 11–15
Supraventricular tachycardias, 403
catheter ablation in patients with HCM, 527–529
Surgery, and hyperlipidemia, 788
Surgeon's General Report (1989), 179
Surrogate endpoints, alternatives to mega-trials, 759–764
Survival
after MI, 519–522
CHF and, 693–695, 697, 700
inotropic agents in heart failure, 703–707
use of beta-blockers and, 399
use of nifedipine and, 398
Survival and Ventricular Enlargement Trial (SAVE), 519, 521, 613, 625, 634–635, 642, 695, 712
Survival curves, 551
Survival of Myocardial Infarction: Longterm Evaluation (SMILE), 519–522, 712
Survival With Oral d-Sotalol (SWORD) trial, 714
SVR, 410
Swallow syncope, 687
Swan-Ganz hemodynamic monitoring, enoximone and systemic and renal hemodynamics, 81–86
Swedish Medical Products Agency, 540
Swedish Twin Registry, 614
Swimming, 223, 224
Swimming (emotional stress), 265
SWORD trial. *See* Survival With Oral d-Sotalol trial
Sympathetic nerves
AII and, 513, 515
cell model for, 660
Sympathetic nervous system (SNS), 265, 268, 400, 405, 663
activation of, 623–625, 693–698, 700, 705, 799, 805
cardiac nerve endings, 657–658, 662–663
efferent, 658, 659
heart rate and, 678, 680, 682
inhibition of, 805
mediating insulin's vascular effects, 215–220
moxonidine benefits for obese hypertension, 275–280
nicotine and peripheral postganglionic, 657, 658, 662
nicotine and postganglionic muscle, 657
nifedipine effect, 413
sympathoadrenergic overactivity and lipid metabolism, 223–229
Sympathetic nervous system activity
calcium antagonists and, 405
cardiovascular function and food restriction, 247–250
correlated to energy expenditure, 220
diet restriction effects, 239, 241–242, 245
1,4-dihydropyridine vs. beta-blockers for hypertension, 397–401
Sympathetic outflow, 203–288
Sympathetic outflow-regulating drugs, and nutritional disorders, 213–214
Sympathetic tone, 679
Sympathoadrenal system, 265, 266
Sympatholytic drugs, 805
Sympathomimetic amines, arbutamine, adrenergic activities of, 39–46
Syncope, 528
induced, 688
Syndrome X, resembling obese hypertension in rats, 275–276, 278–280
Synthetic catalytic scavengers (SCSs), EUK-8 cardioprotective effects, 331–338
Systemic lupus erythematosus, 459
Systemic vascular resistance (SVR)
bosentan effect, 719–723
enoximone and systemic and renal hemodynamics, 81–86
formula, 114
metoprolol vs. carvedilol in hypertensive patients, 116
nanterinone hemodynamic effects, 139, 140, 141
Systolic arterial pressure
cilazapril effect on, 103
mibefradil effect on, 103
Systolic blood pressure (SBP), 371
aortic stiffness and hypertensive therapy, 49–56

calcium antagonists and, 403
captopril and renal impairment, 76
cardiovascular safety of nicotine patches, 179
Cx-induced vascular toxicity and fish oil, 380, 383
clonidine effect, 252–253, 255–257, 259, 260
and congestive heart failure, 618–620
elgodipine effect, 573, 574, 576–579
EUK-8 vs. DMTU cardioprotective effects, 333–335
as hemostatic predictor, 744
high-salt diet effects on rats, 443–445
isosorbide dinitrate effects for angina pectoris patients, 737
isradipine sustained release effects in hypertension, 120, 121
metoprolol vs. carvedilol in hypertensive patients, 113–117
moxonidine effect, 252, 254, 257, 259–260
nifedipine SR effect, 467
pranidipine in hypertension, 59–66
Systolic dysfunction, 403
left ventricular, medical therapy for, 711–715
Systolic time intervals, 704, 706
Systolic $[Ca^{2+}]_i$(sCa), 667, 669–673

Tachyarrhythmias, cardiac, 307, 372
hypothyroidism and, 369
dopamine and, 695
ventricular, 527, 663, 705
ventricular, almokalant and, 543
ventricular, inducible, 555
ventricular, nicotine and, 657
Tachycardia, 495, 624
atrioventricular nodal re-entrant, 527, 528, 529
dopamine and, 695
elgodipine effect, 573–574, 578
isoproterenol-induced, suppressive effects of tilisolol, propranolol, and arotinolol, 26, 27
noradrenaline-induced, 697
paroxysmal, 527
supraventricular, 410
supraventricular paroxysmal, 499
supraventricular reciprocating, 543, 545
ventricular (VT), 372–373, 375, 410, 448, 452, 536–537, 621, 714
ventricular, after myocardial infarction, 486, 488
ventricular, calcium antagonists vs. beta blockade, 457
ventricular, and cardiac sarcoidosis, 497–499, 501
ventricular, catheter ablation and, 527
ventricular, epinephrine-induced arrhythmias, 243
ventricular, inducible monomorphic, 549–555
ventricular, nonsustained, 714
ventricular, spontaneous sustained, 549, 550, 552–555
ventricular, suppression of, 551
Tachycardia induction zone, 159, 162, 163
Tachyphylaxis, of nicotine-evoked catecholamine release, 657, 658, 660, 662
T-cell activation, 706
^{99m}Tc-sestamibi, 91
^{99m}Tc-terburoxime, 91
^{99m}Tc-tetrofosmin, 91
Technetium 99 radionuclide ventriculography, 551
Technetium pyrophosphate (^{99m}TcPYP), 499
Teicholz's formula, 561
Telemetric monitoring, HRV and, 680, 682
Telmisartan, 514
Test stimulus (S2), 535, 536
12–0-tetradecanoyl phorbol-13-acetate (TPA), as protein kinase C activator, 779, 781
Tetraiodothyronine (T_4), amiodarone and, 369, 371–373
Tetra-octylammonium bromide, 322
Tetrodotoxin, 660
Tetrodotoxin-sensitivity, 537
Thallium (201 TI), 499
Thallium scintigraphy, 499
Thebesian vein, 500, 501
Thermoregulation, 678
Thiamine deficiency, 244
and food restriction, 244
Thiazides, 399, 458, 515
for black patients with high blood pressure, 459
in STONE study, 467–468
with diuretics, 617, 618, 619
Thiazide-type diuretics, 387, 694, 803, 807
Thin layer chromatography (TLC), 240, 380
Thiobarbituric acid (TBA) method, 418
Thoracic pain, 13
THP-1 monocytic cell line, 706
Thrombin, 743, 746
Thrombin generation, 405
Thromboembolic disease, pathogenesis of, 633
Thromboembolism, 622
Thrombolysis, 770
after myocardial infarction, 761
calcium blockers, benefits, detriments, 403–406
clinical trials, 754, 756, 757
Thrombolysis in Myocardial Infarction (TIMI)-II trial, 405
Thrombolytic agents, 751, 761
after AMI, 489
mortality/morbidity and, 519, 524
Thrombolytics, 299
EUK-8 cardioprotective effect, 331
Thrombosis, 303
arterial, 743–747
cerebral, 745
Thromboxane A_2 (T_xA_2), 405, 610, 727–731, 733
Thromboxane B_2 (T_xB_2), 732, 733
Thromboxane synthesis, low-dose aspirin, 727–729, 731
Thyroidectomy, 369–376, 552
Thyroid hormone
effect on the heart, 369, 370
serum levels, 371, 372
Thyroxine (T_4), 369, 371–373, 376
TIBET studies. *See* Total Ischemic Burden European Trial
Tick bite, and *Borrelia burgdorferi* cardiomyopathy, 351, 352, 355, 357
Ticlodipine, 745, 747
Tilisolol
in canine coronary circulation, 23–29
intrinsic sympathomimetic activity, 23
membrane-stabilizing activity, 23
Tilisolol hydrochloride. *See* Tilisolol
Tilt table testing (TTT), propantheline bromide in neurocardiogenic syncope, 687–692
Time constant, electrocardiological effects of AWD 23–111, 531–537
Time and frequency domain analysis, HRV and, 677, 680–681, 682
Time domain method, HRV and, 680, 681, 683
Time to arrhythmia recurrence, calculated in propafenone vs. disopyramide therapy trial, 147, 148, 151
Time to fibrillation, measurement of, 448, 449, 451
Time to treatment failure, 147–149
Timolol
after MI, 95% confidence intervals and point estimates for relative risk reduction, late-entry trials, 763
Norwegian Timolol Trial, 759, 761
Tissue adenosine triphosphate, 767
Tissue high energy phosphates (HEP), and preconditioning of rat heart, 129–134
Tissue plasminogen activator (t-PA), 405,512, 514, 610, 641, 744–746
decreased in arterial hypertension, 122
^{201}Tl, 91
T-lymphocyte activation, 706
TM1, neutral endopeptidase prolonged inhibition effect on cardiac hypertrophy, 593–596
Tobacco, smokeless, 657
Tolerance, intermittent vs. continuous transdermal nitroglycerin, 5–9
TOMH study. *See* Treatment of Mild Hypertension Study
Tongue, tissue, 587, 588, 590
Tonin, 512, 514
Tonoprint, 60
Torasemide, 696
Torsade de pointes, 372, 536
Total Ischemic Burden European Trial (TIBET), 398, 459
Total l-thyroxine (TT_4), 370, 372

Total mechanical energy (TME), food restriction effect on heart in rats, 241, 242
Total peripheral vascular resistance, arbutamine as pharmacological cardiac stress agent, 32, 33, 35, 37
Trabeculae, ischemic preconditioning, 771
Trace elements, antioxidants and LDL apheresis, 567–571
TRACE trial. *See* Trandolapril Cardiac Evaluation
Tracheal beta$_2$-adrenergic receptors, 36, 39, 42, 45, 46
Train stimulation method, 371
Trandolapril, 520, 521, 696, 761, 798
  renal hemodynamics and, 804, 805
Trandolapril Cardiac Evaluation (TRACE), 520, 521, 642, 712, 761
Transbronchial lung biopsy (TBLB), 501
Transcription, endothelin release, 795
Transcriptional processes, 516
Transdermal Nitroglycerin Cooperative Study, 5, 6
Transdermal nitroglycerin, intermittent vs. continuous, 5–9
  concomitant antianginal therapy, 5, 7
  different study populations and nitrate responsiveness, 5–6
  dosage, 6
  efficacy evaluation methods, 6
  first-dose effect, 6
  harmful effects in nitrate-free periods, 7–8
  neurohumoral response, 7–8
  nitrate patches or oral nitrates, 8
  optimal doses, 8
  timing of efficacy assessments, 6
Transduction pathway
  PLC-IP$_3$-DAG, 795
  receptor-effector, 798
Transduction system, 679
Transesophageal atrial stimulation, 539
Transforming growth factor-alpha (TGF-α), 798
Transforming growth factor-beta (TGF-ß), 610, 795, 797, 798
Transgenic mice, heart rate, a pharmacological tool, 677–684
Transient inward current (I_{CaT}), 678
Transient ischemia, 768
Transient ischemic attacks, 747
  low-dose aspirin for protection, 727, 732
Transitory myocardial ischemia, amlodipine and ischemic ventricular fibrillation, 447–453
Translation, endothelin release, 795
Transmembrane alpha-helix, M2, 658
Transmembrane ionic homeostasis, changes in, 730
Transplant atherosclerosis, 384
Transplantation, cardiac, 502, 713
  and end-stage heart failure medical treatment, 617, 618, 620–621
  HRV and denervated hearts, 678
  immunosuppressive drugs, 379
  sympathetic nervous system activation in heart failure, 624, 626
Trans-sarcolemmal entry, of trigger calcium ions, 703
Transtelephonic electrocardiographic transmitter device, 151
Trauma, neuroendocrine response, 623
Treatment of Mild Hypertension study (TOMH), 399, 459
TREND trial. *See* Trial on Reversing Endothelial Dysfunction
Trial on Reversing Endothelial Dysfunction (TREND), 469–471, 610–611, 643
Triamterene, 694
Tricuspid regurgitation. *See* Tricuspid valve insufficiency
Tricuspid valve insufficiency, 498
Trifluperazine, anti-ischemic protection of, 175
Triglycerides (TG), 226, 264, 569, 745
  effects of beta-blockers on HMG CoA receptors, 67, 68
  and hyperlipidemia, HMG CoA reductase inhibitors and fibrates effect on, 788–790, 792, 793
  levels following long-term moxonidine treatment, 275, 277, 278
  plasma concentrations, 380, 381, 383, 384
  pravastatin study, 476, 478
3,5,3'-triiodo-l-thyronine (TT_3 and FT_3), 370, 372
Triiodothyronine (T_3), 369, 371–373
Triose phosphates, 768
Triton-X-100 micelles, 782
Tromso Study, 229
Tropomyosin-troponin complex, 703
Troponin, 703
Troponin C, 303, 699, 706
  propranolol stimulating Ca^{2+} binding, 581, 585
T-type channels, 590
Tumor necrosis factor, 728
Tumor necrosis factor-alpha (TNF-α), 626, 627, 706
  gene expression, 706
Tumor-promoting phorbol esters, 776
T waves, 371, 374, 527, 532, 546
  ischemia and, 447–449, 451, 452
  QT intervals and tangential of (QT_{TANG}), 540–543
  QT intervals and end of (QT_{END}), 540–543, 545
II genotype, 632, 633, 634
Tyrode's solution, 532, 533
Tyrosine phosphorylation, 798

UK-61,260. *See* Nanterinone
Ultrastructural analysis, EUK-8 vs. DMTU cardioprotective effects, 335, 337
Ultroser G medium (IBF), 557
Umbilical cord vein endothelial cells, human, 557–559
U.K. General practice research database, 400, 401
U.S. Carvedilol Heart Failure Study, 713
University of Göteborg, ethics committee, 540
Unloading drugs, 693, 696, 700
Upstroke velocity, KT-362 and, 667, 672
Uptake mechanisms, 672, 674
  Ca^{2+}, 672, 674
  uptake$_1$, 662, 663
  uptake$_2$, 662
Urapidil, 283, 284, 288, 805
Urinary hesitancy side effect, 689–691
Urinary output, 699
Urinary protein, moxonidine effect, 277
Urinary retention, 691
Urine collection, 806
Use-dependent block, Ca^{2+} current, 674
"Use-dependent effect," 536, 544
Uteran tissue, 514
Uterus, ET_B receptors in, 795

Vaccines, 752, 757
Vagal tone, 691
  HRV and, 678, 680, 682
Vagal-mediated syncope, 691
Vagus nerve (X) nucleus, 285
Valsalva maneuver, HRV and, 678
Valsartan, 310, 514
Valve replacement surgery, calcium antagonists and, 405
Valvular heart disease, 11, 562
  associated with atrial fibrillation, 154
Variant angina, smoking effect on, 179–180
Varicose veins, 729
Vasa recta, medullary, 78
Vasa vasorum, 501
Vascor. *See* Bepridil
Vascular dilation, renal, 804, 807
Vascular diseases, 568
Vascular elastic properties, aorta and actual blood pressure, 54–56
Vascular endothelium, 559
Vascular inflammatory response, 746, 747
Vascular injury, 404, 633, 743
  calcium antagonism and ACE inhibition effects on neointima formation, 101–104
Vascular muscle tone, endothelin-1 and bosentan efects on, 717, 718, 722, 723
Vascular remodeling, 634, 635, 796, 797, 799
Vascular resistance
  renal (RVR), 803–805, 807
  systemic, 699
Vascular smooth muscle (VSM)
  angiotensin receptors and, 512, 513
  calcium antagonists and, 403
  elgodipine effect, 573
  ET-1 effect, 111, 442
Vascular system, ibopamine and, 696
Vascular thrombotic system, 522
Vascular tone, cholinergic control of, 687, 691

Vascular toxicity, 379
  C_x-induced, 379, 383, 384
Vasoactive amines, 745
Vasoactive cyclooxygenase products, 21
Vasoconstriction, 695, 697, 699
  angiotensin-mediated efferent, 805
  calcium and, 404
  coronary, nicotine and, 663
  ET_B receptor-mediated, 796
  noradrenaline-mediated afferent, 805
  peripheral, 561
  thromboxane effect, 728, 731
Vasoconstrictor activity, 513, 514, 631–633
Vasoconstrictor agonists, in congestive heart failure, endothelin-1 response, 111
Vasoconstrictor peptides, 561
  endothelin and, 795, 796, 798, 799
  endothelin-1, 717, 723
Vasodepressor syncope, 687–691
Vasodilatation, 698
  arterial, 695, 700
  coronary, 728, 729
  peripheral, 696, 697, 699
  venous, 695, 700
Vasodilation, 691
  ACE inhibiting drugs and, 804–806
  endothelin and, 797–799
  KT-362 and, 667
  PDE inhibitors and, 704, 706
Vasodilator in Heart Failure Trial (V-HeFT)
  V-HeFT-I, 695
  V-HeFT-II, 625, 712, 761
  V-HeFT-III, 698, 713
Vasodilators, 380, 384, 410, 561, 564, 590, 624, 626
  ACE inhibitor sympathetic activity, 640–641
  action of, 631, 632, 695, 697–699
  calcium antagonists and, 403
  cardiac sarcoidosis and, 502
  carvedilol hemodynamic effects in hypertensive patients, 113–117
  direct, 805, 806
  and end-stage heart failure medical treatment, 617–620
  for heart failure, 712–713
  hypotensive effect of drugs, 405
  nanterinone hemodynamic effects in heart failure, 137–143
  nitric oxide-mediated, 627
  peripheral, 520
  prostaglandins as, 511, 513–515
Vasomotor tone, coronary, 657, 663
Vasopressin
  captopril and renal impairment, 78
  heart failure effect on, 623, 624
Vasopressin antagonist, drug treatment of heart failure, 693, 699
Vasopressor mechanisms, 514
Vasopressors, 799
Vasospasm, 23, 442
  calcium antagonists for cardiovascular disese, 455–459
Vasospastic angina, propranolol effect on, 29
Vasospastic diseases, 409
Ventricles, cardiac, 514, 587
Ventricular aneurysm. *See* Heart aneurysm
Ventricular chamber dynamics, left, 704
Ventricular dilatation, left, 519–520, 619
Ventricular dilation, 561
Ventricular dysfunction, 705
  left, 561, 704
  left, ACE inhibitors and, 519–523
  left, asymptomatic, 519, 521, 524
  left, in clinical trials, 754
  left, vasopressin antagonists and, 699
Ventricular ectopy, 621
Ventricular effective refractory period (V-ERP), 531, 532, 533, 535–537
  right ventricle and almokalant, 540, 542–544, 546
Ventricular ejection fraction, left (LVEF), 551, 552, 553, 555
Ventricular end-diastolic index, left, 561
Ventricular failure, left, 599
Ventricular fibrillation, 528, 730
  after acute myocardial infarction, 486, 488
  and cardiac sarcoidosis, 498, 502
  EUK-8 vs. DMTU cardioprotective effects, 333, 337
  hypothyroidism and, 369–376
  inducible, 549–550, 555
  ischemic, 371, 372, 375, 376
  ischemic, amlodipine and, 447–453
  spontaneous, 451, 452
  with disopyramide, 148
Ventricular fibrillation threshold (VFT), 451, 452
  hypothyroidism and, 369–376
Ventricular fibrosis, 677
Ventricular function, 403
  effect of calcium in, 403
  left, 398, 522, 523, 527, 528, 631–636
  left, class 1 antiarrhythmic drugs and, 550
  left, metoprolol and quality of life in heart failure, 361
  left, reduced, long-term studies, 642
  left, remodeling, 614–615, 635, 636
  left, TRACE study, 761
Ventricular muscle, sarcolemmal calcium ion channels in, 674
Ventricular paced QT intervals, frequency-dependent effects of almokalant, 539–546
Ventricular pacing, 448, 449, 451–453, 528
Ventricular preload, 523
Ventricular premature beats. *See* Ventricular premature complexes
Ventricular premature complexes, 663, 682
  and cardiac sarcoidosis, 497
Ventricular proarrhythmia, 146
Ventricular repolarization, hypothyroidism and ventricular fibrillation, 369–376
Ventricular septal rupture, after acute myocardial infarction, 486
Ventricular volumes, nitrates effect, 740
Ventricular wall stress, 635
Ventromedial nucleus of the hypothalamus (VMH), 266, 269
  -syndrome, 268, 269, 270
Verapamil, 403–404, 410, 414, 452, 528, 698, 798
  congestive heart failure risk, 464
  DAVIT studies, 455, 457
  effect on platelet and fibrinolytic parameters, 119
  and endothelial function, 439–445
  for hypertensives or those who had nonQ-wave infarcts, 455, 457
  for mild hypertension, 459
  for supraventricular arrhythmias, 15
  for systolic left ventricular dysfunction, not recommended, 712
  inhibiting copper-induced LDL peroxidation, 417–420
  inhibiting peroxidation of membrane lipids, 175
  mortality risk, 464
  myocardial protection, vitamin D_3 and calcium overload, 185–187
  partition coefficient, 435
  as protection, 587, 590
  renal hemodynamics and, 805
  safety documentation for SR in hypertension, 464
  to reduce enhanced reperfusion arrhythmias, 374–375
  vs. elgodipine, 573, 578–580
  vs. metoprolol for effort angina, 455, 456
Verelan, safety documentation for SR in hypertension, 464
Very low density lipoprotein (VLDL), 67
Vesnarinone, 705–706
  drug treatment of heart failure, 693–700
  efficacy and safety, 712
  toxic-therapeutic ratio, 712
Vesnarinone Study, 712
V-HeFT trial. *See* Vasodilator in Heart Failure Trial
Vimentin, 796
Viral infections, 743, 745
  endocardial fibroelastosis, 501
Visual analog (VA) scale, 362
Vitamin A
  as lipophilic antioxidant, 567–570
  toxicity, 571
Vitamin B_{12}, 752, 757
Vitamin D_3, overload, calcium antagonists, myocardial protection, and calcium overload, 185–187
Vitamin E
  /cholesterol ratio, 569, 570
  as lipophilic antioxidant, 567–570

pretreatment to prevent cardiac membrnae changes, 231, 234–236
Vitamins, antioxidants and LDL apheresis, 567–571
Voltage dependence, 682
Voltage-dependent calcium channel, nicotine and sympathetic neurotransmission, 657–663
Voltage-gated calcium channels, 442
Von Kossa's silver staining method, 588, 589
von Willebrand factor, 557, 746
factor VII, 746
factor VIII, 746
V_1-receptors, 699
V_2-receptors, 699
V_1/V_2-receptor antagonist, 699

W-7, vs. felodipine, 175
Warfarin, 622, 715
Water excretion, 806
Water retention, 806
Weight loss, 626
Weight loss-regain cycles, 275, 279
Weight reduction programs, 244, 246
Wenkhebach cycle, 691
Western blotting, 782, 783
West of Scotland trials, 754
White blood cells, 745, 746
Wigner-Ville method, 677, 679–682, 684; *see also* Pseudo-Wigner-Ville transformation
Wilcoxon matched-pairs signed-rank test, 575
Wilcoxon test, 114, 551, 563
Windkessel function, antihypertensive therapy and aortic stiffness, 49–56
Wistar rats, 682
Wolff-Parkinson-White syndrome, 155
concealed, adverse effects of class I antiarrhythmic drugs, 161–165
manifest, adverse effects of class I antiarrhythmic drugs, 160–161, 163
Women
cardiac sarcoidosis in Japanese women, 496
cost-effectiveness of drug therapy for hyperlipidemia, 791–793
postmenopausal, hemostatic predictors of thrombosis, 746
hypertension in postmenopausal, 387
World Congress of Sarcoidosis and other Granulomatous Disorders, symposium of, 497
WOSCOPS study, 760
WPH syndrome, catheter ablation in patients with HCM, 527–529

Xamoterol, 700, 704
Xanthine oxidase, 333
Xenopus oocytes, 658
X-ray, cardiopulmonary, 540

Yates corrected chi-square test, 551
Yohimbine, 285, 288

Zatebradine, 682
ZD-7288, 682
Zero hour effect, 738–739
nitroglycerin patch therapy, 5, 7
Zofenopril, 520–523, 642
Zucker fa/fa "fatty" rat, 266, 268–270
Zucker fatty trait, 276
Zucker rats, 279
Zucker syndrome, 266